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Sumário Executivo 
A indústria farmacêutica enfrenta uma das maiores vagas de expiração de patentes. A 
magnitude do potencial de perda de vendas é tal, que a Datamonitor1, prevê que entre 2011 e 
2012 as receitas do sector de medicamentos vão diminuir, pela primeira vez em quatro 
décadas. 
 
Como alternativa, as tecnologias de Drug Delivery (DD), que consistem na ciência de entregar 
um ingrediente activo no local do corpo onde este é necessário, nas quantidades certas e no 
momento certo da forma mais efectiva e conveniente; estão a impulsionar o crescimento das 
empresas farmacêuticas, aumentando as suas receitas, através do prolongamento do ciclo de 
vida do produto e através de novas formulações e combinações. 
  
De acordo com esta percepção, este plano de marketing foi desenvolvido para uma futura 
empresa, LIFE DELIVERY, que detém a patente de um novo biomaterial, e pretende lançar um 
novo produto – DELIVES | improving life quality –, para o mercado. 
DELIVES é um novo Targeted Drug Delivery (TDD), que consiste num DD direccionado a libertar 
o fármaco localmente na zona de interesse; extremamente versátil que pode ser precisamente 
adaptado a fim de alcançar os objectivos específicos de cada cliente, proporcionando uma 
liberação controlada de fármacos e elaborado através de um processo ambientalmente 
amigável. 
 
Usando três tipos de segmentação (geográfica, por tipo de indústria e por aplicação) e 
aplicando diferentes critérios de avaliação aos segmentos seleccionados, as conclusões finais 
apontam para os seguintes clientes alvo: grandes empresas farmacêuticas, da União Europeia, 
que actuem nos mercados das seguintes áreas terapêuticas: Inflamação e perturbações 
músculo-esqueléticas, desordens metabólicas e doenças cardiovasculares, sendo a última, os 
clientes ideiais para a estratégia de entrada no mercado. 
  
De acordo com a percepção de valor dos clientes-alvo- traduzida em redução de custos-, a LIFE 
DELIEVERY adoptará um posicionamento, baseado em três pilares principais: qualidade, 
inovação e imagem organizacional. 
                                            
1
 Datamonitor é uma empresa de pesquisa e consultoria que aconselha clientes com a tomada de 
decisões operacionais e estratégicas 
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O modelo de negócio adoptado pretende licenciar a tecnologia, recorrendo a diferentes 
estratégias de comunicação, sendo que 322.078.48€ é o custo para execução deste plano de 
marketing, no primeiro ano de vida da empresa. 
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Executive Summary 
The pharmaceutical industry faces one of the biggest waves of patent expirations. The 
magnitude of the potential loss of sales is such that Datamonitor, predicts that between 2011 
and 2012 the revenue from the drug will decrease for the first time in four decades. 
 
Alternatively, the technologies for Drug Delivery (DD), which consist of the science of 
delivering an active ingredient in place of the body where this is necessary, in the right 
quantities at the right time in the most effective and convenient, are boosting the growth of 
pharmaceutical companies, increasing its revenue by extending the product life cycle and 
through new formulations and combinations. 
  
According to this perception, this marketing plan was developed for a future company, LIFE 
DELIVERY, which holds the patent of a new biomaterial, and intends to launch a new product - 
Deliver | Improving life quality - for the market. 
DELIVES is a New Targeted Drug Delivery (TDD), which consists of a DD directed to release the 
drug locally in the area of interest, extremely versatile and can be precisely adjusted to achieve 
the specific objectives of each client, providing a controlled release of drugs and elaborated 
through a process environmentally friendly. 
 
Using three types of segmentation (geographic, industry type and application) and applying 
different evaluation criteria to selected segments, the final conclusions point to the following 
target customers: large pharmaceutical companies, the European Union, acting in the markets 
of the following therapeutic areas: inflammation and Musculosketal, metabolic disorders and 
cardiovascular diseases, the latter being the ideal customers for market entry strategy. 
 
According to the perceived value, of target customers - translated in cost-saving -, LIFE 
DELIEVERY will adopt a position based on three main pillars: quality, innovation and 
organizational image. 
 
The business model adopted aims to license the technology, using different communication 
strategies, and € 322.078.48, is the cost to implement this marketing plan in the first year of 
life of the company. 
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1 Introduction 
 
This master’s thesis aims to present a marketing plan to launch a new technology into the market. 
This technology will be the final product of a current research project2, and will be introduced in the 
market by LIFE DELIVERY – a future spin-off of Faculdade de Ciências e Tecnologia of Universidade 
Nova de Lisboa (FCT/UNL), that will be created by some research team members, with the objective 
of developing and commercialize different products based on a technology platform, designated “Ion 
Jelly”. 
Ion Jelly is a patented new biomaterial, that arises from the combination of gelatine with ionic 
liquids3 and which offers interesting properties, allowing different applications such as batteries or 
battery components, in chemical processes used in industry and laboratories or also in 
pharmaceutical applications. 
Based on this platform technology, one FCT/UNL research team is now developing a novel gelatine-
based targeted drug delivery system4 - named DELIVES - that intends to be an interface between the 
patient and the drug, which will be released by a controlled process. A drug delivery system enables 
the introduction of a therapeutic substance in the body and improves its efficacy and safety by 
controlling the rate, time, and place of release of the drugs in the body (Jain, 2008). The process 
includes the administration of the therapeutic product, the release of the active ingredients by the 
product, and the subsequent transportation of the active ingredients across the biological 
membranes to the site of action. By using new drug delivery systems it is possible to increase 
potentially viable drug candidates and reformulate existing drugs extending the product lifecycle by 
new patent application (Figure 0.1). For now, and since this technology is at under development 
stage, this target drug delivery system has not yet been proved to transport any specific drug, and 
this implies a generalization of this thesis work.  This aspect interferes in the specification of certain 
parts of this work, which could not be more explored due to the development phase of the product. 
Being Ion Jelly, a resulting technology from FCT/UNL and IST research teams investigation, the Ion 
Jelly patent, is owned by Universidade Nova de Lisboa (UNL) and Instituto Superior Técnico (IST). This 
                                            
2 The research project is funded by Fundação para a Ciência e Tecnologia, ongoing between September 2009 
and 2012. 
3
 Ionic liquids are defined as salts 
4
 Targeted drug delivery is the most important goal of pharmaceutical research and development. In this 
context drug targeting is defined in the broadest sense, that is, to optimize a drug’s therapeutic index by strictly 
localizing its pharmacological activity to the site or organ of action. If successful, the result of the targeting 
would be a significant reduction in drug toxicity, reduction of the drug dose, and increased treatment efficacy. 
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ownership, converts the Technology Transfer Office (TTO), of the two universities, the responsible 
offices for the patents management and for the first commercialization or collaborative research 
partnerships efforts.  
 
Figure 1.1 – Drug delivery systems consequences and opportunities
5
 
The intention of this work is to develop a marketing plan regarding the launch of this new product 
(DELIVES), covering the first three years of the startup that will market the final product and also the 
period leading up to the company´s creation – when the platform technology is managed by 
Universidade Nova de Lisboa’s Technology Transfer Office together with the researchers6. During the 
thesis work progression, where contacted several entities in different areas, for example, related to 
pharmaceutical or technology transfer. These contacts are descriminated in Appendix 1. 
  
                                            
5
 3) Macromolecular drugs, which are largely biologics, are currently being delivered only through injections. As 
there are various issues related to solubility, molecular size, toxicity, ineffective absorption, off-target reaction, 
the use of other models of drug delivery has been a challenge (Frost & Sullivan, 2009 A). 
6
 During the development of this work, I´ve been working at UNL’s TTO, and this is the reason why it is only 
refered the efforts made by UNL TTO and not the TTO of IST. 
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2 General Company Description 
 
2.1 Vision 
To preserve and improve people’s lives using green and environmentally friendly procedures. Focus 
on providing value to our clients, through superior products to its customers and society in general, 
by improving pharmacological and therapeutic properties of existing and new drugs.  
Life Delivery wants to conquer a ubiquitous status for their drug delivery systems being the most 
widely used system in clinical applications. 
 
2.2 Mission Statement     
Working together with pharmaceutical and biotechnology industries in order to find better and 
safety solutions to preserve and improve people´s lives. 
 
2.3 Value Proposition  
LIFE DELIVERY | Delivering a safety Future. 
 
2.4 Business Model  
Our strategic partnerships range from joint discovery, co-develop and licensing agreements with a 
wide range of organizations, for the purpose of securing exclusive access to “second generation” 
drugs and delivery systems.  
  
 - 4 - 
 
  
 - 5 - 
3 The Problem and Solution  
 
3.1 Current situation of DELIVE´s potential customers   
For the pharmaceutical and biopharmaceutical industries, the current and next years will bring an 
increase in financial and regulatory pressures caused by continuing patent expirations of blockbuster 
drugs, dwindling product pipelines due to financial risks of drug discovery and development process, 
increasingly cautious government regulators in order to, for example, environmental concerns 
policies — not to mention company downsizings due to mergers, acquisitions and outright 
dissolutions caused by, the risk of this kind of business. 
 
 
 
 
 
 
 
 
 
 
“The era that created the modern pharmaceutical industry is in fact over,”  
Richard Evans, a former Wall Street analyst and now a pharmaceutical consultant 
 
 
 
Figure 3.1 - Summary of Pharmaceutical and Biopharmaceutical 
companies main problems 
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1) Risky Financial Business 
Pharmaceutical and Biopharmaceutical companies and 
industries, which typically commercialize only 2-3 new 
products per year, have to face long and costly product 
development cycles.  
According to the European Federation of Pharmaceutical 
Industries and Associations, the discovering7, development8 process and clinical trials9 needed to 
market a new drug involves estimated costs of €1,059 million, and takes between 12 to 13 years to 
reach the market since the first synthesis of the new active substance (EFPIA, 2009). In the next years 
we will assist to an increasing in R&D expenditures for successful new molecular entity (NME) launch 
(see Appendix 2). The investment made in a new drug development process is risky, because on 
average, only one or two of every 10.000 promising substances demonstrates quality, safety and 
effectiveness in the demanding tests of research and become a marketable product (EFPIA, 2009) 
(see also Appendix 3). 40% of drug failures have been associated to poor pharmacokinetics 
properties (a process by which a drug is absorbed, distributed, metabolized and eliminated by the 
body) which represents on average, a loss of 4,236 trillion Euros to pharmaceutical companies, and 
that could be overcome, by using different and innovative drug delivery systems ( Frost & Sullivan, 
2010). 
 
As was referred before, 60% of New Drug Applications submitted to the FDA during the 1990s were 
for drugs containing existing active ingredients. The reformulation strategy is more cost and time 
effective, than the development of a completely new drug (Table 3.1).  
                                            
7 Drug discovery is the process that involves finding out the target that causes the disease. Next, chemical or 
biological compounds are screened and tested against these targets or assays, which are representative of 
these targets, to find leading drug candidates for further development (Ng, R., 2004). 
8
 Tests are performed on the lead compounds in test tubers (laboratory, in vitro) and on animals (in vivo) to 
check how they affect the biological system. The tests, often called preclinical research activities, include 
toxicology, pharmacodynamics and pharmacokinetics, as well as optimization of drug delivery systems. Many 
interactions are carried out, and the leading compounds are modified and synthesized to improve their 
interactions with the targets, or to reduce the toxicity or improve pharmacokinetics performance. At the end of 
this process, an optimized compound is found and this becomes a potential drug ready for clinical trial in 
humans (Ng, R., 2004). 
9
 Clinical trials are trials conducted on human subjects. The pertinent parameters for clinical trials are protocols 
(methods about how trials are to be conducted), safety and respect for human subjects, responsibilities of 
investigator, institutional review board, informed consent, trial monitoring and adverse event reporting (Ng, R., 
2004). Clinical trials have to follow regulations and guidelines from the Food and Drug Administration, the 
European Agency for the Evaluation of Medicinal Products (EMEA) of the European Union (EU) or European 
Member States, Japan’s Ministry of Health, Labor and Welfare (MHLW), or regulatory authorities in other 
prospective countries where the drug is intended to be registered and commercialized. Clinical trials are 
conducted in accordance with Good Clinical Practice (GCP). 
The need to reduce 
financial risks on new drugs 
development investments 
 - 7 - 
This reformulation is also necessary to increase the medicines effectiveness and reduce side effects. 
It is urgent to enhance the existing solutions to treat diseases. 
  
Table 3.1 – Development factors and average sales of new drugs and reformulated drugs (adapted from 
Pharmaceutical Lifecycle Management June 2005 cutting edge information) 
 Years to develop Cost of 
development (US$MM) 
Average Peak 
sales (US$MM) 
NCE / Discovery 
compound 
9-12 900 300-500 
Optimization / 
Reformulation 
4-5 40 100-200 
 
In the optimization / reformulation, it is obtained a final medicine with different characteristics, and 
therefore, according to the Division of Drug information of U.S. Food and Drug Administration (FDA), 
“Changing the drug delivery system to an approved drug application would likely require a 
supplement to the drug application”, and “the types of 
studies required (i.e. clinical versus nonclinical data) would 
depend on a variety of factors” (the description of this 
contact is present in Appendix 1). So, using certain 
equivalences and reducing the number of studies required, it 
is possible to decrease the costs and time needed for these regulatory procedures
10. 
 
2) Patent Expirations 
According to Datamonitor Inc., a market analysis firm, about 
USD 140 billion in annual sales are expected to be lost by 
2016 as blockbuster drugs (typically defined as one with more 
than $1bn in annual sales) lose their patent protection and 
face generic competition (see also Appendix 4). 
In accordance with European Parliament, the period between the filing of a patent application for a 
new medicinal product and the authorisation to place it on the market constitutes one of the factors 
which actually reduces the effective protection afforded by the patent and can compromise the 
                                            
10
 Note: These regulatory affairs must be conducted by the owner of the API or the medicine formulation 
patent i.e. the pharmaceutical company that will be the client of LIFE DELIVERY. 
The need to overcome the 
drugs off-patent portfolio  
It is possible to optimize or 
also put new drugs into the 
market using DELIVES 
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amortisation of the investment in the research. The lack of sufficient protection can also lead 
research centres based in the Member States to relocate to countries offering better protection11. 
 
In addition to cost and time consuming process of drug discovery, development and approval, the 
time of patent exploitation and the sales made during this period, could not be sufficient to offset 
the investment made and will reduce the sales revenue, being necessary new solutions to overcome 
this concerning scenario. 
 
In the countries that joined to PCT (Patent Cooperation Treaty)12 the drug patent of a new drug 
expires after 20 years (with a possibility of extension for more 5 years) from the date of filling13, and 
taking into account the time taken for preclinical and clinical trials made after drug patent 
application, drugs generally lose patent protection about 12 years after they are first sold 
(Lichtenberg, F. 2009) (see also Appendix 3). 
To cope with this massive patent expiration, manufacturers use different tactics and normally 
pharmaceutical companies use three main types of strategies to extend the product lifecycle: Merges 
& Acquisitions, enter on generic market and Reformulation. 
Reformulation14 is perhaps the most common. Given the high cost of creating a completely new 
molecular compound (NME), it should come as no surprise that 60% of New Drug Applications 
submitted to the FDA during the 1990s were for drugs containing existing active ingredients 
(Yoshitani, 2007). A relatively small investment (compared to developing a completely new drug) 
could buy a technology that offers a new lease on life to the drug as an "enhanced" version: longer 
                                            
11
 Regulation (European Commission) No. 469/2009 of the European Parliament. 
12
 The Patent Cooperation Treaty (PCT) is an international patent law treaty, dated of 1970. It provides a unified 
procedure for filing patent applications to protect inventions in each of its contracting states. A patent 
application filed under the PCT is called an international application, or PCT application. Until January 2010, 
were 142 the signatory states of the Patent Cooperation Treaty (online, World Intellectual Property 
Organization).This treaty allows a single place holder application to be filed within one year of the original filing 
date which reserves the right to file in most significant countries in the world, without having to actually file a 
patent application in each country until 30 months after the original filing date or 18 months after the PCT 
filing. This gives the inventor or his company more time to evaluate the invention without loss of any rights 
before having to file it worldwide at significant expense (Voet, 2008). 
13
 The company has a period – up to 25 years after the patent application – to recover all costs in the 
investment phase (Marcelino, 2009). 
14
 Many products have gone this way, incorporating controlled release or other drug-delivery technologies: 
Procardia became Procardia XL, Prozac became Prozac Weekly. Strong branding paves the way as people 
happily switch to a more effective version of the product. 
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lasting, stronger action, easier dosing (Colyer, 2003). Reformulation approaches can be classified into 
three categories: reformulation of the molecular entity, new deliveries and new indications. 
With a reformulation made by changes in the drug delivery system it is possible to extend the patent 
protection or also apply for a new patent. 
In order to extend the protection granted by a patent, it is possible to request a Supplementary 
Protection Certificate (SPC). For European Union member states, this is an Industrial Property right 
that extends the protection to a product, medicinal or plant protection, for a maximum period of 5 
years, as long as the product is protected by the original patent.15  
In accordance with Engª Isaura Monteiro (Patents Examiner of Portuguese Institute of Industrial 
Property), the reformulation of a drug (changing the system used to deliver the API), could apply for 
a SPC, since the API is claimed in the base patent (the API should be described in the patent claims) 
and the product must have obtained a Market Introduction Authorization (MIA)16 . 
Also in the United States of America, it is possible to apply for a Patent Term Extension (PTE) with a 
maximum duration of 5 years, as set forth in section 1.701 of Chapter 37 of the Code of Federal 
Regulations.  
These SPC and PTE were created in order to compensate the time taken to obtain regulatory 
approval before drugs could be marketed. However, in some cases it is not possible to apply for 
these rights, and in other cases it’s a better strategy to fill for a new patent application. 
 
                                            
15
 The creation of Supplementary Protection Certificates for medicines and phytopharmaceutical products are 
presented at community regulations, (EEC) Nº 1768/92 of the Council of 18th June 1992 and (EC) Nº 1610/96 of 
the European Parliament and the Council of 23rd July 1996. 
16
 Note: It isn’t possible to present a single request for all the European member states. 
The requests need to be presented individually for each member state and it only has effect in the country for 
which it is granted.  
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Figure 3.2 – Benefits of use Drug Delivery in drugs reformulation (Adapted from Frost & Sullivan, 2009 A) 
 
 
3) Increase of Environmental Regulations and  Concerns 
As the world becomes focused on the environment and the 
potential for long-term harm from manufacturing there has 
been a concerted push to “go green” (Frost & Sullivan, 2009 
A). 
The pharmaceutical industry is finding itself under increasing 
pressure from patients, shareholders, and policy makers to address the growing environmental 
concerns associated with drug development. By making products free of dangerous chemicals, 
companies no longer have to deal with the cost of hazardous waste disposal or the medical bills from 
injured or exposed employees. This is reinforced by the last communication of commission of the 
European communities, where the environment issue also comes into play via the proposing of 
measures aimed at reducing the negative effects of pharmaceuticals on the environment and public 
health (Commission of the European Communities, 2008). 
 
In addition to the advantages presented above, the production process of DELIVES, being made using 
environmental friendly techniques and products, enables a distinctive green character of this 
product, compared with TDD available solutions, which suits the needs of pharmaceutical industries 
with respect to the current obligations of environmental care. 
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Conclusion 
The pharmaceutical market is very competitive and it is imperative that pharmaceutical and 
biopharmaceutical companies, large or small, find new solutions to remain competitive.  
Novel or improved drug delivery systems (process of administering a pharmaceutical compound to 
achieve a therapeutic effect) can revive promising compounds which have been abandoned due to 
formulation problems and can be used to add something new to a marketable compound to get a 
market advantage, extending the life of pharmaceutical products. Drug delivery technologies can 
clearly differentiate a drug in today’s increasingly complex, crowded and competitive markets. 
Drug delivery is a fast-growing and highly dynamic segment, in the pharmaceutical and 
biotechnology industry. Various factors have contributed to the growth of this area. Poor drug 
efficacy, patent expirations and the urgent need for lifecycle management are some of the major 
factors facing the current drugs (Frost & Sullivan, 2009 A). 
 
Figure 3.3 - Summary of the two main problems that could be overcome using new drug delivery system 
 
Deliver new compounds with poor pharmacological properties: 
Recent advances in the field of biotechnology coupled with 
modern synthetic methodologies have resulted in a large 
number of commercially available macromolecular drugs 
(Singh, 2003). There are lots of new compounds in R&D 
companies’ pipelines that could not reach the market due to a lack of an appropriate drug delivery 
system. DELIVES could help these molecules with potential for a wide range of therapeutic 
indications, to get their propouse and achieve a therapeutic effect, getting regulatory approval to 
enter into the market. 
 
Rescuing drug candidates 
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Reformulate marketable drugs: 
Through reformulation, a drug company can change enough 
characteristics of a brand-name drug just to qualify for a new 
patent, while keeping other characteristics to use previous 
clinical testing results for the purpose of regulatory approval. 
It has been analysed that the introduction of novel delivery systems (one reformulation strategy 
approach), offers a definitive competitive edge, aiding in better market penetration, bringing 
benefits to medical community, enhancing brand image, extending lifecycle product management 
and thereby offering a great opportunity in increasing market share and revenues of the 
organization. 
Improving existing pharmaceuticals using reformulation strategies, particularly drug delivery 
changes, means improve efficacy and specificity that can be translated in different administrated 
doses, administration routes; enhance convenience for patients and improvements in toxicity, 
stability and specific targeting. 
 
We are moving on the direction of an ideal that consists in easy-to-use formulations with favourable 
side effects to increase uptake and adherence – As patients convenience gains more importance, 
demand for easy-to-use formulations is increasing. Due to these facts, companies are reformulating 
drugs more frequently (Frost & Sullivan, 2009 B).   
Novel drug delivery systems can act as a strategic tool providing various advantages to patients, 
physicians and pharmaceutical/biotechnology companies (Frost & Sullivan, 2008 B). Given this 
perception, and owning a patent for a new extreme versatile biomaterial – the Ion Jelly-, LIFE 
DELIVERY is developing an innovative targeted drug delivery system called DELIVES to improve the 
therapeutic effects of a large number of pharmaceutical compounds and also deliver compunds that 
otherwise could not reach the market. 
 
This is an urgent and needed solution with advantages to the pharmaceutical and biopharmaceutical 
industry, physicians, patients and the society in general. 
Make old drugs new 
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4 Product Description 
 
DELIVES| improving life quality; is a unique compilation of products that utilize ion-jelly based 
material to overcome common industry challenges and deliver cost-effective drugs and enhance the 
selective uptake of drugs to target tissues or cells. 
Unlike other options offered in the market, DELIVES is extremely versatile and can be precisely 
tailored to achieve each client’s specific objectives, providing the controlled release of drugs, made 
using an environmentally friendly process.  
The composition and linker chemistry are chosen to optimize the release of the specific drug. 
 
DELIVES helps pharmaceutical and biopharmaceutical companies achieve:  
 Improved bioavailability, particularly for poorly water soluble compounds 
 Different routes of administration for marketable drugs  
 Improved efficacy and controlled release of marketable drugs  
 Ease of scale-up and validation 
 4 to 5 years to enter in the market17 
 
 
 
 
 
 
 
 
 
 
 
                                            
17
 1 year to client´s product specifications adjustments + expected maximum of 3 to 4 years to regulatory affairs 
(this time was achieved using information about duration of market introduction authorization procedures 
made into reformulations of drug delivery forms. Consult section 2.2 – “The solution”). 
 Ionic Liquid selection / design; 
 Incorporation of API in the Ion Jelly drug 
delivery system; 
 Surface modification selection (in order to 
create a target effect); 
 Selection and design of final DELIVES ‘s 
morphologic profile. 
 
DELIVES API 
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Due to confidentiality reasons related to Intellectual Property we are unable to give more technical 
details.   
 
4.1 Intellectual Property 
 
Ion Jelly® is an exclusive technology with protected IP. There are one Portuguese and four PCT patent 
applications pending for this technology, filed in 2007 (PT103765) and 2009 (EP2006231; KR10-2008-
0058173; JP2008-160947; USA20080319164) respectively.
All patents are co-owned by the Universidade Nova de Lisboa (UNL) and Instituto Superior Técnico 
(IST); and the research team is constituted by Susana Filipe Barreiros, Pedro Miguel Vidinha, Nuno 
Lourenço, Joaquim Sampaio Cabral, Ines Batista Ribeiro and Carlos Alberto Afonso (inventors). 
The search report and official written opinion provided so far by the Portuguese Patent Office (INPI) 
did not identify any relevant document regarding state-of-the-art that can hinder the novelty and 
inventive step of this invention. In addition, there is a high level of know-how associated with this 
technology which took more than 10 years to develop by the inventors. The scientific team is widely 
multidisciplinary, from various fields covering chemistry and bio-sciences, for example. 
Also, the innovative degree of this technology has been highlighted by several prestigious sources as 
specified in Appendix 5.  
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5 Market Selection  
 
In order to select the market to enter, it was used 
R&D expenditure as a first criterion, since it provides a 
measure of the financial input to innovative activity 
that may lead to process innovation, fundamental new 
findings, new products or improvements of existing 
products.  
Globally, and according to Frost & Sullivan market 
study about opportunities in drug delivery, USA 
(66,004.1 Million USD), Europe (48,673.1 Million USD) 
and Japan (11,081.3 Million USD), are currently the 
world regions with higher pharmaceutical R&D 
expenditures, and will continue to be until 2012 (see 
Appendix 7, 8,9 and 10) (Frost & Sullivan, 2009 A). 
According to the same source the venture capital 
added to the government investments in biotech R&D 
at 2012 will represent 120,196.9 Million USD in USA, 23,614.5 Million USD in Europe and 4,988.5 
Million USD in Japan (see also Appendix 11 and 12) (Frost & Sullivan, 2009 A). 
 
In these 3 geographical areas, the second criterion evaluated was the dimension of the markets for 
pharmaceuticals, and according to IMS Health Company, and their last figures from 2008, the largest 
markets for pharmaceuticals are USA, Spain, United Kingdom, France, Germany, Italy and Japan (IMS, 
2008). 
 
The following step was to evaluate the expected growth of each market and the last forecast 
estimated (IMS, 2008): 
 An expected growth rate of 1 to 2 percent in 2009 for the United States which represents 
sales of $292 to $302 billion, and reflects the impact of continuing patent expirations, fewer 
new product launches and a tighter economy.  
 The top five E.U. countries (France, Germany, Italy, Spain and the United Kingdom) were 
forecasted to grow 3 - 4 percent in 2011, reaching sales of $162 to $172 billion. In Europe, 
the growth is driven by the continued aging of the region’s population and rising demand for 
preventive care and will be tempered by the increased impact of health technology 
All countries 
Largest Market 
opportunity 
(E.U.) 
Similar culture and environment, 
presence of mature 
pharmaceutical companies and 
their headquarters 
 (USA and top 5 E.U. countries) 
Largest pharmaceutical markets 
(UK, France, Germany, Spain, Italy (the 
top 5 pharmaceutical markets), USA 
and Japan) 
 
 
Higher pharmaceutical R&D 
expenditures  
(USA, Europe and Japan) 
Figure 5.1 – The options to market selection 
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assessments, the use of contracting by payers as a means to control costs, and the 
decentralization of government healthcare budgets.  
 Japan, the world’s second-largest market, was expected to see higher growth of 4 to 5 
percent, reaching $84 - $88 billion. Approvals of new anti-cancer agents, disease prevention 
programs, and the absence of the Japan government’s biennial price cuts all contribute to 
stronger growth. Government efforts to promote the use of generics will have only a modest 
impact on the Japan market in 2009. 
 
In addition to the similar culture and environment18, U.S.A. and E.U. present highest mature 
pharmaceutical and biopharmaceutical markets. These criteria led to the disregardation of Japan. 
Between the U.S.A. and the E.U. countries, our last criteria evaluated the potential of the market 
opportunity, with E.U. seeming to be the major potential market to be explored. The main reason for 
this is the intensive presence of Pharmaceutical companies’ headquarters in E.U.19 (where it’s 
possible to find the decision makers20) and a highest number of targeted drug delivery companies in 
the U.S.A. market, a read ocean for drug delivery companies (consult Appendix 13). 
 
                                            
18
  For example the uniformization of all countries in terms of clinical trials - Requirements for the conduct of 
clinical trials in the EU are provided for in "Directive 2001/20/EC” 
19
 The choice of European Union and not all the Europe is based not only on the uniformization of laws and 
policies in the E.U. member states, but also on the highest revenue of E.U market ($ 90,600 Million) compared 
to the rest of Europe ($ 11,300 Million) (IMS, 2003). 
20
 Inside the pharmaceutical and biopharmaceutical companies the decision makers are the business and 
product managers. 
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6 Current Situation Analysis  
 
EXTERNAL ENVIRONMENT  
According to the market selection presented above, the current situation analysis was made in 
European Union. 
1. Economic and Political/Legal environment 
According to Datamonitor, The European pharmaceutical market generated total revenues of $177.6 
billion in 2008, representing a compound annual growth rate (CAGR) of 4.4% for the period spanning 
2004-2008 (Datamonitor, 2010). 
Intensity of R&D aid in Member States  
In accordance with the Barcelona objectives, research and development (R&D) expenditure should 
reach 3% of the GDP of the European Union by 2010, compared with the 1.93% in E.U. 25 at 2002 
(Eurostat - May 2005). 
The Eurostat Report highlights three groups of countries:  
 Countries with low R&D intensity (new Member States, Greece, Portugal, Spain and Ireland) 
showed increases in their respective R&D intensities due to a catching-up phenomenon. 
However, there are important disparities. 
 Countries where R&D intensity is higher recorded significant progress (Austria and Denmark) 
or reached the 3% threshold (Sweden and Finland). 
 Former Member States where R&D intensity is close to the European average (values from 
1.5 to 2.5%). For this last group including in particular France, United Kingdom, Germany, the 
Netherlands and Italy, R&D intensity did not increase.  
The European Union is responsible for policies, regulations and recommendations that affect the 27 
member states. In the EU legislation, as regards to the Pharmaceutical and cosmetic products, it is 
possible to highlight a renewed vision for the pharmaceutical sector – a communication of 21st 
December 2008, that lays down objectives relating to the future of the pharmaceutical sector, like:  
 The new regulatory framework should contribute to reinforcing the safety of 
pharmaceuticals, encouraging innovation and making medicines more accessible for 
European patients. 
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The environment issue also comes into play via the proposing of measures aimed at reducing the 
negative effects of pharmaceuticals on the environment and public health (Commission of the 
European Communities, Dec. 2008). 
Also related with the environmental issue, E.U. made valuable contributions related with the 
promotion of corporate social responsibility (CSR) (Commission of the European Communities, March 
2006). This communications and policies emphasize the importance of environment issues in 
pharmaceutical sector and encourage innovation in this industry. 
2. Technological environment 
Access to innovative medicines: 
In a call for action to strengthen the European-based pharmaceutical industry for the benefit of the 
patient, the commission highlight: 
The development of innovative medicines with a high added therapeutic value should be encouraged 
under the 6th Framework Programme for Research. In addition the Commission, through its proposal 
for a review of pharmaceutical legislation, has demonstrated its desire to support research into 
innovative medicines and provide sufficient protection for the exclusivity of the data on such 
medicines (Commission of the European Communities, July 2003). 
According to Frost & Sullivan, in the technology area, cost-effective manufacturing of the drug 
delivery devices is likely to heighten profit margins. The R&D arena offers tremendous opportunity 
when novel drug delivery technology is expanded to various indications and therapeutic areas. In 
addition, huge opportunity exists for companies that develop novel drug delivery technology along 
with unique formulation technology. Companies focussing on drug delivery technologies must 
concentrate on improving the drug delivery methods, in order to expand the applications in various 
indications and to have a wide therapeutic reach.  
The patent expirations are expected to stimulate a surge in novel drug delivery methods for existing 
products. Sophisticated reformulation, coupled with cost-effective and efficient drug delivery 
methods, is likely to attract commendable revenues in the European market. The future potential for 
drug delivery in the European market is likely to be propelled by the influx of novel drug delivery 
methods. Also, according with Frost & Sullivan, Drug delivery is a fast-growing and highly dynamic 
segment in the pharmaceutical and biotechnology industry. Various factors have contributed to the 
growth of this area. Poor drug efficacy, patent expirations and the urgent need for life cycle 
management are some of the major factors facing the current drugs (Frost & Sullivan, 2009 A). 
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An ideal novel drug delivery system will focus on patient benefits, cost-effective and commercially 
viable.  
The opportunity level of drug delivery business remains to be the highest in all areas except the 
regulatory level, however regulatory approval and patent protection will follow suit, as the other 
criteria are met (Frost & Sullivan, 2009 A). 
 
The intensity of R&D efforts made in DD systems at E.U. is very intensive, but still remains far from 
U.S.A. 
  
3. Social environment 
The report by the High Level Group on Innovation and Provision of Medicines (2002) recommended 
that the EU institutions and member states should work towards ways of improving the penetration 
of generic medicines.  The communication - a call for action to strengthen the European-based 
pharmaceutical industry for the benefit of the patient - also points out that, as part of the reform of 
the Community code relating to medicinal products for human use, the Council's common position 
suggests the possibility of introducing a marketing authorisation application for a generic and to 
grant this authorisation in the last two years of the data protection period of the reference product 
for all products except those falling within the mandatory scope of the centralised procedure.  
 
Another E.U. environment weakness is the increasing of competitiveness of generic manufacturing, 
hinder the market development. With an increasing number of generics companies based out of low-
cost countries making in-roads into the European market, manufacturing is expected to get highly 
competitive. Companies that are strongly backward integrated into the pharmaceutical value chain 
and have their active pharmaceutical ingredients and excipients manufactured at very competitive 
prices in the Asia Pacific region are likely to significantly challenge European participants. Although 
the uptake of generics in Europe continues to increase, heightened competition is expected to strain 
margins. This fact incurs on the decreasing of attractiveness of product’s life cycle management. 
Is very important to clarify that this product not intends to be a competitor of generics, but a solution 
to already existing medicines, that effectively needs improvements or also to introduce new and 
needed medicines into the market. 
 
 
 
 
 
 
 
 - 20 - 
4. Customers / Competitors analysis  
Costumores´ analysis 
This section is developed in part 8.1 – “Market segmentation”. 
Competitors´ analysis 
According to ESPICON market report about Targeted drug delivery analysis, by 2018, over 30 new 
products will be launched resulting in a global market for advanced targeted delivery products worth 
over US$8.5 billion (Epsicom, 2009). 
DELIVES, is for now a technology with a huge potential to serve as vehicle to deliver a great diversity 
of existing and potential drugs. However, it is necessary to analyse each drug case in order to 
evaluate the truth potential of DELIVES application. Derived from its character, for now, more 
generalist of this technology, it is necessary to assume all the targeted drug delivery companies as 
competitors (even though most of them exploit technologies targeted only to one specific 
therapeutic area).  
From the Epsicom report, results the number of targeted drug delivery companies (29 companies). A 
detailed document of the companies and respective products, based on each company´s official 
website information, is present in Appendix 13. 
 
 
 
Summarizing: The pharmaceutical market growth connected with the patent expirations and 
dry pipelines, and still with the E.U. policies about drugs safety, R&D support and 
environmental issues; form great opportunities to LIFE DELIVERY. Notwithstanding, this 
company will face a solid and strong competition, in a untapped market, that will assist to 
the coming of more entrants.  
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INTERNAL ENVIRONMENT 
1. LIFE DELIVERY: 
Human resources of LIFE DELIVERY have a strong and recognized scientific know-how, with 
outstanding commitment, initiative; prove of entrepreneurial spirit and privileged relationships with 
another research groups, universities, and R&D institutions. The team commitment such as the 
entrepreneurial spirit and business knowledge are well demonstrated by LIFE DELIVERY’s CRO - Pedro 
Vidinha - and his business plan competition and entrepreneurship prizes21. These competitions prizes 
may be important to company initial funding. However there is a lack of strong market / industry 
knowledge and management know-how inside LIFE DELIVERY staff that needs to be fulfilled. 
Despite the youth and non commercial experience of this technology company (no previous 
performance or current offerings), LIFE DELIVERY (an University spin-off), has the advantage of using 
the privileged relations with Universidade Nova de Lisboa (UNL) and consequently privileged 
relationships with the market. Using the network of UNL’s Technology Transfer Office it’s easier to 
build interesting business relationships and access to information to successfully implement the 
marketing plan. 
Beyond the market access advantages, the strategic alliances with referred educational institutions 
could allow the access to juridical services (including patent protection and management), and 
financial services. 
 
2. DELIVES technology: 
The combination of the chemical versatility of an ionic liquid (IL) with the morphological flexibility of 
gelatine (G) generated a new gelatine-based biomaterial (IL-G) (Vidinha, 2008). The excellent 
tuneable solvent power of ILs mixed with the biocompatibility and bioavailability of a natural 
biopolymer like G, makes this innovative material an excellent candidate for developing new drug 
delivery systems. 
                                            
21
 Business plans competitions prizes and participations, wined by the research team, using the Ion Jelly 
Technology:  
 E-DAY -2007 (2
nd
 place) – Elevator-pitch Competition 
 Idea to Product (I2P) Global Competition – 2008 (1
st
 place) - early-stage technology commercialization 
plan competition 
 BES – 2008 (1
st
 place) – National Innovation Competition 
 Prémio Start – 2009 (Finalist) – National Entrepreneurship Prize  
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According to this, DELIVES is a new targeted drug delivery system that is extremely versatile and 
could encapsulate and deliver a very large spectrum of drugs in the body. This technology also uses a 
clean and environmentally friendly production process, which is an important issue for 
pharmaceutical industry.  
Nevertheless, is important to highlight the controversial “green” designation of Ionic Liquids. This 
contorversia appears due to toxicity of raw materials used in the production process. Nevertheless, 
this question doesnt apply to Ion Jelly because the ionic liquids are biocompatibles and do not use 
toxic compuonds, the preconceived image of Ionic Liquids could affect DELIVES’s image. 
A comparative analysis between DELIVES and its main technology competitors is made in Table 6.1 
(for further information about the competitors technologies, consult Appendix 13). 
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Main Technology Competitors22:   
 
Table 6.1 – Main technology competitors’ comparative analysis 
 
DELIVES 
(LIFE DELIVERY) 
Advanced Polymer 
Conjugate 
Technology 
(NEKTAR) 
DIFFUCAPS 
(EURAND) 
 
SMARTICLES® 
(NOVOSOM AG) 
Versatility of 
applications √ √  х 
Environmental 
friendly 
process/product 
√ х - х 
Ease of Synthesis 
process 
√ х х  
Tests made using 
different API’s = 
Time to market 
х √ √ √ 
Different 
administrative 
routes possibilities 
√ х √ х 
 
 
Summarizing:  Although the worries about being a new entrant with initial funding needs, this 
company has an excellent and qualified team that comes from a prestige institution – and this image 
is extremely important to the clients.  
The potential of the product that LIFE DELIVERY intends to commercialize is also increased by the 
versatility of applications and the environmental friendly process used. Nevertheless it will be 
necessary to transmit a credible image, to surpass the preconceived concept of toxicity associated 
with Ionic liquids. 
Since the research is currently ongoing, at this moment the early-stage status of the technology is the 
reason for the non-existence of a current offer, being this the major constraint of the technology. 
 
                                            
22
 This analysis was made using technologies available information and also according to previous discussions 
with Pedro Vidinha. According to the versatility of DELIVES, the main competitors of DELIVES technology is the 
Nektar’s proprietary Advanced Polymer Conjugate Technology platform, where both large and small molecules, 
can be enabled or made more efficacious to dial in desired therapeutic properties and create an optimized and 
potentially superior therapeutic. 
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7 SWOT and TWOS Analysis 
7.1 SWOT Analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How can Life Delivery use the strengths?  
Organization: 
 Shorten the collaborative research time and 
speed the time to market 
 Build up market relations and use the 
institution prestige 
Technology: 
 Build a medium-long term strategy to enter 
in new markets 
 Appeal to the client´s corporate social 
responsibility 
  
Strengths 
Organization: 
 Strong  scientific know-how, team 
commitment and entrepreneurial spirit 
 University Spin-off 
 
Technology: 
 Versatility of applications 
 Environmental friendly product and process 
How can Life Delivery stop the weaknesses? 
Organization: 
 Strength relations with client´s partners 
working in the distribution chain  
 Outsourcing and strategic  alliances to bridge 
the human resources gap 
Technology: 
 Get  a first partner with privileged relations 
with LIFE DELIVERY´s target market 
 
 
Weaknesses 
Organization: 
 Unknown company 
 No funding 
 Lack of human resources with 
market/industry knowledge and 
management 
Technology: 
 No current offer 
 Poor reputation of ionic liquids (toxicity 
related) 
How can Life Deliver use the opportunities?  
Organization: 
 Search for collaborative researh funding 
 Apply for R&D funding available 
 
Technology: 
 Justify the market need for this solution  
 Use the recent and growing importance of 
final customer opinion and concerns as a 
business strategy 
 Link environmental issues to E.U. promotion 
and stimulus of corporate social   
responsibility  
 
Opportunities  
Organization: 
 E.U. R&D support 
 Pharmaceutical and biopharmaceutical 
market growth 
Technology: 
 Dry pipelines, Patent expirations and Generic 
competition  
 Policies in order to reinforce the 
pharmaceuticals safety 
 Companies environmental issues  
How can Life Delivery stop the threats? 
Organization: 
 Reinforce the product life cycle 
management strategy 
Technology: 
 Reinforce the improvements made on 
the products. Brand loyalty 
 Practice competitive license fees 
 
 
Threats 
Organization: 
 Merge and acquisition of companies 
 Entrant of new competitors 
 Possibility of a wrong perceived concept 
related withintention of substitution of 
generic medicines by DELIVES 
Technology: 
 High cost of advanced drug delivery solutions 
 Entrant of new technologies  
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7.2 TOWS Analysis  
  
Strengths 
 
Organization: 
 Strong  scientific know-how, 
team commitment and 
entrepreneurial spirit 
 University Spin-off 
 
Technology: 
 Versatility of applications 
 Environmental friendly 
product and process 
 
Weaknesses 
 
Organization: 
 Unknown company 
 No funding 
 Lack of human resources 
with market/industry 
knowledge and management 
Technology: 
 No current offer 
 Poor reputation of ionic 
liquids (toxicity related) 
 
 
Opportunities 
 
Organization: 
 E.U. R&D support 
 Pharmaceutical and 
biopharmaceutical market 
growth 
Technology: 
 Dry pipelines, Patent 
expirations and Generic 
competition  
 Policies in order to reinforce 
the pharmaceuticals safety 
 Companies environmental 
issues  
 
 
SO (Identification of strategies for 
advancement) 
 
Organization: 
 Use R&D funding available 
 
Technology: 
 Build a medium-long term 
strategy to enter in new 
markets 
 Use the technology to 
reformulate already 
marketable products in 
order to extend their  
profitable lifecycle 
 Appeal to the client’s 
corporate social 
responsibility 
 
WO (Identification of strategies for 
overcome weakness) 
 
Organization: 
 Build up market relations 
and use the institution 
prestige 
 Outsourcing and strategic  
alliances to bridge the 
human resources gap 
 
Technology: 
 Get  a first partner with 
privileged relations with LIFE 
DELIVERY´s target market 
(collaborative R&D 
agreement) 
 
Threats 
 
Organization: 
 Large companies due to 
increasing  merges and 
acquisitions 
 Entrant of new competitors 
 The power of current 
competition 
Technology: 
 High cost of advanced drug 
delivery platforms 
 Entrant of new technologies  
 
 
ST (Identification of strategies for 
avoid threats) 
 
Organization: 
 Get recognition to expand 
the product to new 
therapeutic areas 
Technology: 
 Practice competitive prices  
 Link environmental issues to 
E.U. promotion and stimulus 
of corporate social 
responsability 
 
 
WT (Identification of strategies for 
avoid and overcome) 
 
Organization: 
 Establish a close relationship 
with clients during all the 
license process 
 Ion Jelly brand loyalty 
promotion 
 
Technology: 
 Reinforce the improvements 
made on the products. 
Brand loyalty 
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8 Strategic Triangle 
 
Once it is not possible to reach all of the market potential customers, companies have to select a 
specific target market, in order to avoid waste of time and resources. Considering this, the first step 
is market segmentation, followed by the definition of the most attractive segments (target market) 
and finally, the design of strategies to reach the target market, attending to the product and 
company positioning relatively to the competition and the consumer relevant needs.  
As mentioned in Part 3 – “The Problem and the Solution”, the market soluctions offered by this 
technology are the reformulation of existing drugs and the new solutions for the delivery of 
macromolecules, and as will be showed after, this two solutions are translated in two different 
markets, that could also be sub-divided due to the different therapeutical area of application. 
 
8.1 Market segmentation  
Besides the geographic segmentation was also used a segmentation by industry and a segmentation 
by specific therapeutic area.  
1. Segmentation by industry 
There are three main types of pharmaceutical and biopharmaceutical companies being this an U.S.A. 
fact, but also encountered worldwide (United States Department of Labour, 2010): 
a) Large or mainline, pharmaceutical and biopharmaceutical companies (from now on, referred 
as companies with Development / Production and Marketing – DPM companies). These are 
established firms that have many approved drugs already on the market. These companies 
often have significant numbers of R&D laboratories and manufacturing plants. In contrast; 
b) smaller pharmaceutical and biopharmaceutical (from now on, referred as R&D companies): 
they are usually newer firms that often do not have any approved drugs on the market and as 
a result, almost exclusively perform R&D. In addition to developing their own drugs, some 
small pharmaceutical companies perform contract research for other pharmaceutical 
companies; and 
c) Generic pharmaceutical companies: these companies manufacture drugs that are no longer 
protected by patents. Because their products are all established drugs, they devote fewer 
resources to R&D and more to manufacturing. Given all that, this market segment is of no 
interest for this study. 
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According to Frost & Sullivan, it is possible to distinguish between Pharmaceutical and 
Biopharmaceutical companies, being the Biopharmaceutical – also called Biotech companies - the 
ones that have macromolecules as core while the Pharmaceutical companies have concentrated on 
small molecules (Frost & Sullivan, 2009 A). However, the line between pharmaceutical companies 
and biopharmaceutical companies is blurred, taking into account that pharmaceutical companies 
have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline 
in this direction through strategic acquisitions and partnerships with biotech companies and/or 
through their own in-house research efforts.   
Using these definitions and profiles, we decided to segment the market in four groups of direct 
customers:  
a) Pharmaceutical DPM;  
b) Pharmaceutical R&D;  
c) Biopharmaceutical DPM; and  
d) Biopharmaceutical R&D companies. 
 
 
1. Segmentation by application (therapeutic area) 
As a result of the current credit crisis and in order to preserve liquid assets, companies in the 
healthcare sector are restructuring and focusing only on their most advanced, high growth 
therapeutic programs. 
Companies are shifting focus from a fragmented approach that focuses on multiple diseases 
towards specialized business models such as niche therapeutic areas and generics. By focusing on 
specific areas companies are able to develop expertise, which promotes brand recognition and 
saves money by allowing the company to consolidate sales teams and R&D (Frost & Sullivan, 2009 
B). 
 
Moreover, each type of customer should be subdivided by research areas (therapeutic areas). 
The relevant therapeutic areas that should be attended are defined using two different aspects 
related with the Deals between drug delivery companies and pharmaceutical and Biotechnology 
companies trends (that indicate the tendency of drug delivery systems licensing) and the 
Biologics pipeline (where is possible to understand the trends of biologics drugs discovery and 
development). 
 
According to Frost & Sullivan market study about European drug delivery markets, the deals 
between drug delivery companies and pharma / biopharmaceutical companies have been 
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increasing in Europe (Appendix 14) (Frost & Sullivan, 2008 A). Looking at  Figure 8.1 that lists the 
drug delivery deals broken by therapy area and by deal type in European drug delivery market in 
2007, it’s possible to observe four attractive therapeutic areas to license a drug delivery product 
(licensing procedure is incorporated in the “others” – blue area of the chart). Inflammation and 
Musculosketal, Genitourinary, Neurological (from now, represented as Central Nervous System – 
CNS) and Respiratory.  
 
Figure 0.1 - Drug delivery deals broken by therapy area by deal type in European drug delivery market in 
2007 Note: Others include licensing, co-development, collaborative R&D, rights, marketing and 
Manufacture. Source: Frost & Sullivan, 2008 A 
 
On the other hand, the industry is showing a huge and growing interest in macromolecule23 based 
drugs (Frost & Sullivan, 2009 A). The number of biologic drugs in the pipeline has increased 
significantly over the last year and it must be noted that biologics in Cancer therapy have been 
given significant attention, followed by the Endocrine and Metabolic disorders, Vaccines, 
Cardiovascular and Autoimmune disorders (that will be represent by Immunologic therapeutic 
area), as showed in Figure 8.224. 
                                            
23
 Macromolecule - any very large complex molecule; found only in plants and animals ([online] Princeton 
word definition). 
 
24
 Despite the vaccines represents 9% of biologics pipeline, this therapeutic area was discarded , according 
with Pedro Vidinha, because the product (DELIVES) does not constitute an important asset to this area. The 
vaccines are used to prevent illness and in all pharmaceutical descriptions they are in separated areas from 
prescription and OTC medicines.  
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Figure 0.2 – Drug Delivery Market: Biologics Pipeline by Therapeutic Area (World), 2009. Source: Frost & 
Sullivan, 2009 A 
 
 
On one hand license agreements tendencies are fairly representative of current trends in this 
business (in relation to therapeutic areas). 
On the other hand it is important to know the trends regarding the emergence of macromolecules 
that require DD systems. 
For the reasons outlined above it is important to use these two data to obtain the relevant 
therapeutic areas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                    
 
Neurological drugs 3%
Urological 3%
Autoimmune disorders 
7%
Others 8%
Antiviral 4%
Vaccines 9%
Blood Disorders 6%
Cancer 27%
Immunosuppressants 4% Ophtalmological 4%
Digestive Disorders 4%
Respiratory 4%
Cardiovascular 8%
Endocrine and Metabolic 
Disorders 9%
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Segmentation summary 
 
 
 
 
Figure 0.3 – Segmentation summary 
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Potential market25  
The total potential market comprises 62 companies divided by type of customers and 
therapeutic areas of focus as shown in Figure 8.4. To consult the list of E.U. pharmaceutical and 
biopharmaceutical companies that belongs to each segmented area, see Appendix 15. 
 
 
Figure 0.4 – Summary of Total Potential Market analysis 
                                            
25
 The potential market represents the maximum number of E.U. customers who might be interested in the 
product. The list of Pharmaceutical and Biopharmaceutical companies, was achieved using the website 
http://pharmalicensing.com/public/, where was applied the criteria - Geographic Location: Europe to their 
profiled companies’ database. Then it was been analysed all the companies and selected the 
Pharmaceutical and Biopharmaceutical companies that make R&D and/or Production, Manufacture and 
Marketing of products, located at European Union. Innovaro Pharmalicensing is a global resource for 
partnering, licensing, and business development within the life science and biopharmaceutical industries. 
This information was cross with the database of the Pharmaceutical Business Review 
(http://www.pharmaceutical-business-review.com/about-us). In order to obtain a more precise database of 
Pharmaceutical and Biopharmaceutical companies, all the E. U. national pharmaceutical industry 
associations, members of European Federation of Pharmaceutical (EFPIA) manufacturers and EuropaBio, 
was contacted by e-mail in order to get a list of each country companies list (see also appendix25). EFPIA 
represents the pharmaceutical industry operating in Europe. Through its direct membership of 31 national 
associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 2,200 
companies committed to researching, developing and bringing to patients new medicines that improve 
health and the quality of life around the world. 
 
Pharmaceutical DPM (32 companies ≈  51,61 %) 
 
 
 
Pharmaceutical R&D (4 companies ≈  6,45 %) 
 
 
Biopharmaceutical DPM (11 companies ≈ 17,74 %) 
 
 
Biopharmaceutical R&D (15 companies ≈ 24,19 %) 
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8.2 Market Targeting 
 
The evaluation and selection of segments to target was made attending to the attractiveness of 
each segment in terms of opportunity, environment, reach and response (external variables), and 
fitting each with internal considerations such as mission, image, core competencies, resources 
and performance (Wood, 2008). Each target criteria will be classified in a scale between 0 
(unattractive) to 10 (extremely attractive). 
Market segments differ on four major attractiveness factors: Receptivity, and Capital to invest 
that are the main external variables and on the other hand, LIFE DELIVERY objectives, resources 
and competences, that are defined by Power against competitors and Match with DELIVES 
competencies (internal variables).  
All the criterias used to target the market were  weighted, with the following percentages: 20% to 
Receptivity, 35 % to Capital to invest, 20 % to Power against competitors and 25 % to Match with 
DELIVES competencies. Although the subjectivity of these percentages, this choice takes into 
account several experts views, such as CEO´s of medical devices companies and Technology 
Transfer Officers (see Appendix 1).  
 
Receptivity 
It is possible to assume that companies more focused on R&D procedures, working in the first 
lines of drug discovery and development are more risky-friendly with regard to the bet made in 
new technologies of drug delivery. However, and taking into account the costly process of this 
business and the low capital available to invest, it is very difficult to this type of companies, to 
invest in systems to deliver their discovered drugs.  
Nuno Arantes - Oliveira (Alfama CEO), believes that for a small biopharmaceutical company (more 
focused on R&D) the license acquisition of a drug delivery system is very risky. However if the 
company has a specific problem on delivering an API (active pharmaceutical ingredient), then 
perhaps it could occur the merging of the drug delivery and pharma / biopharmaceutical 
companies. According with Sérgio Simões (vice-president of Bluepharma), “smaller and bigger 
companies could have interest on drug delivery system acquisition”. Capital to invest is based on 
financial resources of the companies. The importance of this variable entails a great importance 
attending to the high costs of lisenses and collaborative research (needed in the previous phase of 
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the agreement).  Despite the blurred line between pharmaceutical and biopharmaceutical 
companies, it is still possible to say that the companies most focused only on the segment “bio” of 
pharma are much more capital injection dependent contrarily to the pharmaceutical companies 
that are more powerful in economic terms. 
According with expert’s testimonials it was assigned a value to the receptivity of each type of 
client, as can be seen in Table 8.1. 
 
Table 0.1 – Summary of Receptivity Assigning Values 
Type of client Receptivity 
Pharmaceutical DPM 8,00 
Pharmaceutical R&D 4,00 
Biopharmaceutical DPM 5,00 
Biopharmaceutical R&D 4,00 
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Capital to invest 
This criteria is based on financial resources of the companies. This variable entails a great 
importance attending to the high costs of license agreements (for further information about these 
costs, please consult the section 9.2– “Pricing”).   
Indeed, and despite the adverse financial climate, the biotech sector seems to be holding up 
relatively well. Up with the support to innovation made by programmes to stimulate research in 
drug development such as European Innovative Medicines Initiative, the competition for 
investment among biopharmaceutical companies is intense. Venture Capitalists have become 
more selective, putting their money into later-stage companies or moving to other sectors 
(Schofield, 2010). 
The companies’ capital to invest was achieved using their 2009 turnover26 which was converted 
into a 0 to 10 scale (Table 8.2). The turnover ranges and respective assigned classification were 
defined based on the maximum and minimum value of all the analysed companies’ turnovers (for 
further information about each company turnover value, please consult Appendix 16). 
Table 0.2 - Capital to Invest Assigning Values 
 
 
 
 
 
 
 
                                            
26
 Turnover represents the Annual sales volume net of all discounts and sales taxes. 
 
 
 
Turnover range (USD $ Million)  Capital to invest  
(0 to 10 scale) 
0-100 0 
100-500 1 
500-1000 2 
1000-5000 3 
5000-15000 4 
15000-25000 5 
25000-30000 6 
30000-35000 7 
35000-40000 8 
40000-45000 9 
45000-50000 10 
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Table 8.3 summarizes the value of capital to invest by therapeutic area. To obtain this value it was 
made an average of capital to invest (in a 0 to 10 scale) of all companies present in the sub-
segment (therapeutic area). 
Table 0.3 – Summary of Capital to Invest Value (in 0-10 scale) 
Type of client Therapeutic area Capital to 
invest 
Pharmaceutical 
DPM 
Cancer 4,69 
Immunologic 4,80 
Cardiovascular 5,05 
Inflammation and 
Musculosketal 
4,20 
Genitourinary 3,50 
CNS 4,06 
Respiratory 4,11 
Metabolic dis. 7,00 
Pharmaceutical 
R&D 
Cancer 4,00 
Immunologic 0,50 
Cardiovascular 0,00 
CNS ? 
Metabolic dis. 0,00 
Biopharmaceutical 
DPM 
Cancer 0,75 
Immunologic 2,00 
Cardiovascular 1,67 
Inflammation and 
Musculosketal 
2,50 
CNS 2,60 
Respiratory 2,33 
Metabolic dis. 0,00 
Biopharmaceutical 
R&D 
Cancer 0,25 
Immunologic 0,00 
Cardiovascular 0,00 
Inflammation and 
Musculosketal 
0,50 
CNS 0,00 
Respiratory 0,00 
Metabolic dis. 0,00 
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Power against competitors  
 
The power against competitors refers to the evaluation of therapeutic segments with more or less 
“actors” (intensity of competition based on presented therapeutic areas solutions) and to the 
power (dimension and reputation) of competitors 
Intensity of competition 
Between the main competitors it exists a clearly division at therapeutic areas of focus, 
representing cancer (with 54%), the therapeutic area with more market available solutions to API 
delivering problems / improvements. This data converts cancer in a red ocean in terms of 
competition). Based on the percentage of competition intensity it was made a scale in order to 
convert this value into a 0 to 10 scale (see Appendix 17). 
 
Figure 0.5 - Intensity of competition by therapeutic areas 
 
Power of competition 
According to Business Insights (an up-to-date incisive market and company analysis), Alkermes 
and Nektar are, with large distance comparative to others, the leading companies of targeted 
drug delivery, which act mainly in the segments of CNS and Immunology. Using this information it 
was considered that these two segments are the most powerful ones in terms of power of 
competition. On the other hand, and according to the versatility of LIFE DELIVERY product 
possible applications, was also considered that competitors that act across many therapeutic 
areas are the most powerful ones. 
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Table 0.4 - Power against competitors27 
  Intensity of competition Power of competition TOTAL 
Cancer 3 8 5,5 
CNS 9 3 6 
Immunology 9 3 6 
Inflammation 9 8 8.5 
Cardiovascular 10 8 9 
Others 8 8 8 
Across many therapeutic areas 8 1 4.5 
 
Match with LIFE DELIVERY competencies  
This criteria refers to the competences and strategic interest of the company. According with 
Pedro Vidinha (one of the technology inventors) and company’s CRO, although DELIVES could be 
applied in a great range of therapeutic areas, for now, this drug delivery is more indicated to 
Inflammation and Metabolic disorders. Quoting Pedro Vidinha “We believe that an Ion Jelly could 
be extremely useful to apply to drug delivery systems where gelatin is already used as an 
encapsulation polymer since the presence of ionic liquids  enhance gelatin encapsulation and 
delivery properties.  This fact is particularly clear on anti-inflammatory delivery systems where 
gelatin is currently be used to design different anti-inflammatory delivery systems. The 
introduction of ionic liquids through ion jelly technology could scope the number of anti-
inflammatory compounds that can be used on those systems. More recently different gelatin 
based delivery systems were also developed for metabolic disorders treatment. Thus we believe 
inflammation and metabolic disorders could very promising field to introduce Ion Jelly as drug 
delivery matrix”.  
Table 0.5 – Match with LIFE DELIVERY competencies 
Therapeutic area 
Match with 
LIFE DELIVERY competencies 
Cancer 5 
Immunologic 5 
Cardiovascular 5 
Inflammation  
and Musculosketal 8 
Genitourinary 5 
CNS 5 
Respiratory 5 
 
                                            
27 The valuation of this criterias gave a highest value to the segmented areas where there is less intensity of 
competition and also less power of competitors. 
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Table 0.6 - Targeting variables weight summary 
 
Type of industry 
 
Therapeutic 
area 
External variables Internal variables  
Total Receptivity 
(20%) 
Capital to 
invest 
(35%) 
Power 
against 
competitors 
(20%) 
Match with 
DELIVES 
competencies 
(25%) 
 
 
Pharmaceutical 
DPM 
Cancer 1,60 1,56 1,10 1,25 5,51 
Immunologic 1,60 1,66 1,20 1,25 5,71 
Cardiovascular 1,60 1,65 1,80 1,25 6,30 
Inflammation and 
Musculosketal 
1,60 1,47 1,70 2,00 6,77 
Genitourinary 1,60 2,33 0,90 1,25 6,08 
CNS 1,60 1,42 1,20 1,25 5,47 
Respiratory 1,60 1,44 0,90 1,25 5,19 
Metabolic dis. 1,60 2,39 0,90 1,50 6,39 
 
 
Pharmaceutical 
R&D 
Cancer 
 
0,80 1,40 1,10 1,25 4,55 
Immunologic 
 
0,80 0,18 1,20 1,25 3,43 
Cardiovascular 
 
0,80 0,00 1,80 1,25 3,85 
Inflammation and 
Musculosketal 
 
0,80 - 1,70 2,00 4,50 
Genitourinary 0,80 - 0,90 1,25 2,95 
CNS 
 
0,80 - 1,20 1,25 3,25 
Respiratory 
 
0,80 - 0,90 1,25 2,95 
Metabolic dis. 0,80 0,00 0,90 1,50 3,20 
 
 
Biopharmaceutical 
DPM 
Cancer 1,60 0,26 1,10 1,25 4,21 
Immunologic 1,60 0,70 1,20 1,25 4,75 
Cardiovascular 1,60 0,58 1,80 1,25 5,23 
Inflammation and 
Musculosketal 
1,60 0,88 1,70 2,00 6,18 
Genitourinary 1,60 - 0,90 1,25 3,75 
CNS 1,60 0,91 1,20 1,25 4,96 
Respiratory 1,60 0,82 0,90 1,25 4,57 
Metabolic dis. 1,60 0,00 0,90 1,50 4,00 
 
 
Biopharmaceutical 
R&D 
Cancer 0,80 0,09 1,10 1,25 3,24 
Immunologic 0,80 0,00 1,20 1,25 3,25 
Cardiovascular 0,80 0,00 1,80 1,25 3,85 
Inflammation and 
Musculosketal 
0,80 0,18 1,70 2,00 4,68 
Genitourinary 0,80 - 0,90 1,25 2,95 
CNS 0,80 0,00 1,20 1,25 3,25 
Respiratory 0,80 0,00 0,90 1,25 2,95 
Metabolic dis. 0,80 0,00 0,90 1,50 3,20 
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Conclusion 
Table 8.6 demonstrates that the fittest target of LIFE DELIVERY in E.U., in a first approach to the 
market, is the large Pharmaceutical Companies which have Inflammation and Musculosketal, 
Cardiovascular and Metabolic disorders as a business core therapeutic area.   
 
Figure 0.6 - Number of Pharmaceutical DPM companies by therapeutic area.  
There are 27 European large Pharmaceutical companies that operate in the therapeutic 
areas selected, as referred in the tables bellow. 
 
226
8
1
2
3
     Metabolic      
disorders 
F. Hoffmann-La Roche Ltd. 
GlaxoSmithKline plc 
Krka d.d. Novo Mesto 
Les Laboratoires Servier 
Novartis AG 
Grupo Ferrer 
Biomedica Foscama 
Sanofi-Aventis 
             
Cardiovascular 
Ark Therapeutics Group plc 
AstraZeneca PLC 
Bayer AG 
EGIS Pharmaceuticals Plc 
F. Hoffmann-La Roche Ltd. 
Gedeon Richter Plc. 
GlaxoSmithKline plc 
Ipsen S.A 
Krka d.d. Novo Mesto 
Les Laboratoires Servier 
Meda AB 
Merck 
Novartis AG 
Nycomed International Manag. GmbH 
Orion Corporation 
Sanofi-Aventis 
Boehring Ingelheim 
Chiesi Farmaceutici 
Grupo Ferrer 
Italfarmaco 
Rafarm 
Schwable Pharmaceuticals 
Inflammation 
and 
Musculosketal 
GlaxoSmithKline plc 
Chiesi Farmaceutici 
Rafarm 
Abiogen Pharma 
Dr. Kade Pharmazeutische GmbH 
Novartis AG 
 
 
Cardiovascular 
 
 
 
 
Inflammation and Musculosketal 
 
 
 
 
Metabolic Disorders 
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8.2.1  Ideal Customers 
 
According to targeting process made before, LIFE DELIVERY´s ideal customers it will be, at first 
sight to enter-to-market, the larger pharmaceutical companies (DPM Pharmaceutical companies), 
that are increasingly under pressure in order to bring forward innovative future products. 
 
According to this perception, the use of DELIVES to reformulate already approved drugs take away 
the element of risk involved in the approval of main ingredients, and could also improve their 
efficacy and reduce the amount of drug used, giving competitive advantages to pharmaceutical 
market place. This means that this initial strategy presents higher potential, compared to the 
DELIVES use in countless number of new compounds with poor pharmacological proprieties that 
are not yet approved. 
Looking only to DPM Pharmaceutical companies is obvious to say that their sub-segments differ 
only on the therapeutical focus area, and because of this, they present similar patterns of 
purchase, such as value-added to customers and to organization. Nonetheless the variable size, 
that measures each sub-segment dimension combined with the historic of drug delivery systems 
licensing acquired to extent products lifecycle, are important factors in order to determine the 
ideal customers.  
According to this, the ideal customer is a company which acts in a great variety of therapeutic 
areas (therapeutic area presence); with a significant number of pipeline products (that will allow 
the reformulation of a greater number of drugs using LIFE DELIVERY product - DELIVES); and with 
a past of license deals with drug delivery companies. 
The size of each sub-segment is also evaluated by the number of companies, using the 
correspondent weight.  
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1) Number of companies: 
Using the number of companies present in each sub-segment (therapeutic area), it was calculated 
the respective weight in a 0 to 10 scale (Weight of companies’ number). The weight of 
companies’ number was calculated multiplying the number of companies in the therapeutic area 
by 10 (the maximum value of this classification), and dividing by the total number of 
Pharmaceutical DPM companies that exists in the 8 therapeutic studied areas (32 companies). 
 
Table 0.7 – Assigning values for Number of companies by therapeutic area 
 Number of companies Weight of companies number 
(0 to 10 scale) 
Cardiovascular 22 6,88 
Inflammation and Musculoketal 6 1,88 
Genitourinary 4 1,25 
Metabolic dis. 8 2,50 
 
 
 
2) Therapeutic area presence: 
Considering the versatility of DELIVES applications, the value of a client that acts only in one 
therapeutic area with a less number of products is completely different comparing with the value 
of a pharmaceutical company that has different products in different therapeutic areas. 
To measure the Weight of companies therapeutic area presence, the number of each company 
therapeutic areas presence was multiplied by 10 (the maximum value of this classification), and 
divided by the total number of therapeutic areas studied - 8. 
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Table 0.8 – Assigning values to therapeutic area presence for companies acting in cardiovascular therapies  
Cardiovascular 
Company Name Number of sub- 
segments presence 
Weight of sub-
segments presence 
Total Size 
of Segment 
Ark Therapeutics Group plc 2 2,5 
4,60 
AstraZeneca PLC 5 6,25 
Bayer AG 3 3,75 
EGIS Pharmaceuticals Plc 4 5 
F. Hoffmann-La Roche Ltd. 5 6,25 
Gedeon Richter Plc. 2 2,5 
GlaxoSmithKline plc 7 8,75 
Ipsen S.A 3 3,75 
Krka d.d. Novo Mesto 4 5 
Les Laboratoires Servier 5 6,25 
Meda AB 2 2,5 
Merck 2 2,5 
Novartis AG 8 10 
Nycomed Int. Manag. 
GmbH 
2 2,5 
Orion Corporation 2 2,5 
Sanofi-Aventis 4 5 
Boehring Ingelheim 1 1,25 
Chiesi Farmaceutici 3 3,75 
Grupo Ferrer 5 6,25 
Italfarmaco 4 5 
Rafarm 5 6,25 
Schwable Pharmaceuticals 3 3,75 
  
 
 
 
 
Table 0.9 - Assigning values to therapeutic area presence for companies acting in metabolic disorders therapies  
 
Metabolic dis. 
 
Company Name 
Number of sub- 
segments presence 
Weight of sub-
segments presence 
Total Size 
of Segment 
F. Hoffmann-La 
Roche Ltd. 
5 6,25 
6,25 
GlaxoSmithKline plc 7 8,75 
Krka d.d. Novo 
Mesto 
4 5 
Les Laboratoires 
Servier 
5 6,25 
Novart s AG 8 10 
Grupo Ferrer 5 6,25 
Biomedica Foscama 2 2,5 
Sanofi-Aventis 4 5 
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Table 0.10 - Assigning values to therapeutic area presence for companies acting in inflammation and musculosketal 
therapies  
 
 
Inflammation 
and 
Musculoketal 
 
Company Name 
Number of sub- 
segments presence 
Weight of sub-
segments presence 
Total Size 
of Segment 
GlaxoSmithKline plc 7 8,75 
5,83 
Chiesi Farmaceutici 3 3,75 
Rafarm 5 6,25 
Abiogen Pharma 4 5 
Dr. Kade Pharmazeutische F. 
GmbH 
1 1,25 
Novartis AG 8 10 
 
 
3) Pipeline products28: 
Through public information of each company (as the company official website), it was determined 
the number of products of each company actually commercialise by therapeutic area targeted.  
The weight of pipeline dimension was determined using the total number of products as the 
maximum of the scale. 
Table 0.11 – Number of pipeline drugs for Inflammation and Musculosketal 
 Company Name 
Number 
of 
products 
Total 
Inflammation and 
Musculosketal 
GlaxoSmithKline plc 19 
38 
Chiesi Farmaceutici 2 
Rafarm 10 
Abiogen Pharma 5 
Novartis AG 3 
Dr. Kade Pharmazeutische Fabrik 
GmbH 
2 
 
                                            
28
 Calculation explanation:  
 Total number of products (all therapeutic areas) = 108 + 13 + 52 + 38 = 211  
 211 products correspond to the maximum value of the scale - 10 
 
o Cardiovascular - 108 = 5,12 
o Genitourinary - 13 = 0,62 
o Metabolic disorders - 52 = 2,46 
o Inflammation and musculosketal - 38 = 1,8 
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Table 0.12 - Number of pipeline drugs for Metabolic disorders 
 Company Name 
Number 
of 
products 
Total 
Metabolic 
disorders 
F. Hoffmann-La Roche 
Ltd. 
2 
52 
GlaxoSmithKline plc 8 
Krka d.d. Novo Mesto 19 
Les Laboratoires Servier 1 
Novartis AG 12 
Grupo Ferrer 3 
Biomedica Foscama 2 
Sanofi-Aventis 5 
 
 
 
Table 0.13 - Number of pipeline drugs for Cardiovascular 
 Company Name Number of products Total 
Cardiovascular 
Ark Therapeutics Group plc No own brand products 
108 
AstraZeneca PLC  10 
Bayer AG  2 
EGIS Pharmaceuticals  No own brand products 
F. Hoffmann-La Roche Ltd.  19 
Gedeon Richter Plc. 4 
GlaxoSmithKline plc 7 7 
Ipsen S.A  2 
Krka d.d. Novo Mesto  12 
Les Laboratoires Servier   6 
Meda AB  2 
Merck  9 
Novartis AG  10 
Nycomed International 
Manag. GmbH  
No own brand products 
Orion Corporation  2 
Sanofi-Aventis   8 
Boehring Ingelheim  1 
Chiesi Farmaceutici 1 
Grupo Ferrer  No own brand products 
Italfarmaco No own brand products 
Rafarm  12 
Schwable Pharmaceuticals  1 
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The variables referred above are summarizing in Table 8.14, where the total number represents 
the simple average of the three variables, due to the difficulty in attribute specific weights to each 
variable. 
Table 0.14- Size of sub-segments targeted 
 
Weight of 
number of 
companies 
Weight of Companies 
therapeutic area 
presence  
Pipeline dimension 
Weight 
TOTAL 
Cardiovascular 6,88 4,60 5,12 5,53 
Inflammation and 
Musculoketal 
1,88 5,83 1,8 3,17 
Metabolic disorders 2,50 6,25 2,46 3,74 
 
Summarizing, the ideal customers will be DPM Pharamaceutical Companies with a business core 
focused on development, production and marketing of cardiovascular drugs, that shows an 
historic interest in developing partnerships with small companies in order to reformulate already 
marketable drugs, improving their efficacy using a different drug delivery system.  
For that, companies like Novartis AG or Bayer that already had sign licensing agreements in order 
to exploit new drug delivery systems, are the ideal customers of LIFE DELIVERY product – DELIVES. 
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8.2.2 Market Strategy 
 
Despite the similarity between the ideal customers referred above (similar pattern of purchase - 
who is the buyer, why they buy and how they buy), and given LIFE DELIVERY characteristics and 
current situation analysis, the company will adopte a strategy of market entry, divided in two 
phases: 
1st phase – FCT-UNL and the research team of DELIVES, is already developing contacts with 
healthcare companies that have privileged relationships with pharmaceutical companies, being 
their suppliers of different healthcare solutions. Using this strategy is expected to develop drug 
delivery systems tailored to specific objectives of healthcare companies partners (pharmaceutical 
companies), allowing our client to license the final product to their partner. This way, it is possible 
for LIFE DELIVERY to get recognition of their products in the market and use the credibility of 
healthcare companies to reach the pharmaceutical giants.  
2nd phase - In a later stage, LIFE DELIVERY will establish contact with the rest of the European 
pharmaceutical companies targeted, in order to license DELIVES improved version to a specific 
pharmaceutical company that could apply this product to all of their pipeline medicines (after a 
first collaborative research necessary to fit the product to the specifications of each medicine). 
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8.3 Positioning 
 
Positioning the product refers to the process by which the firm decides how it should best depict 
the product in the market / market segment vis-à-vis competition and hopefully in the mind of 
the customer (O’Shaugnessy, 1995). 
 
Positioning factors 
In the targeted drug delivery systems business, and according to the contacts made with some of 
the large pharmaceutical companies targeted; the most important factors are the Product Quality 
and safety as well the Innovation that such technology, introduces to the final product - the 
medicine (to see the templates used to interview several companies to know more about the 
positioning factors, please consult Appendix 18). 
In the health business, especially when it comes to products or services that may directly affect 
the peoples’ lives, the most important and decisive factors are the quality and performance, with 
the price occupying a less important position. 
When it comes to drugs changes, and taking into account the inherently high investment cost and 
also according to the interviews it becomes obvious, that innovation, and improvements 
introduced on the final product (output), must be raised to their maximum, in order to make the 
business a good investment bet. These two factors are not optional factors, but required ones for 
the companys’ success in the market. 
 
Also classified as very important, is the possibility of use the same drug delivery system to 
different API’s (versatility). The potential clients look for this factor, as a very important 
competitive advantage for the company.  
 
In a second plan, appears the organization's image in the market as well as the image of its 
research and development staff, since these are key actors in the process of collaborative 
research carried out for each drug reformulation. The organization's image and reputation refers 
to credibility. 
Then, with less weight than the above factors, is the price of the technology, which in this case, 
will be the licensing price (see also section 9.2 – “Pricing”).  
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Despite the costs involved in this operation being much lower than in the case of betting on a 
completely new drug, this must be always evaluated at this level. 
In the same level of price, appears the environmental issue that seems not to be already a 
decisive factor, comparatively with the others. 
 
 
Figure 0.7 - Positioning factors classified by the clients (large pharmaceutical companies) 
 
 
Competitors’ positioning 
LIFE DELIVERY has two main competitors in the E.U. market, Eurand and Novosom AG. This 
statement is based on the power of these two competitors and because they have solutions to fit 
the therapeutic areas targeted above. 
Eurand is a speciality pharmaceutical company that develops, manufactures and commercializes 
enhanced pharmaceutical and biopharmaceutical products using their proprietary drug 
formulation technologies. One of Eurand’s drug delivery technologies is directed to 
cardiovascular, sleep aid, gastroenterology, nutrition, pain and respiratory therapeutic areas that 
intends to be incorporated in products in order to create new formulations with proven patient 
benefits. Eurand has a broad and validated portfolio of drug formulation technologies, including 
platforms focused on bioavailability enhancement of poorly soluble drugs, custom release 
profiles, and taste-masking/orally disintegrating tablet (ODT) formulations. Within its portfolio of 
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drug delivery products, the product that competes, more directly, with DELIVES is Diffucaps 
Technology - ideal for drugs exhibiting poor solubility. 
Eurand business strategy is focused on the co-development of partnered products and the out-
licensing of Eurand’s products worldwide, and they already established partnerships and 
collaborations with pharmaceutical companies such as Novartis, Bayer, Roche, among others 
(Eurand, 2010). 
Through official documents of the company, and also according with the opinion of their partners 
/ clientsn it is clear that the bet of this company, in order to position their drug delivery products, 
is made using the innovation introduced on the final and improved quality characteristics.  
However, Eurand product portfolio is focused primarily on the therapeutic category of 
gastrointestinal disorders (GI) and cystic fibrosis (therapeutic areas that are not included in LIFE 
DELIVERY first target market).  
 
Novosom AG, recently (July 27th, 2010) sold its SMARTICLES® technology (drug delivery) to Marina 
Biotech, Inc.  
Marina Biotech is a biotechnology company focused on the development and commercialization 
of therapeutic products based on RNA interference (RNAi). Marina Biotech is building multiple 
cutting-edge drug discovery and development platforms based on the premise that no single RNAi 
technology or delivery approach can be broadly applied to the treatment of all human diseases.  
Since the acquisition of this drug delivery is very recent, Marina Biotech has not yet made an 
effective entry to the market with SMARTICLES.  However, two of their six collaborations have 
been disclosed (with AstraZeneca and Pfizer), and three effective license agreements with 
Hoffmann-La Roche Ltd, Novartis Institutes for BioMedical Research, Inc and ViThera 
Laboratories, LLC, in order to, respectively, develop and market, their RNAi based technologies. 
Due to the recent enter in the drug delivery market; this company doesn’t have for now a defined 
image to their collaborators. However, and according to the available public information about 
this company and according to the testimony of one of his partner / client (Appendix 1), the main 
positioning factors of this company are the innovation of the final product and the quality of the 
drug delivery system. However, the image that clients have relatively to factors such as 
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Organizational image, R&D staff prestige, or drug delivery solutions that serves to different 
applications are lower comparatively to Eurand. 
The positioning of these two competitors is shown in Figure 8.8. 
 
 
Figure 0.8 - Positioning factors of Main competitors 
Note: since the product sales are in the form of licensing agreements and the details of this deal 
are not public, it was not possible to determine the placement criteria for the price. 
LIFE DELIVERY positioning 
Taking into account the relevance of each positioning factor and the competitor’s positioning, as 
well as, the company features, LIFE DELIVERY should be perceived by customers as an innovative 
biotechnology company with unique and high quality products.  
Since the product quality is one required factor, the company must first of all, guarantee the 
perception of higher innovation introduced to the final product. 
Second, is very important to build an organizational image of trust, credibility and 
professionalism, transmit one image associated to a quality scientific staff and management 
board. 
Finally, the price is the less important positioning factor that must be considered and transmitted 
to create the clients perception. This assumption is also reinforced by the licenses specificity 
profile and process, explained in detail at section 9.2. 
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Figure 0.9 - Comparison of LIFE DELIVERY’s positioning factors and their competitors 
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9 Marketing Mix 
 
Marketing mix usually refers to the determination of four important characteristic of the business 
- Product, Price, Distribution and Marketing Communications. For commercialization of DELIVES, 
and according to the business model, that only covers one first collaborative research and a final 
license, the distribution was not covered in this specific marketing plan, since DELIVES is not a 
final product.  
 
9.1 Product 
 
Quality  
DELIVES fits the change in adopted Pharmaceutical and Biopharmaceutical industry business 
models, creating a target drug delivery system appropriate for each kind of need and therapeutic 
area. 
In order to attend the final customers aspirations, the R&D partnership between LIFE DELIVERY 
and their client, pretends to achieve an easy-to-use with favourable side effects drug.  
DELIVES is made using one very popular vehicle material (gelatine), and all the materials used are 
already approved by regulatory entities in other products for medical use. These facts give a 
quality stamp to DELIVES. 
 
 
Features and benefits 
DELIVES is made using a new biomaterial (Ion Jelly) that allows the administration and the target 
of medicines. Gelatine - one of the main components of this new biomaterial - is already widely 
used and approved as component of medicines. The other main component – the ionic liquid – 
will stabilise the API, allowing its transport through the body. Finally, the surface modifications 
will direct the medicine to the specific target in the body. 
 
Customers buy a product not only for the features - specific attributes that contribute to 
functionality - but also for the benefits - the need-satisfaction outcomes they want or expect. 
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The core benefits are the reduced development time reflected in a quick market entry and the 
lower risk compared to other available strategies. However the main benefits of this product 
relatively to competitor products is the large possibility of applications that this product allows 
(versatility), being possible to reformulate different company’s drugs, through the 
accomplishment of only one partnership with LIFE DELIVERY. Otherwise this product is the only 
one in the market that addresses the environmental concerns that are increasing inside the 
pharmaceutical and biotechnology industry. 
 
Brand   
Company brand 
The name LIFE DELIVERY transmits the essential message to reach a company in the healthcare 
industry and could be recognized and associated to the concept of drug delivery systems 
(association of company’s image with the product). 
 
Product brand 
To build research, development, marketing and sales partnerships in order to fit DELIVES with 
clients product specifications or put the product into the market, it’s essential to build a 
recognized and trusted R&D image related to the scientific staff and organizational image. 
Therefore, it is important that LIFE DELIVERY will be created as a Universidade Nova de Lisboa 
spin-off. This choice will enhance the credibility and trust of a new company and a new product, 
like these. 
 
 
 
9.2 Pricing 
 
As already mentioned, LIFE DELIVERY will be the owner, or in a first stage the licensee of “Ion 
Jelly” technology, that servers different applications. Currently, there is a research ongoing, in 
order to develop one of these possible applications. For now it is not possible to determine if the 
results of these new developments will have enough matter to be subject of a new patent 
application.  
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When the intellectual property is the central asset, a company can profitably exploit these rights 
in several ways (Megantz, 2002), presented below and ordered by degree of risk and potential of 
reward. 
 Selling the intellectual property rights to a third party; 
 Forming a strategic alliance; 
 Licensing; 
 Establishing a joint venture; 
 Buying an existing company with the required assets; 
 Initiating a new venture to develop, manufacture, and sell products. 
Attending to the characteristics of DELIVES and the market in which operates, the best option to 
commercialization through licensing the technology, making the Industrial Property the central 
asset of this company. In the case of there is not sufficient material to submit a new patent to 
DELIVES, LIFE DELIVERY will license exclusively, the patent of Ion Jelly for application to drug 
delivery systems. In the case of a new patent submission, LIFE DELIVERY will license directly the 
patent that refers to the product DELIVES and not the base technology. 
This strategy follows the trend of the healthcare companies, both large and small, where the 
patents are the most important intellectual property for creating competitive advantages, and 
even the perception of these companies about the most significant goals associated with licensing 
intellectual property into their organizations are compensating for lack of research and 
development and options for future development (Parr, 2006). Using this strategy much of the 
risk is transferred to the licensee, who is responsible for developing, manufacturing and 
marketing the licensed products (Megantz R., 2002). 
Before the license agreement, it will precede a collaborative research agreement supported by 
the client in order to fit the product – DELIVES, to the specifications of the client medicines 
pipeline. 
There are many considerations and options that should me made in the process of drawing and 
defining the strategy and process of licensing. First of all, it is very useful, valuate the technology.  
Beyond reasons such as mergers & acquisitions or strategic planning, this valuation is also 
important to define the strategy of licensing and to define the parameters of license negotiations.  
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After that, it is important to define some licensee variables, such as the Scope of Exclusivity 
(exclusivity versus non-exclusivity), Duration of the Protection, value of Licensee Fee, the rate of 
Royalties29 and the Monitoring of License Agreement. 
Technology Valuation 
The valuation of DELIVES technology should be made to different field of therapeutic applications 
and using the Relief from Royalty Valuation Method. To implement this method, there are eight 
important inputs to be determined (the first five are related to all sorts of technologies, while the 
last three are required additional factors used to value cases of early-stage technologies): 
_ Remaining life of the patent protection – This variable will change depending on the date of 
licensee agreement. 
_ Forecast revenues – This variable will be estimate according to the Licensee’s specific product 
and respective market. 
_ Royalty Rate – It is estimated as the rate at which the owner would have had to pay to license 
the patent rights had it not owned them (Parr, 2006). In this case, the royalty is not available 
because the patent has not been licensed yet. As a result a proxy royalty rate must be developed. 
A proxy is often obtained from market data reporting the royalty rate at which similar patent 
rights have been licensed between independent third parties or using the Profit split rule of 
Thumbs or Profit Differential Calculation (Parr, 2006). 
The highest rates of royalties are associated with pharmaceuticals, due to the high profit margins 
that many medical therapies can command and vary between 2 to 10%.  
_ Tax Rate – This input converts the royalty savings into an after tax cash flow, which is converted 
into a patent value (Parr, 2006). 
_ Discount Rate – represent the risk associated with obtaining the forecasted income.  
The Discount Rate referred before, should impact more that the general business risk and must 
also reflect the time and money and time spent on development efforts, represented as 
                                            
29
 Royalty definition is a fee paid for use of Licensed IP, usually a specified sum or percentage for each 
licensed unit sold. Some  approaches used to determine (or aid to determining) royalties are discounted 
cash flows analysis, regular and established royaty, return on investment analysis and twenty-five percent 
of profits. The royalty rate is a percentage that is multiplied by a royalty base (the unit sales of wich a 
percentage of royalty is applied) to determine a royalty, or some other (e.g, fixed) rate (Megantz, R., 2002). 
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development costs and revenue timing respectively. This rate should finally account the non-
acceptance of the technology by the market. 
_ Development costs – Until this moment the research project was funded with 175 thousand 
euros in order to develop a first drug delivery system till 2013. The previsions estimate further 
additional costs of 225 thousand euros in order to develop different delivery routes and different 
modifications to target specific “problems”.  
_ Revenue timing – According to the CRO Pedro Vidinha the predicted time to ensure the 
collaborative research and put the product in the market is three years.  This means that during 
the first three years of ownership cash flows are negative. During this time funds are expended to 
prove and develop the technology for commercialization. 
_ Development risk – even if the technology is successfully developed the market may not accept 
the technology. Once the pharmaceutical product, where this technology will be implemented, is 
already accepted and successful on the market, this risk represents only the value perceived by 
the final clients (the patients), related to the quality and safety improvements made on the final 
product. 
When it comes time to consider the price to pay for a license, comparable licenses are important 
factor to consider. In order to check the DD technology’s commercialization deals made during 
2009, please consult Appendix 20. 
 
Scope of Exclusivity 
In terms of scope of exclusivity, there are two types of licensing strategy, including the exclusive 
and non-exclusive approach. The exclusive approach over valuates the technology and is 
extremely important to licensees that could take competitive market advantages from this. 
 
License Fee 
The up-front license fee is meant to cover the licensor costs for transferring the patent and 
technical kow-how to the licensee and will be paid immediately on signing a license agreement. 
This license fee will be estimated by the costs of the development collaboration made between 
LIFE DELIEVRY and the Pharmaceutical Company, in order to fit the product to specifications of a 
specific client product. 
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Royalties 
The other part of revenues obtained from license a technology is obtained in form of running 
royalties. The royalty arrangement will be based on a percentage of sales. 
To define the royalty rates of DELIVES to a specific therapeutic area, the following impacting 
factors should be addressed: 
 Scope of exclusivity, Comparable License Rates and Duration of protection, already 
mentioned above.  
 Licensee anticipated profits – this could be estimated using the anterior sales of the 
product that will be enhanced using DELIVES technology. 
 Utility over old modes, which means that licensing executives will pay more for significant 
enhancements over other technologies of minor enhancements. 
 Commercial Success – this variable will have greater weight as the number of agreements 
to license increase. 
Attending to all the factors explaining above and according with some technology transfer 
experts, in this specific case, the better approach to future royalty calculations, will be the 
Twenty-five percent rule. This rule is by definition an approach used in determining an 
appropriate royalty rate, by estimating a royalty rate that would be twenty-five percent of the 
Licensee’s profits for the Licensed Product (Megantz R., 2002). 
 
Monitoring of License Agreement  
Is very important to not ignore the monitoring of license agreement that should be included in the 
license agreement, as well the future expenses made with Royalty audits that refer to an analysis 
of information to determine whether a licensee is performing in accordance with a license 
agreement. 
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Conclusion 
According to ABG Patents Madrid - a Spanish consulting firm of Intellectual Property - a small 
company that intends to license a drug delivery (DD) system should apply a strategy comprising 
finding different licensees willing to develop the DD system for different non-competing products, 
benefit from the opportunity for several royalty steams licensing the DD system to drug products 
already on the market to avoid double risk and keep improving IP position. 
According to the valuation at a specific moment in time, the terms of the license agreement 
should include an initial license fee and the payment of royalties based on product sales and a 
certain minimum commitments by licensee for commercialization expenditures during the first 
four years of the product launch. The agreement should also include three staged clinical and 
regulatory progress milestones payments, subject to LIFE DELIVERY’s achievement of 
contractually specified conditions. 
 
 
“We believe current market environment is favorable for small biotech companies in terms of 
out-licensing to and partnering with big pharma/biotech companies. This strategy will greatly 
reduce the risks associated with drug development and help to build shareholder value rapidly.” 
Grant Zeng, CFA, Bio-Path Holdings, Inc30 
 
 
 
 
 
 
                                            
30
 Bio-Path Holdings, Inc. is a development stage biotech company. The Company was founded with 
technology from The University of Texas, MD Anderson Cancer Center dedicated to developing novel cancer 
drugs under an exclusive license arrangement. Since its inception, the Company has acquired three 
exclusive licenses from MD Anderson Cancer Center for three lead products and related nucleic acid drug 
delivery technology, including tumor targeting technology. 
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9.3 Marketing Communications 
 
In order to better introduce DELIVES in the market, LIFE DELIVERY will adopt an Integrated Market 
Communications (IMC) approach, designed specifically to attend the characteristics of the 
product, the market, the target audience and the company communication objectives (Wood, 
2008). To further details about marketing communications timeline, please consult the section 
“10.2 - Minute”. 
 
Communication objectives 
First of all LIFE DELIVERY intends to create awareness of the product and its capacity to meet the 
customer’s needs. In second place, the company wishes to instigate brand building by enhancing 
LIFE DELIVERY technologies and use the Ion Jelly brand as a new material with a considerable 
perceived value to the customers. 
Considering the product characteristics and the market where LIFE DELIVERY will operate, is 
crucial to build an image of credibility.  
 Following this, the company proposes to achieve the following goals:  
. Create DELIVES awareness, which means, sign a collaborative research (with pa preferable 
option for acquisition through license, at the final of the research) with a pharmaceutical 
company in the final of the first year; 
. Create LIFE DELIVERY awareness, using the image of scientific staff and the Platform Technology; 
. Build DELIVES brand, enforcing the factors of quality and safety and using their major benefits 
and competitive advantages offered to the clients. 
 . Reach 45% of the initial targeted clients in the first year which means the scheduling of 10 
meetings. 
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Target audience 
The target audience will comprise all the targeted companies referred in the conclusion of section 
8.2, prioritizing segment of E.U large pharmaceutical companies focused on Cardiovascular and 
Inflammation therapeutic areas.  
Efforts should be focused on the purchasing decision makers, who have the ultimate authority to 
choose between the different options to deal with a patent expiration, different suppliers and 
deal with the formalities of the trade. 
IMC Tools: 
LIFE DELIVERY will invest greatly in Advertising and Personal selling (two of the five major IMC 
tools). In a later stage, the company, will use Direct marketing tools, as well as internet 
communications and public relations in order to create a greater proximity with licensee’s and 
potential clients. 
 Advertising (see also Appendix 21) 
Used in the first stage of product life cycle, in order to inform, the advertising tool will address the 
specific communication goals of creating product and company awareness. The advertising it will 
be made in the following media:  
→ European Journal of Pharmaceutical Sciences - is the official journal of the European Federation 
for Pharmaceutical Sciences (EUFEPS). The journal publishes research reports, review articles and 
scientific commentaries on all aspects of the pharmaceutical sciences with strong emphasis on 
originality and scientific quality. The Editors welcome articles in this multidisciplinary field, ranging 
from drug discovery, over drug delivery to drug development.  
The European Journal of Pharmaceutical Sciences is a free channel to publicity the product and a 
relevant one, according to their impact factor of 2.60831.  
                                            
31
 The impact factor is a measure of the frequency with which the average article in a journal has been cited 
in a particular year or period. It is one of the evaluation tools provided by Thomson Reuters Journal Citation 
Reports® (JCR®). 
 
The annual Journal Citation Reports impact factor is a ratio between citations and recent citable items 
published: a journal's impact factor is calculated by dividing the number of current year citations to the 
source items published in that journal during the previous two years ([online] Thomson Reuters). 
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Beyond this, the importance of this journal is related to the impact of scientist in the build of 
thrust and promotion of license agreements with pharmaceutical companies. According to a study 
made by National Institutes of Health (NIH) Office of Technology Transfer (OTT) that analyse the 
origins of 281 licence agreements completed by NIH between 2001 and 2004, where the results 
shows that inventor contact constituted approximately 38 per cent of the leads, followed by 
marketing (technology transfer employees efforts and the OTT website) 34 per cent and public 
information 28 per cent. When analysing licensing leads that were acquired because of access to 
public information, it was found that “inventor publications (58 per cent) was the most important 
factor that led to license inquiries” and also that the role of the inventor is more effective to 
larger business because of their greater ability to deploy more resources to technology scouting 
and therefore may rely more on other sources of information such as publications, inventor 
presentations and personal contact between scientists and inventors (Ramakrishnan, V., 2005).  
In this specific case, the strategy is the publication of a paper in this journal. 
 
→ Drug Delivery Technology  - is a print and digital publication exclusively committed to advancing 
the applied science, technology, and related business practices of pharmaceutical and biological 
drug development, including for example Drug delivery technologies, Business development, Life-
cycle management, Pipeline/portfolio management. This publication provides pharmaceutical 
professionals with practical solutions to the unique issues, opportunities, and challenges in this 
ever-evolving industry. This website has 10,998 monthly visits from 110 countries including US, 
Europe, United Kingdom, Canada, India, Japan, China, Israel, Indonesia, Australia, South Korea, 
and Singapore ([online] Drug Delivery Tech). 
 
The last data of 2009, indicate that 61.4% of the subscribers are Pharmaceutical / Biotechnology / 
Drug Delivery Companies and their job function are predominantly Pharmaceutical R&D - Drug 
Delivery Scientists - Pre-formulation, Formulation Development, Stability Testing (43.4%) and 
Business Development - Licensing, Technology Assessment, Product Life-cycle Management 
(16.2%). 
 
The advertisement on this channel it will be made by the News Letter - Drug Delivery Weekly, 
reaching 12,000 subscribers with the banner surrounded by the latest news of business deals, 
alliances, and technology breakthroughs.   
Beyond the recognized reputation of this channel by pharmaceutical industry, this advertisement 
option carries another free added value services. 
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Doing this advertise, LIFE DELIVERY will earn: 
o FREE Technology Showcase: All advertisers earn a free 1/4 page, 4-color Technology 
Showcase (120-word write-up & photo) in the same or subsequent issue(s). 
o FREE Electronic Edition: Advertisements & Technology Showcases appear for FREE in the 
electronic edition with links to your website. 
o FREE Company Profile: All full-page advertisers in the Annual Resource Directory and 
Company Profile issue in November receive a FREE – 1-Page, 4-color Company Profile. 
o FREE Listings in Annual Resource Directory: Listings in the Annual Resource Directory are 
free and available to all companies providing technologies, products, and services for: 
Drug Delivery, Specialty Pharma, Contract Services, Manufacturing and Laboratory 
Equipment. 
→ European Pharmaceutical Review magazine - Covering new technologies and developments 
within the pharmaceutical industry, European Pharmaceutical Review is the leading bi-monthly 
publication and essential reading for anyone involved in the pharmaceutical business. 
Typical readers of the magazine include Managing Directors, Procurement Directors, Heads of 
R&D, Senior Scientists, Laboratory Managers, Process Engineers, Chief Engineers, Production 
Directors, Plant Managers, Product Managers, Quality Assurance Managers and Quality Control 
Managers. 
According to ABC (an independent audit watchdog service for printed publications 
www.abc.org.uk), the European Pharmaceutical Review magazine has a geographical breakdown 
that impacts mostly on United Kingdom (25%), Germany (12%), France (9%) and Italy (8%). The 
Job function breakdown indicates that 24% of readers are related with Production / 
Manufacturing, 21% are CEO /Management Directors and 20% to R&D /Product Development. 
The importance of this communication channel is the distribution of this magazine per 11,494 
senior managers and key decision-makers in the pharmaceutical, life sciences and drug discovery 
industries predominantly across Europe. The strategy designed is to make an Online & digital 
advertising that will target 8,800 dedicated readers through email newsletter bi-weekly and the 
magazine offer the possibility to target a specific segment of their subscriber list. 
 
Due to the widespread utilization of this Magazine’s website by the pharmaceutical decision 
makers and other players in this area (such as potential partners), in this case the advertising 
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strategy it will be based on a website banner advertising during three months (in different periods 
of one month each). 
→ Finally, being a member of Europabio32 (the European Association for Bioindustries) and GIRP33.  
 
 Personal selling 
In a second stage of the product life cycle and in order to efectivate the proximity between the 
company and potential clients, LIFE DELIVERY will use the personal selling tool. Each therapeutic 
area of interest to license DELIVES, has limited potential customers and this fact enables the 
direct contact of companies by a sales representative. This customized tool and the sales reps are 
essential to explain the product features and benefits, recommend solutions, answer questions, 
but also to receive feedback of selected audience allowing to understanding the customer’s needs 
and build a trust and strengthening relationship. 
The process to be adopted will focus on scheduling meetings with the potential clients to present 
the technology and give some examples of improvements made in other already tested 
medicines. The conduction of approach to potential interested in licensing will be made using an 
information package (consult Appendix 23). 
The activities of promotion and technological marketing need to be appropriately accomplished 
by legal issues, in order to secure the safety publicized and exchange of information. Thereby, was 
prepared a Non disclosure agreement (NDA) template, aimed to regulate the exchange of 
information (see Appendix 24). 
 
                                            
32
 EuropaBio is the European Association for Bioindustries and was created in 1996 to provide a voice for 
the biotech industry at the EU level. EuropaBio's mission is to promote an innovative and dynamic 
biotechnology-based industry in Europe.  
 
33
 GIRP is the umbrella organisation of pharmaceutical full-line wholesalers in Europe. It represents the 
national associations of over 600 pharmaceutical full-line wholesalers serving 31 European countries, 
including major pan - European pharmaceutical full-line wholesaling companies. Trough their network of 
operational facilities they distribute over 100 billion euros worth of medicines every year. In the 
performance of their public service role they absolutely guarantee the highest levels of quality, integrity 
and excellence. GIRP members are the trusted supply chain partners of manufacturers, pharmacists, 
healthcare professionals and above all patients for medicines safety. 
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 Direct Marketing 
In a maturity stage it will be important to use the tool of Direct marketing, in order to strengthen 
the relationship with licensees and potential licensees and remind them the latest discoveries, 
products or product enhancements derived from the technology platform (Ion Jelly). This 
communications will be made using direct mail to the customers and potential customers 
database builded by the company.  
 
 Internet Communications  
The corporate website will reinforce the credibility of the company, creating a section in which 
each partner access the last information and results about the development research made on 
the first part of license agreement. This tool will give useful clients feedback in order to target 
their specific needs and share value informations about the market and final consumer’s needs. 
 
 Public Relations 
In order to publicize the product and company inside the circuit of customers, it is important to 
make public relations in some important events and conferences. To consult the list of 
conferences and events, see Appendix 24. The presence in the conferences it will be made using a 
stand to publicize the company and the main products developed. 
From the conferences list presented in Appendix 24 will be chosen three of four per year, based 
on the presence of potential customers and / or partners. 
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10 Implementation and Control Plan  
 
10.1 Man 
 
Nowadays, and as referred above, during the period that preceedes LIFE DELIVERY creation, the 
first commercialization efforts will be managed by the Technology Transfer office of FCT/UNL, 
with the intervention of Pedro Vidinha, the principal investigator and future Chief Research and 
Strategy Officer (CRO) of LIFE DELIVERY. 
After the conclusion of the first part of DELIVES research, LIFE DELIVERY´s implementation and 
control will be managed by LIFE DELIVERY´s leader (Pedro Vidinha) and the commercial director 
(that will be hired). To further details about research activities and company implementation 
timeline, please consult the section “10.2 - Minute”. 
A report will be held every four months (in a startup it is necessary to frequently updating, 
reporting more regularly, and this time could be expanded as the business grows to consider the 
most important achievements, as well as, the failures (Kawasaky, G.; 2004). This analysis will keep 
up-to-date information on new needs and, therefore, new actions to take further. 
This part of the implementation plan is divided in Organization and Talent & Staff Required. 
Organization 
Preceding the launch of DELIVES, LIFE DELIVERY needs to build a certain amount of legitimacy to 
secure the necessary resources. This is based on legal terms, localization and industry interaction 
(Dorf, 2008). 
First, LIFE DELIVERY must start by its incorporation and legalization as Universidade Nova de 
Lisboa spin-off, and the assurance of its patents, signing with UNL and Instituto Superior Técnico 
(IST) – the patent owners; an exclusive License agreement to the Ion Jelly Patent (see Appendix 
19). In the License Agreement the Licensors give rights to the use and exploitation of Ion Jelly 
technology, in return of the Industrial Property costs supported by the two owner institutions till 
the moment of the agreement and also an accorded percentage of royalties. The payments will 
only be made when LIFE DELIVERY starts the effective commercialization. 
 - 68 - 
Regarding to location, should be taking into account three major factors: customers and 
employees’ location, advantages of being located in a cluster (knowledge-based business) and its 
costs (Dorf, 2008).  
The core company’s work lies on the development and optimization of the Drug delivery in 
accordance with the instructions and customer needs and product. Thus, the location of 
Researchers and technical staff in the different areas involved in the development of DELIVES 
(that are located at Portugal) are a key point to make this decision. Furthermore it is also 
important to have mobility of sales people across the EU Countries (mainly from countries where 
the largest number of potential customers is, such as: United Kingdom, Switzerland, Germany, 
Italy and France; and finally the establishment of a close relationship with European Medicines 
Agency (EMEA), located at United Kingdom (see also Appendix 25). 
Following this, LIFE DELIVERY will be located at “Parque Científico de Madrid (PCM)” – the Science 
Park of Madrid, a Spanish incubator. This choice is based on the prestige of the incubator, its 
proximity and established contacts with LIFE DELIVERY’s potential clients and also with the 
proximity origin of LIFE DELIVERY research team. 
This location offers to the company great advantages like the credibility of the incubator name, 
relative low prices, legal and technology transfer advice and financial services (consult a list of all 
advantages in Appendix 26). 
Finally, the industry interaction is based on partnerships and memberships with associations and 
foundations like Europabio. 
 
Talent and Staff required 
For the first three years of implementation, LIFE DELIVERY will have three technical people 
(divided by three expertise fields - biocompatible ionic liquids and encapsulation of API´s, Surface 
modifications to target the drug delivery and cellular release and interactions) in Spain, one Chief 
Research and Strategy Officer (CRO), one commercial director, one salespeople and one 
administrative assistant.  This team will be managed by a LIFE DELIVERY leader based in Madrid, 
that will be the CRO that initially also accumulate the function of company CEO.  
The CRO will be based in Madrid and will be the LIFE DELIVERY leader in Spain it will be one of the 
technology inventors with expertise in biocompatible ionic liquids and the encapsulation of API’s. 
 - 69 - 
The Commercial director will be based in Madrid and will be LIFE DELIVERY’s leader in Spain and 
attending to the profile of one initial company, will also accumulate the role of LIFE DELIVERY’s 
CEO. 
There will be 1 salespeople based in Germany. The number of salespeople is defined through 
objective-task approach, that is, number and geographic concentration of potential clients, and 
number of potential meetings by week (Assael, 1990). Both will report directly to the commercial 
director. The administrative assistant will also be based in Madrid and she / he will report directly 
to the commercial director too.  
The technical staff will be selected and managed by the CRO, being mandatory to fulfill specific 
requisites such as scientific background in the relevant areas mentioned above. 
Attending to the already established contacts and experience with the industry and also according 
with the inventor status of Pedro Vidinha the commercial director recruitment and selection will 
be led by the CRO.  
The sales people recruitment and selection will be led by “EUPI Consultores”; a Human Resources 
company specialized in commercial departments. For the selected candidates it is mandatory to 
have experience on similar functions in the Pharmaceutical Industry and have good knowledge of 
English. Moreover, a pharmaceutical / biotechnology / chemistry background is also mandatory to 
salespeople (Lidstone and MacLennan, 1999). 
The administrative assistant recruitment and selection will be made directly by the commercial 
director. 
In the near future, the company will need to outsource the services of an Intellectual Property 
strategist. 
It is extremely important not to forget the Advisory Board constitution, which should focus on 
three main areas: contract management, patents and research, and should be constituted by an 
international profile, with pharmaceutical industry connections. Among other contributions, this 
advisory board will be essential in order to anticipate trends.  
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10.2 Minute 
 
As was referred before, this marketing plan refers to an early-stage under-development 
technology and the expected time to the conclusion of the research is two years (final of 2012). 
Therefore, we presented here, the activities timeline before and after LIFE DELIVERY formation. 
The forecasted time duration of each activity was discussed with the principal investigator and 
future CRO (Pedro Vidinha) and with the Technology Transfer Advisor of Universidade Nova de 
Lisboa (Dina Chaves). 
 
Figure 10.1 - Schedule of activities previous company formation
34
 
 
Note: During these two years TTO will also promote efforts in order to contact the industry. 
                                            
34
 To the date, the research team, designed biocompatible ionic liquids and Ionic Liquids-API (that are at this 
moment, generating one provisional patent application). 
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Figure 10.2 - Schedule of activities during and after company formation 
 
 
 
10.3 Money 
The presented marketing plan was made to five years. However, it is important to notice that the 
constitution of the company is planned to be made only in 2013, i.e. in the beginning of the third 
year.  Until this moment, the research will continue to take place in the University, and funded by 
the Portuguese Science and Technology Foundation (fund already assigned). This means that the 
majority of the marketing actions planed in this document and the company costs are forecasting 
for three years, starting from 2013. 
 
This kind of financial projections are only projections and shouldn’t be assumed as “universal 
truths” / facts, during the implementation of this plan. Mainly the sales but even the costs could 
not be, at this moment, precisely estimated. This section of the marketing plan should be flexible 
and revised semi-annually. 
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In order to implement and control the marketing plan, LIFE DELIVERY will use an objective and 
task budgeting method, a floor-up option (budgets originate in the marketing department and 
move upward for review), that allocates marketing funding according to the cost of the tasks to 
be accomplished in achieving marketing plan objectives (Wood, 2008).  
 
Regarding this, several costs were taken into account, such as: promotional costs (advertising, 
conferences and events travels and promotional material, associations’ membership fees, 
corporate website construction and management); the facilities costs, human resources cost, 
commercial costs (business travels, communications, among others) as well as raw materials and 
technical equipment and analysis costs. 
 
Promotional costs 
o Advertising 
Table 10.1 - Advertising estimated costs. Cost sources: [online] Drug delivery tech and [online] 
Pharmaceutical Business Review 
Advertising 
channel 
Type of advertise Price (month) (€) Time (months) Total cost(€) 
European 
Pharmaceutical 
Review magazine 
Button 120x120 
pixels 15 KB Flash 
SWF 
235,85 3 707,55 
Drug Delivery 
Technology 
Website banner 
advertising  
(home page 
banner in the 
center with 100 x 
300 pixels) 
751,17 1 751,17 
Note: 1€ = 0,848 £ and 1€ = 1,3246 $ exchange rates of 3 December of 2010. Source: 
[online] Banco de Portugal. 
 
o Website creation and management  
The company´s website it will be an important tool, once it will serve as connection and 
monitoring platform during the collaborative research agreement. In order to have a proposal 
for the website creation and management was contacted an Information Technology UNL 
spin-off (Javali), that presented the tender attached in Appendix 27 with a cost of 3.400,00 €. 
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o Travels  
The importance of the travels are related with the conferences presence and meeting with the 
potential clients. These costs forecast were made based on the medium prices of flight travels to 
the main localizations of potential clients and also the conferences location. 
The main locations to the travels are Paris, Berlin and London and the average travel costs are 
presented in the table bellow. 
 
Table 10.2 - Annual travels estimated costs. Average prices source: [online] Momondo 
Departure Destination Average price (€) 
Annual Estimated 
frequency 
Total cost (€) 
Madrid Paris 97 2 194 
Madrid Berlin 134 2 268 
Madrid London 100 2 200 
Annual estimated total cost 662 
 
According to the expected commercialization of the technology at the end of the first year of 
company life (2013), the travels costs during the second and third year it will be lower than those 
described above. 
 
o Communications  
In order to estimate the communications costs was made a research of Spanish 
teclecomunications companys and their services and respective tariffs. 
The better option found was form Vodafone España and their companys plan with a monthly fee 
of 39,90 €, that includes daytime nacional calls  and with international calls costs of 0,49 € 
(connection stablishment) + 0,45 € /min. 
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Table 10.3 - Monthly estimated communications costs 
Monthly fee (€) 
Monthly International 
calls 
Average minutes per 
call 
Total cost / month (€) 
39,90 6 5 56,34 
 
According to the expected commercialization of the technology at the end of the first year of 
company life (2013), the communication costs during the second and third year it will be lower 
than those described above. 
 
Facilities costs 
Laboratory and office rent at Parque Científico de Madrid (Bioincubator I) 
Table 10.4 - Facilities costs 
Price (€ / m2 / month) Area35 Tax Rent / month (€) 
36 without tax 40 m2 18% 1.699,20 
Source: Cátia Rabaça (PCM Business Development Unit) 
This rent price, include: 
 Electricity  - 8 A;  
 Water - 1 m3 / month; 
 Distilled water – 20 L /day 
 Special gases: 
o N2 (99%) – 9,41 m3/ month 
o CO2 (99,98%) – 5 m3/ month 
o He (99,99%) – 9,10 m3/ month 
 Waste management – 428,57 Kg / month 
 In addition to general services mentioned in appendix 23, the rent of bioincubator I, also 
includes: 
o Free access  to electronic scientific magazines and specialized press 
o Access to shared infrastructures and equipment 
o Cleaning and sterilization of glass material 
o Maintenance of the Culture room 
o Share use of glass material 
o Cryoprotection sample service 
o Supply and delivery of carbonic snow 
                                            
35
 This area was estimated based on the actual area of the research laboratory and respective offices. 
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Human Resources costs 
Table 10.5 - Estimated human resources costs. These data were based on Michael Page Helthcare salary 
studies (Michael Page Healthcare, 2010). 
Job Cost (€) / year Number of positions Total (€) / year 
CRO 45.000 1 45.000 
Technical staff 20.800 3 62.400 
Commercial Director 40.000 1 40.000 
Sales Person 35.000 1 35.000 
Administrative Assistant 15.600 1 15.600 
 
Materials and Analytic analysis costs 
According with Pedro Vidinha and costs of investigation which is ongoing, the next table present 
the estimated cost to materials and analytic analysis. 
Table 10.6 - Estimated Materials and Analytic costs 
Analyis /Raw materials Cost (€) / year Obs. 
Analytical analysis 1.800  
200L of Ionic liquids 60.000 1L = 300€ (average 
price) 
1 ton of Gelatine 1.000  
Functionalization 
materials 
5.000  
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Ion Jelly License costs36 
These costs will be paid at the beginning of commercialization. 
 
 Ion Jelly patent costs 
Description Legal Office Value (€) 
European Patent request J. Pereira da Cruz, S.A. 
 
6189,77 
National phase of Patent in 
South Korea 
J. Pereira da Cruz, S.A. 
 
3282 
National phase of Patent in 
South Korea 
J. Pereira da Cruz, S.A. 
 
3282 
National phase of Patent in 
U.S.A. 
J. Pereira da Cruz, S.A. 
 
1500 
Related to annual taxes of 
national , European and 
national phases of the patents, 
and preparation of answers to 
notifications 
Garrigues 25.000 
TOTAL 39253,77 
 
 A percentage of royalties to be defined should be paid to the patent owners at the time of 
commercialization. 
 
                                            
36
 - This costs were supported by the owners of the patents (UNL and IST), divided in different percentages 
of 40% for Instituto Superior Técnico and 60% for Universidade Nova de Lisboa. This division of joint actions 
and exploration of the patent was made using an agreement between the institutions celebrated at August 
of 2007. 
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Summary  
Table 10.7 - Total estimated costs 
 2013 2014 2015 
Intellectual Property  
Ion Jelly patent costs - - 39.253,7737 
Facilities costs  
Office rent 20.390,40 20.390,40 20.390,40 
Office supplies 550,00 550,00 550,00 
SUB -TOTAL 20.940,40 20.940,40 20.940,40 
Promotion costs  
Advertising - 707,55 751,17 
Website creation 3.400,00 - - 
SUB -TOTAL 3.400,00 707,55 751,17 
Commercial costs  
Business travels 662 331 331 
Communications 676,08 338,04 338,04 
SUB -TOTAL 1.338,08 669,04 669,04 
Human resources 
costs 
 
CRO 45.000 45.000 45.000 
Commercial Director 40.000 40.000 40.000 
Sales Person 35.000 35.000 35.000 
Administrative 
Assistant 
15.600 15.600 15.600 
Technical staff 62.400 62.400 62.400 
SUB -TOTAL 198.000,00 198.000,00 198.000,00 
Raw Materials and 
Equipments 
 
Analytic analysis 1.800 1.800 1.800 
Ionic  liquids + 
gelatine + 
functionalization 
materials 
66.000 66.000 66.000 
SUB -TOTAL 67.800,00 67.800,00 67.800,00 
 
 
 
 
TOTAL 322.078,48 288.116,99 327.414,38 
                                            
37
 The Ion Jelly patent costs it will be paid in the final of third year of the company, assuming that the 
collaborative research with the client it will be finished at this date and the final product(s) will be 
commercialized by the company at this date. 
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11 Conclusions 
 
As has been discussed several times in the course of this work, the stage of technology 
development represents an enormous obstacle, to the realization of this marketing plan. 
However, like other marketing plans which envisaged the launch of technologies in a higher stage 
of development, this work must be periodically reviewed and updated. 
Either way, this work is an important and required tool as first approximation of the technology to 
the market and one essential procedure of technology transfer process.  
The usefulness of the issues raised during the market plan development, are very important not 
only for the initial work of the TTO, as also to the first steps of the startup (eg in obtaining 
financing), and even to direct the research activities. 
Through the marketing plan presented, is possible to conclude, that this technology, though still 
being too early stage, responds to a real need and has innovative features that can bring major 
benefits to competitive markets in which will enter. 
According with the competition analysis (wich has no obvious lider) and also with the disruptive 
and innovative profile of the technology, it is possible to conclude that this specific product has 
marketlace and this business represents a market opportunity. 
The conclusion of market segmentation and targeting, points to Large Pharmaceutical companies 
with Development, Production and Marketing process, as the initial target market of DELIVES. 
However, it is important to highlight, that at long-term, and according with the ownership of the 
technology platform, it will be possible to enter in different markets (such as the biotechnology 
companies more focused to medicines with large compounds and consequently with higher 
complexity deliver process). 
In order to reach this target market it will be necessary to assume a positioning that differentiate 
LIFE DELIVERY and DELIVES from de competition, that will be based on the versatility of the 
product. Nevertheless, in this market field, more than create differentiative meaning to the 
customers, is mandatory to fulfill required features as the product quality and the benefits to the 
final customers. So, LIFE DELIVERY must incorporate these mandatory criterias in the positioning 
values, although it is necessary to trasmite them as obvious to the product life. 
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If we take a deep look to the landscape of maket where DELIVES will be introduced and also to the 
future start-up conditionings, it is possible to assume licensing as the best commercialization 
option (versus patent sell and also own commercialization). The main reasons are the highest size 
and experience of clients compared wuth LIFE DELIVERY, the inability to produce and market the 
final product and also the commercial explotation possibility of different applications using the 
patented technology platform. 
As a start-up company, the risk is very high and is a challenge to attract experienced staff and 
financing to an unknown business with small initial capital. The University support in the previous 
phase of company creation it will be, with no doubts, very important to the establishment of 
proximity between LIFE DELIVERY and the industry. 
The biggest weakness of this work is connected to the impossibility of defining the expected 
return for this business. Despite being an important point, the financial provisions of a start-up 
company, are always plenty of unknowns, both to the company and even to the potential 
financiers. 
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13 Appendixes 
 
Appendix 1 – List of Contacts 
 
Date Name Company Theme 
Type of 
contact 
Obs. 
05/02/09 Íris Batalha MIT PhD student 
Drug delivery 
systems 
Conversation  
08/02/2010 
Drª Fabiana Simões 
(Clinical Trial  
coordinator) 
CEDOES – Centro 
de Densitometria 
Ossea do Espirito 
Santo 
Clinical Trials Skype  
19/02/10 
 
Drº Oliveira Costa 
 
________ 
(oncology 
physician) 
 
Oncology drugs and 
treatments 
Conversation  
09/07/2010 Drª Ana Gaspar 
PHARMaffais – 
pharmaceutical 
consulting 
Marketing 
segmentations and 
market size 
Conversation  
04/04/2005 
Drº Francisco Bernardo 
Noriega 
European Patent 
Attorney – ABG 
Patents 
Madrid 
Managing Patent 
License agreements 
Conference 
 
 
02/04/2009 Drª Cátia Rabaça 
Scientific Park of 
Madrid 
Scientific Park of 
Madrid incubation 
advantages 
Conversation  
09/12/2010 Engª Isaura Monteiro 
Portuguese 
Institute of 
Industrial Property 
Supplementary 
Protection Certificate 
(SPC) 
Telephone  
08/12/2010 
Division of Drug 
information 
Food and Drug 
Administration 
Food and Drug 
Administration 
Regulatory affairs E-mail  
13/12/2010 
Thomas Johnson 
 
Delcath Systems, 
Inc 
 
Positioning factors E-mail  
09/12/2010 
Vedin Monika 
 
Meda AB 
 
Positioning factors E-mail  
15/06/2010 Curt Stone 
Director of Quality of 
Life Technology 
Center, Carnegie 
Mellon University 
Targeting criteria 
weights 
Conversation  
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Appendix 2 – R&D cost increase for successful NME launch 
 
 
 
Figure 13.1 – R&D Cost Increse. Source: Frost & Sullivan, 2010 
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Appendix 3 – The Drug discovery process 
                     
 
 
 
 
 
 
 
 
Figure 13.2 – The R&D Process: Long, Complex, and costly. Source: PhRMA, 2009 
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Appendix 4 – Patent Loss ($ Billion) 2008-2012 
 
 
 
Figure 13.3 – Patent Loss ($ Billion). Source: Frost & Sullivan, 2010. 
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Appendix 5 – Ion Jelly publications  
 
Papers 
 Date: 30/11/2008 
Title: Ion Jelly: a tailor-made conducting material for smart electrochemical devices 
Source: Pub Med. 2008 Nov 30; (44):5842-4. 
 
 Source: Chem. Commun., 2008, Issue 44 5842-5844 
Site: http://www.rsc.org/suppdata/cc/b8/b811647d/b811647d.pdf 
Title: Ion Jelly: a tailor-made conducting material for smart electrochemical device 
 
 
International 
 Date: 18/10/2008 
Source: Thaindian News 
Title: Ion Jelly could be used for making eco-friendly batteries 
Site: http://www.thaindian.com/newsportal/india-news/ion-jelly-could-be-used-for-making-
eco-friendly-batteries_100108716.html 
 
 Date:18/10/2008 
Source: Nanotechnology now 
Title: Ion jelly could satisfy appetite for greender batteries 
Site: http://www.nanotech-now.com/news.cgi?story_id=31054 
 
 Date: 17/10/2008 
Source: New scientist 
Title: Ion jelly could satisfy appetite for greender batteries 
Site: http://www.newscientist.com/article/dn14975-ion-jelly-could-satisfy-appetite-for-
greener-batteries.html 
 
 Date: 16/07/2009 
Source: printed electronics world 
Title: New Ion jelly material for use in electrolytic devices 
Site: 
http://www.printedelectronicsworld.com/articles/new_ion_jelly_material_for_use_in_electr
olytic_devices_00001558.asp?sessionid=1 
 
 Date:17/10/2008 
Source: Cleantech 
Title: ‘Ion jelly’ for better, cheaper batteries 
Site: http://cleantech.com/news/3724/%E2%80%98ion-jelly%E2%80%99-better-cheaper-
batteries 
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National 
 Date: 11/11/2008 
Source: Expresso 
Title: Projecto portugues premiado nos E.U.A. 
Site: http://aeiou.expresso.pt/projecto-portugues-premiado-nos-eua=f450311 
 
 Date : 22/10/2008  
Source: Correio da manhã 
Title: Ciência: Portugueses descobrem novo material condutor Criada a receita da gelatina 
iónica  
Site: http://www.cmjornal.xl.pt/noticia.aspx?channelid=00000219-0000-0000-0000-
000000000219&contentid=10C75722-4B7A-40CA-B61F-9F665B9FD269 
 
Websites, newspapers and blogues 
 Date : 21/11/2008  
Site: http://diario.iol.pt/tecnologia/tecnologia-electronica-gelatina/1004508-4069.html 
Title: Portugueses descobrem gelatina que pode revolucionar a electrónica 
 
 Date: 22/11/2008 
Source: http://ciberia.aeiou.pt/?st=10399 
Title: Gelatina iónica: Portugueses descobrem novo material condutor mais barato e 
ecológico 
 
 Date: 24/10/2008 
Title: Criado o “ION JELLY” receita da gelatina iónica 
Site: http://entranaciencia.blogspot.com/2008/10/criada-receita-da-gelatina-inica.html 
 
 Date: 22/10/2008 
Site: http://cienciahoje.pt/index.php?oid=28168&op=all 
Title: Portugueses patenteiam gelatina iónica 
 
 
 Date: 22/10/2008 
Title: Gelatina iónica  
Site: http://pplware.sapo.pt/high-tech/gelatina-ionica/ 
 
 
 
 - 93 - 
Appendix 6 – Targeted drug delivery technologies and companies information  
 
 
 
Drug delivery companies 
profile38  
  
                                            
38
 All this information was based on the companies’ oficial websites, according with the reference.  
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Access Pharmaceuticals, Inc39  
 
About Access Pharmaceuticals, Inc.  
 
Access Pharmaceuticals is an emerging biopharmaceutical company specializing in products for 
cancer and supportive care. Access currently has one FDA-approved product, two products in Phase II 
clinical development, and three products in preclinical development.  
Several of the company's products are based on Access' proprietary nanopolymer  technologies 
which provide enhanced drug delivery options for both new and approved  pharmaceutical active 
ingredients.  
While its primary focus is in oncology, Access' drug delivery technologies also yield candidates that 
enable and enhance the absorption of drugs by exploiting the body's own vitamin B-12 absorption 
system.  
Mucositis is a frequent side-effect of cancer therapy for which there is no established treatment. 
MuGard™ is Access' approved proprietary nanopolymer formulation for the management of 
mucositis. This ready–to–use rinse provides a soothing oral coating. A clinical study has shown that 
when MuGard is used by patients at the start of cancer therapy, the incidence and severity of 
mucositis are reduced. MuGard is available in Europe by prescription through Access' marketing 
partner, SpePharm. Access will be marketing MuGard in the United States in 2010, and marketing 
partners in Asia are advancing Regulatory approval of MuGard in South Korea and China.  
Access is focusing its development effort on three products/technologies: ProLindac™, Thiarabine™, 
and Cobalamin™. The company's lead development candidate for the treatment of cancer is 
ProLindac™, a nanopolymer DACH platinum prodrug. ProLindac has successfully completed a 
European Phase II trial in patients with ovarian cancer, and Access and its Asian partners are planning 
to start Phase II combination studies shortly. Oxaliplatin (Eloxatin, Sanofi-Aventis) is the only DACH 
platinum currently approved; it has sales in excess of $2 billion. Aventis) is the only DACH platinum 
currently approved; it has sales in excess of $2 billion.   
Thiarabine&trade; is a Phase II nucleoside analog with considerable potential for treatment of 
lymphoma and leukemia. Extensive preclinical data shows that Thiarabine has good efficacy in a 
variety of tumor models.  
 
Cobalamin&trade; is Access' proprietary nanopolymer oral drug delivery technology. Using  a 'Trojan 
Horse' approach, the technology uses the body's natural vitamin B12 uptake  mechanism in the gut 
to transport drugs that otherwise would have little or no oral  bioavailability. The company is 
currently developing products for the oral delivery of insulin and human growth hormone (HGH), and 
is collaborating with a number of companies to develop additional formulations of various other 
pharmaceutically-active compounds.  
                                            
39 www.accesspharma.com 
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Technology  
 
Cobalamin™ -Mediated Disease Targeting  
Introduction  
In many diseases which involve cell proliferation, there is increased demand for certain vitamins or 
vitamin analogs compared with normal tissue. Access Pharmaceuticals has developed technology 
which takes advantage of this increase in demand. By coupling drugs to Cobalamin™ (an analog of 
vitamin B12 or VB12), more drug is taken up by diseased cells. This effect can be amplified by 
attaching Cobalamin™ and several molecules of the drug to a polymer, or encapsulating the drug in a 
nanoparticle coated with Cobalamin.  
Access owns several patents and patent applications which provide the company with a proprietary 
position in amplified Cobalamin™-mediated targeted delivery of drugs to diseased cells.  
 
 
 
 
There are several diseases for which this targeting approach holds promise; for example, cancer, 
rheumatoid arthritis, psoriasis, acute leukemia, lymphomas, Crohn’s disease, ulcerative colitis, and 
multiple sclerosis. Access Pharmaceuticals is developing applications of this technology in the area of 
oncology, while seeking collaborations and partnerships for development of this technology for other 
diseases.  
 
• Access has conducted studies which have provided proof-of-principle of vitamin mediated targeting 
of cancer cells as well as sites of some other diseases.  
• Efficacy of vitamin-targeted polymer conjugates was demonstrated in rodent tumor and 
rheumatoid arthritis models.  
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• Access has patents and patent applications which provide intellectual property protection for 
disease targeting of polymers and nanoparticles using Cobalamin™, folates, and biotin.  
 
Opportunities  
Access Pharmaceutical’s proprietary Cobalamin™ - mediated disease targeting technology provides a 
drug delivery and targeting option for a wide variety of diseases in which increased demand for 
vitamins or vitamin analogs in diseased cells is known to occur. In addition to the oncology program 
described here, Access has conducted initial studies demonstrating proof-of-concept that 
Cobalamin™-mediated targeting could be very effective in treating rheumatoid arthritis and colitis. 
Access’ approach involves the coupling of the drug to a polymer or the encapsulation of the drug in a 
nanoparticle and targeting these constructs to the sites of disease through the attachment of 
Cobalamin™.  
Access has considerable expertise in drug-particle encapsulation, drug-polymer conjugation, and the 
chemistry of Cobalamin™ attachment, and has developed in vitro, in vivo, and ex-vivo models for the 
biological evaluation of Cobalamin™- targeted drug delivery systems.  
Access Pharmaceuticals is currently seeking development partnerships with biotech and 
pharmaceutical companies requiring a targeted approach to increase drug efficacy and/or decrease 
side-effects of novel active pharmaceutical compounds and/or improve the efficacy/safety profile of 
an established active pharmaceutical agent to gain a competitive advantage over other formulations.  
 
Business Development  
The Business Development team at Access Pharmaceuticals is interested in identifying outlicensing 
candidates, as well as alliance and merger opportunities for Access oncology and dermatology 
products, as well as for our nanopolymer technologies, including Cobalamin™ for oral drug delivery, 
Cobalamin™ for disease targeting, and SEPA, Access’ nail and transdermal drug delivery technology.  
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ALKERMES 40 
 
About Alkermes  
 
At Alkermes, developing medicines with the potential to change people's lives for the better doesn’t 
start with science. It starts with patients.  
We look at the everyday needs and challenges of people living with disease. Then we apply our 
proprietary technologies and scientific expertise to overcome common barriers to treatment success. 
Our goal is to bring forward safe and effective medicines that can make it easier for patients to 
consistently get the medication they need, day after day.  
Products  
Alkermes focuses on therapies for widespread, chronic diseases, such as central nervous system 
disorders, addiction, diabetes and autoimmune disorders, where we feel we havethe opportunity to 
make the greatest impact.  
Pipeline  
We are building a robust pipeline of product candidates based on our proprietary  technologies, 
scientific knowledge and clinical expertise.  
Corporate Profile  
Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative 
medicines to improve patients' lives. Alkermes developed, manufactures and commercializes 
VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and 
bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable, pulmonary and 
oral products for the treatment of prevalent, chronic diseases, and such as central nervous system 
disorders. 
Headquartered in Waltham, Massachusetts Alkermes has a commercial manufacturing facility in 
Ohio.  
Products Summary  
“Our products use sophisticated drug technologies or novel molecules to help patients consistently 
and easily get the medicine they need, when they need it. It’s an approach designed to offer more 
than just compliance or convenience. Our goal is to provide safe and effective medications that can 
offer improved outcomes for patients. Below, learn more about our commercial products and 
pipeline candidates in development.” 
 
 
 
                                            
40
 www.alkermes.com 
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Addiction 
VIVITROL 
VIVITROL® (naltrexone for extended-release injectable suspension) is the first and only once-monthly 
injectable medication for alcohol dependence. 
Vivitrol is currently in development for the treatment of opioid dependence and is not currently 
approved for this indication. 
ALSK 29 
Is an oral compound in development for the treatment of alcohol dependence. 
ALSK 33 
Is an oral molecule in development for the treatment of addiction and other CNS disorders. 
 
Mental Health 
 
RISPERDAL® CONSTA® (risperidone) long-acting injection is the first and only long-acting atypical 
antipsychotic approved in the U.S. for the treatment of both schizophrenia and bipolar disorders. 
 
ALSK 8070 
Is an extended–release injectable product candidate in development for the treatment of 
schizophrenia. 
 
Pain 
 
ALSK 36 
Is an oral compound in development for the treatment of pain. 
 
ALSK 37 
Is an oral molecule in development for the treatment of opioid-induced constipation. 
 
Rheumatoid Arthritis 
 
ALSK 6931 
Is an extended-release formulation in development for the treatment of rheumatoid arthritis and 
related autoimmune diseases. 
 
Diabetes 
 
Exenatide once weekly 
Is an extended-release injectable formulation in development for the treatment of type 2 diabetes. 
 
Pulmonary Disease 
 
ALSK 27 
Is an inhaled candidate in delopment for the treatment of chronic obstructive pulmonary disease. 
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Proprietary Technology Platforms  
 
Alkermes has four proprietary technologies that enable delivery of both small molecules and 
complex macromolecules.  
Medisorb® Technology  
Alkermes’ proprietary, injectable extended-release technology, called the Medisorb® technology, 
enables us to develop treatments that sustain effective levels of medication in the body over a 
prolonged time period. We have two commercial products based on this technology, RISPERDAL® 
CONSTA® and VIVITROL®.  
Our extended-release technology allows us to encapsulate small molecules, peptides and proteins 
in microspheres made of biodegradable polymers. With extended-release profiles lasting from days 
to months, these microspheres are designed to eliminate the need for frequent dosing.  
Alkermes’ extended-release technology is distinguished by:  
• Clinically-proven extended-release of medication from microspheres in humans  
• Demonstrated safety and tolerability in human clinical trials  
• Potential to improve patient adherence to therapy, especially where extended-release dosage 
administration is an important factor for the selection of a medication for treatment  
• Broad applicability to small molecules, peptides and proteins  
• Demonstrated manufacturing capability at laboratory scale, pilot scale and commercial 
manufacturing scale, in compliance with cGMPs  
 
AIR® Technology  
Alkermes’ pulmonary drug delivery technology, called the AIR® technology, offers a unique, 
proprietary delivery system for optimized drug delivery to the lungs. First published in the journal, 
Science, our technology represents a major innovation among pulmonary delivery systems. We are 
currently developing ALKS 27 based on this technology.  
The pulmonary delivery system can provide efficient dry-powder delivery of small molecule, peptide, 
protein and other macromolecule drug particles to the deep lung, with significant advantages over 
other delivery methods.  
Benefits include:  
• Systemic delivery of small molecules, peptides, proteins, and other macromolecules  
• Local or targeted delivery of wide dosage range  
• A small, easy-to-use delivery device  
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• Proven scalability and commercial-scale production of drug  
• Demonstrated safety and tolerability in large-scale human clinical trials  
 
Medifusion ™ Technology  
Alkermes’ proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, 
is designed to extend the circulating half-life of proteins and peptides in order to create an effective, 
long-acting injectable medication. The Medifusion technology is able to extend the half-life of 
proteins and peptides through the combined action of Fc fusion and hyperglycosylation. The 
resulting extended systemic half-life of the therapeutic compound allows for reduced dosing 
frequency. We are currently developing ALKS 6931 based on this technology. We are currently 
developing ALKS 6931 based on this technology.  
Alkermes’ Medifusion technology is distinguished by:  
• Systemic delivery of Fc fusion peptides and proteins  
• Potential to achieve a customized extended-release profile lasting from days to months  
• Potential to improve patient adherence to therapy, especially where extended-release dosage 
administration is an important factor for the selection of a medication for treatment  
LinkeRx ™ Technology  
Alkermes’ long-acting proprietary LinkeRx™ technology platform enables the creation of extended-
release injectable versions of antipsychotic therapies and may also be useful in other disease areas in 
which long action may provide therapeutic benefits. The technology uses proprietary linker-tail 
chemistry to create New Molecular Entities (NMEs) derived from known agents. These NMEs are 
designed to have improved clinical utility, manufacturing and ease-of-use compared to other long-
acting medications. We are currently developing ALKS 9070 using this technology.  
 
Alkermes’ LinkeRx technology is distinguished by:  
• Potential to achieve an extended-release profile lasting from days to months  
• Potential to improve patient adherence to therapy, especially where extended-release dosage 
administration is an important factor for the selection of a medication for treatment   
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ArmaGen41  
ArmaGen Technologies, Inc.  
914 Colorado Ave.  
Santa Monica, CA 90401  
Ph: (310) 917-1275 Fax: (310) 917-1276  
Email: contact@armagen.com  
 
About ArmaGen  
ArmaGen® provides platform technology solutions to the 'blood-brain barrier' problem, and can 
non-invasively target recombinant proteins, therapeutic monoclonal antibodies, and siRNA to the 
brain.  
 
About the blood-brain barrier (BBB)  
Effective drugs have not been developed for most brain disorders  
 
Big Pharma only develops a certain class of drug called small molecules. 
Although it is widely believed that any small molecule crosses the blood-
brain barrier (BBB), just the opposite is true. In order to cross the BBB, 
the small molecule must have a molecular weight (MW) < 400 Daltons, 
and must also be lipid soluble. The number of small molecules that have 
these chemical properties is <2% of all drugs. All other drugs do not cross 
the BBB. Since Big Pharma does not develop BBB solutions, >98% of all 
drugs that could potentially treat the brain are not developed. The only 
drugs currently developed for the brain are lipid soluble drugs with a MW 
< 400 Daltons, and only a few brain disorders respond to such drugs (see 
Table 1). The majority of brain disorders do not respond to lipid soluble 
drugs with a MW < 400 Daltons, and consequently, no treatments are available (see Table 2 below).  
 
The global CNS drug market is greatly under-penetrated  
 
The global market for drugs for the central nervous system (CNS) is greatly underpenetrated, and 
would have to grow by >500% just to equal the cardiovascular drug market.  
The problem of under-penetration of the brain drug market will become even more severein the next 
20 years as the population ages and the number of people afflicted with Alzheimer's disease, 
                                            
41
 http://www.armagen.com  
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Parkinson's disease, or stroke increases by 50%. Without new drug treatments and new methods for 
early diagnosis, the annual cost of health care for patients with Alzheimer's disease alone could 
approximate $0.5 trillion in 2020 in the U.S.  
Using this model, it is increasingly difficult to build a successful CNS drug development program for 
brain diseases other than affective disorders, pain, or epilepsy. This approach leaves un-developed 
very large markets of unmet needs that could be addressed if the BBB problem were not rate-
limiting. The inability to treat most CNS disorders is not due to the lack of effective CNS drug 
discovery. Rather, it is due to the ineffective CNS drug delivery.  
 
ArmaGen Products  
 
• AGT-3  
An avidin antibody fusion protein for intravenous RNAi and the in vivo delivery of short interfering 
RNA (siRNA)  
AGT-3 is a genetically engineered fusion protein of avidin and a monoclonal antibody to a human cell 
membrane receptor, which binds mono-biotinylated siRNA with high affinity to enable intravenous 
RNA interference. The avidin-biotin bond is highly stable in vivo, and the siRNA knocks down target 
mRNAs while still bound to avidin. Avidin is fused to a genetically engineered receptor specific 
monoclonal antibody (MAb), which is endocytosed by virtually all human cells, including the cells 
comprising the blood-brain barrier (BBB). ArmaGen's siRNA delivery system is encompassed within 
the broad claims of issued U.S. patent 6,287,792, which covers the use of avidin-biotin technology in 
drug delivery.  
 
• AGT-110  
An IgG-TNFR fusion protein for acute and chronic brain disease  
 
• AGT-120  
A neuroprotection drug for stroke that crosses the blood-brain barrier and is active in brain following 
delayed intravenous administration  
 
• AGT-160  
An anti-amyloid drug that crosses the blood-brain barrier for reducing the brain amyloid  
burden of Alzheimer's disease  
 
• AGT-181  
A lysosomal enzyme replacement therapy for the brain  
 
• AGT-185  
A CNS-acting chemical nerve gas antidote  
 
• AGT-190  
A neuroprotection drug for stroke or Parkinson's disease  
 
• AGT-2000  
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A non-viral, intravenous gene therapy for either primary or metastatic brain cancer  
 
Protein drug delivery technology  
ArmaGen Technologies' molecular Trojan horses deliver protein neurotherapeutics to the brain. 
  
POTENTIAL OF PROTEIN-BASED THERAPEUTICS IN THE TREATMENT OF BRAIN DISEASES  
Many disorders of the brain have proven refractory to small molecule therapeutics, and could be 
treated with protein therapeutics. Indeed, many protein lead drug candidates have been identified 
for brain diseases, but these proteins do not enter CNS drug development, because the proteins do 
not cross the blood-brain barrier (BBB). Instead, attempts are made to isolate small molecule 
peptidomimetics. However, it is very difficult to produce small molecule peptidomimetics. Moreover, 
in the rare case that a small molecule agonist is identified, this lead drug candidate most likely will 
not cross the BBB. Those small molecules that have a molecular weight > 400 Daltons, or form even a 
few hydrogen bonds, will not cross the BBB in pharmacologically significant amounts. An alternative 
strategy is to re-formulate the protein drug candidate to enable transport across the BBB in vivo. This 
is done by genetically engineering a novel fusion protein, wherein the protein drug is fused to 
ArmaGen Technologies' molecular Trojan horse (MTH). The MTH part of the fusion protein triggers 
transport across the BBB via an endogenous receptor-mediated transport system.  
RE-FORMULATION OF PEPTIDES, RECOMBINANT PROTEINS, ENZYMES, OR MONOCLONAL 
ANTIBODIES AS FUSION PROTEINS TO ENABLE TRANSPORT ACROSS THE BBB  
Scientists at ArmaGen Technologies have developed proprietary MTHs that cross the primate and 
human BBB faster than neuroactive small molecules such as morphine. The lead MTHs, AGT-1 and 
AGT-2, have been genetically engineered to enable chronic use in humans without immune 
reactions. With the genes encoding AGT-1 or AGT-2, ArmaGen scientists can create novel fusion 
genes that encode for fusion proteins that have dual functions: (a) cross the BBB on one of the 
endogenous BBB RMT systems, and (b) bind the neuronal or glial receptor in brain to trigger the 
desired pharmacological effect. This bi-functionality is illustrated in the adjacent figure: the "head" of 
the fusion protein binds a BBB receptor to trigger uptake of the fusion protein into the brain, and the 
"tail" of the fusion protein then activates an endogenous receptor on brain cell membranes. In the 
case of enzyme drugs, where the enzyme must also distribute into the intra-cellular space of brain 
cells, the MTH also causes the receptormediated endocytosis of the enzyme into brain cells.  
 
Drug developers may own the intellectual property of novel recombinant proteins, enzymes or 
monoclonal antibodies, that by themselves do not cross the BBB, and have little chance of being 
successful as a brain drug in clinical trials. ArmaGen can partner with CNS drug developers to re-
formulate their protein-based neurotherapeutic and create a novel fusion protein that both crosses 
the human BBB and acts at specific drug receptors once inside the brain. ArmaGen Technologies has 
genetically engineered and expressed several fusion proteins, and these recombinant proteins retain 
the bi-functionality of both the BBB delivery part and the protein drug part.  
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Small molecule BBB drug delivery technology  
What restricts the free diffusion of small molecules across the BBB?  
Small molecules cross the BBB in pharmacologically significant amounts only if the molecule has the 
following characteristics:  
• Molecular weight under a 400 Dalton threshold  
• Lipid solubility  
• Absence of restrictive plasma protein binding  
• Absence of affinity for one of several BBB active efflux transporters (AETs), such as p-glycoprotein  
 
Gene delivery technology  
• non-viral  
• non-invasive  
• intravenous administration in small volumes  
• non-toxic, non-immunogenic  
• delivers plasmid DNA to all cells in brain following an intravenous administration  
• ectopic gene expression eliminated with specific gene promoters  
• enables intravenous RNA interference (RNAi)  
• reduced to practise in mice, rats, and Rhesus monkeys  
• enables adult transgenics in 24 hours  
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Avidimer Therapeutics, Inc. 42 
P.O. Box 7735  
Ann Arbor, MI 48107  
United States  
Phone: 866-229-1387  
About Avidimer  
Avidimer Therapeutics, Inc. develops and commercializes pharmaceuticals. The company focuses on 
cancer detection and treatment. It offers avidimers, cancer product candidates that are designed to 
maximize damage to disease targets and minimizes collateral damage to healthy tissue, as well as for 
the treatment of ovarian, breast, lung, and colon cancers.  
Avidimer Therapeutics, Inc. was founded as NanoCure Corporation in 2003 and changed its name to 
Avidimer Therapeutics, Inc. in May 2005. The company is based in Ann Arbor, Michigan.  
 
Technologies  
Avidimer Therapeutics is producing nanosized polymer dendrimers, or “avidimers,” that act as inert 
scaffolding for imaging and/or therapeutic agents, which are attached via chemical linkers. The 
avidimer complex also includes multiple targeting vectors, which increase drug payload, tightly 
attached to the dendrimers to guide the desired molecules to target tissue. The vectors employ cell 
surface markers expressed on diseased cells to guide the avidimers to diseased, not healthy cells. A 
dendrimer is generally about 5 nm in diameter, which is about the same size and shape as a molecule 
of hemoglobin. A fully loaded avidimer is smaller than 15 nm in diameter and flexible, enabling it to 
move without recognition throughout the body, according to the company. Avidimers are delivered 
via injection and are excreted within 72 hours via the urinary tract.  
Avidimer is focusing on cancer. Its lead candidate, ATI-001, is formed by the covalent attachment of 
4–5 folic acid molecules and 5–6 methotrexate molecules to a dendrimer backbone.  
The linker mechanism employed to attach drugs to avidimers are chosen either to retain the drug on 
the dendrimer throughout its lifetime or allow the drug to disassociate (i.e., cleave) after delivery to 
its target. Maintaining the drug attached to the dendrimer in transit to the disease target is 
important in sparing healthy tissue, i.e., minimizing toxicity, but in some cases, the drug must be 
released from the dendrimer at its intended destination to express biological activity, while in other 
cases, the drug retains its activity when attached to the dendrimer, the company reports.  
 
ATI-001 targets cancers that overexpress the high affinity folate receptor on ovarian, breast, lung, 
and colon cancer, among others. A study published in 2005 demonstrated that thisdrug was 
significantly more efficacious in vitro and in vivo with much less toxicity compared to free 
methotrexate administered at comparable doses.  
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Calando Pharmaceuticals 43 
c/o Arrowhead Research Corp.  
201 S. Lake Ave, Suite 703  
Pasadena, CA 91101  
Phone: 626.304.3400  
Fax: 626.304.3401  
 
info@calandopharma.com  
 
About Calando  
Combined with a safe and effective delivery method, RNAi-based treatments for life threatening and 
fatal diseases like cancer, AIDS, hepatitis C, Huntington's disease and others become possible. 
 
Company Overview  
Calando is a clinical stage nanobiotechnology company at the forefront of RNAi therapeutics. We 
develop nanoparticle therapeutics that use our patented sugar (cyclodextrin)-based polymer 
technologies as a drug delivery system for siRNA.  
Our products are based on pioneering technology invented in the Chemical Engineering Department 
of the California Institute of Technology. Engineered to reduce the debilitating effects of cancer 
treatment, our proprietary molecules are designed to improve the safety and efficacy of cancer 
therapeutics using siRNA as the active ingredient. The target-agnostic platform technology has the 
potential to be applied to a wide range of diseases beyond cancer as well as to therapeutic classes 
beyond siRNA therapeutics.  
In 2009, we successfully completed a Phase 1 clinical study with our first anti-cancer drug and 
therapeutic candidate, IT-101. IT-101, along with Calando's drug delivery platform, Cyclosert™, now 
is partnered for further development to Cerulean Pharma Inc.  
 
In the Clinic  
We are focused on the clinical development of RONDEL™, our siRNA delivery technology, and CALAA-
01, the associated drug candidate.  
RONDEL, which overcomes the significant hurdles to efficient, systemic delivery of siRNA, features 
many benefits: Repeat dosing with no indication of significant, dose-limiting immune reactions.  
Proven to overcome the extra-and intra-cellular barriers to siRNA delivery. Scaled and manufactured 
for clinical use.  
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CALAA-01 entered the clinic in April 2008. To our knowledge, this was the first entry into a Phase I 
clinical study of fully formulated and targeted of asiRNA drug candidate targeting cancer.  
In addition to our therapeutic pipeline, our patented and proprietary delivery systems have utility in 
multiple application areas. As a result, we are exploring opportunities to combine our innovative 
technologies with companies that require delivery solutions.  
 
Technologies  
 
RONDEL™ for siRNA Delivery  
Years of research leading to clinical breakthroughs.  
We are creating and developing new targeted, siRNA-containing therapeutics using our proprietary 
three part RNAi/Oligonucleotide Nanoparticle Delivery (RONDEL) technology, the foundation of 
which is our cyclodextrin-containing polymer.  
One of the key challenges to using RNAi therapy has been the inability to systemically deliver siRNA 
in humans. "Naked" siRNA is degraded and destroyed by nucleases in the bloodstream and is not 
taken up by cells. It also causes harmful immune reactions.  
With our RONDEL system, siRNA is protected by our cyclodextrin-containing polymers and thus can 
reach its destination and perform its intended job, for example, to stop the runaway growth of tumor 
cells. By encapsulating the siRNA, RONDEL also protects the body from the immune reactions caused 
by naked siRNA.  
Pending successful clinical testing, RONDEL provides an enabling technology for siRNAbased 
therapeutics to become effective disease treatments.  
 
RONDEL™ Benefits  
Benefits of Calando's RONDEL Technology  
• More Effective Delivery  
o RONDEL binds to and self-assembles with siRNA to form uniform colloidalsized particles. 
Analysis has shown that these particles are spherical and less than 100 nm in diameter, which allows 
for accumulation at the tumor site.  
o Calando and its partners have demonstrated successful delivery of functional siRNA 
therapeutics to tumor cells and to hepatocytes by systemic administration and confirmed sequence-
specific gene inhibition.  
 
• Modularity  
o RONDEL is a two vial system with the active siRNA included in one vial and the delivery 
excipients in the other, allowing easy exchange of the active siRNA ingredient.  
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• Fewer Immune Reactions  
o The delivery vector allows for repeat dosing with no indication of significant, dose-limiting 
immune reactions. Unlike lipid delivery vehicles, the cyclodextrin-based  
RONDEL delivery system does not cause an interferon response.  
o The fully formulated polymer/siRNA particles exhibit a significant therapeutic window of 
safety in animals, even when repeated doses are used.  
 
• Increased Stability  
o The particles have been shown to be stable under physiological conditions.  
 
• Designed to Work With Human Physiology and Cell Biology  
o Overcomes the extra-and intra-cellular barriers to siRNA delivery.  
 
In the Clinic  
CALAA-01, Calando's leading drug candidate, is a combination of RONDEL™ and a patented siRNA 
targeting the M2 subunit of ribonucleotide reductase, a clinically-validated cancer target. 
Ribonucleotide reductase catalyzes the conversion of ribonucleosides to deoxyribonucleosides and is 
necessary for DNA synthesis and replication; it is a critical component in the proliferation of cancer 
cells. Calando's siRNA and CALAA-01 have demonstrated potent anti-proliferative activity across 
multiple types of cancer cells. 01 have demonstrated potent anti-proliferative activity across multiple 
types of cancer cells.  
 
CALAA-01 Phase I Clinical Trial  
This is an open-label, dose-escalating study of the safety of intravenous CALAA-01 in adults with solid 
tumors refractory to standard-of-care therapies. Patients who satisfy the inclusion and exclusion 
criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four infusions administered 
on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered 
consisting of infusions on days 22, 24, 29, and 31 followed by 11 days of rest.  
 
IT-101  
Originally developed by Insert Therapeutics, a Calando predecessor company, IT-101 is an 
experimental, nanoparticle therapeutic that consists of the drug camptothecin (CPT) conjugated to a 
cyclodextrin polymer. IT-101 is based on the Cyclosert™ delivery platform developed by Insert 
scientists for small molecule drugs. Cyclosert™ is based on a linear cyclodextrin polymer similar to 
the one used in the RONDEL system. Both IT-101 and Cyclosert have been partnered with Cerulean 
Pharma, Inc., a Cambridge, MA based biotech company.  
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Partnering to extend the reach of our technology.  
Cyclosert™ was designed by Calando's scientists for the delivery of small molecule drugs and 
provides many of the same benefits as the RONDEL™ system. Calando completed a Phase 1 trial with 
IT-101, the associated drug candidate that is comprised of Calando's proprietary drug delivery 
polymer and Camptothecin, a potent anti-cancer drug, with a positive safety profile and indications 
of efficacy. In June 2009, Calando entered into agreements to partner Cyclosert and IT-101 to 
Cerulean Pharma, Inc. ("Cerulean"), a Boston-based biotech company.  
Under the terms of the agreements, Calando granted Cerulean an exclusive royalty-bearing 
worldwide license to certain patent rights to Cerulean related to the linear-cyclodextrin drug delivery 
platform and IT-101. Calando retains the rights to its RONDEL platform, as well as the CALAA-01 lead 
drug.  
 
Calando’s RONDEL™ delivery system extends the reach of RNAi therapy by answering the new field's 
most pressing need — an effective and safe systemic delivery method.  
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Cell Therapeutics, Inc. 44 
Cell Therapeutics, Inc. & Subsidiaries  
Cell Therapeutics, Inc. Corporate Headquarters  
501 Elliott Ave. W. #400  
Seattle, WA 98119  
 
About CTI  
“Where Cancer Treatment Gets Personal“ 
Within every cell of every person is a genetic blueprint. Known as the genome, this blueprint 
instructs the cell how to respond to its environment, when to reproduce, and when to die. These 
genetic blueprints help to explain why each one of us is unique. They also explain why different cells 
and different patients respond to cancer treatment in different ways—and why one person may 
respond favorably to a drug, while another may experience debilitating side effects with little or no 
therapeutic benefit.  
 
At Cell Therapeutics, Inc. (CTI), we use genomic information to develop a personalized approach to 
cancer therapy with the goal of making standard-of-care treatment less toxic and more effective for 
individual patients. Our approach is based on matching a drug candidate to a person's genetic profile 
along with other clinical and diagnostic information to achieve the highest anti-tumor activity, at the 
lowest dose, and with the fewest side effects. This personalized information can also be used to 
identify patients for clinical trials who are most likely to respond to the drug candidate.  
 
Significant progress has already been made. Using a personalized approach to guide our drug 
development and commercialization programs may potentially lower our drug development costs, 
shorten approval time, and help improve the lives of patients by treating cancer according to each 
individual's genetic blueprint. 
Mission  
CTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In 
our pursuit of making cancer more treatable, we are developing a diversified portfolio of oncology 
products focused on identifying and developing new, less toxic, and more effective ways to treat 
cancer.  
Values  
Our priority and sense of purpose is our customer—the PATIENT. We are reminded daily that there is 
not a life or a moment to lose. CTI’s patient focus shapes our culture, organization, and values. 
Company success is dependent on our EMPLOYEES’ creativity and dedication. Without this talent, 
commitment, and focus, we would not reach the ambitious goals we set for ourselves.  
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Our employees are dedicated to TEAMWORK. We have a true sense of ownership for our work and 
how it is tied directly to products that may significantly improve the outcome of patients’ lives.  
We feel a responsibility to give back to our COMMUNITY. We contribute to numerous local 
organizations and support employee initiatives beyond the workplace.  
The “patient first” focus gives us a greater understanding of our market—it is the key to serving our 
customers well and creating true SHAREHOLDER value. When we are successful in achieving these 
values, our shareholders will benefit.  
 
Technologies  
“Developing Drugs that Patients Can Live With” 
Personalizing cancer therapy is a multidisciplinary pursuit based on a variety of interdependent 
product development programs. Our scientists are advancing these programs through close 
collaboration and the integration of powerful technologies that will help us achieve our goal of 
hurting the cancer more than the patient. These technologies include:  
• Our polyglutamate delivery technology may open the way to the selective delivery of cancer 
therapies to tumor tissue, potentially reducing the toxic side effects of widely used and well-
characterized therapies.  
• Our Genetic Polymer ™ technology supports the need for new rDNA-derived protein-based drugs 
by potentially extending plasma half-life. This could reduce the time and cost of developing new 
drugs, so patients can benefit sooner from breakthrough scientific discoveries.  
• Our advanced systems biology platform addresses context of vulnerability. Every tumor and every 
patient has a specific set of genomic and clinical characteristics. Potentially, these characteristics can 
be used in synchrony to accelerate drug development and identify patients who will respond to 
treatment.  
 
POLYGLUTAMATE TECHNOLOGY  
Special Delivery  
Using polyglutamate drug delivery technology, we are developing a new way to deliver paclitaxel 
preferentially to tumor tissue. This approach could potentially reduce the toxic side effects of 
paclitaxel to normal organs and tissues and improve its anti-tumor activity.  
One of the unique characteristics of our product candidate OPAXIO™ (paclitaxel poliglumex, CT-2103; 
formerly known as XYOTAX) is that it links, or conjugates, paclitaxel to the biodegradable polymer 
polyglutamate.  
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Potential Benefits  
Based on preclinical animal studies and clinical trial data, we believe that OPAXIO may be able to 
achieve a number of benefits over existing taxanes, including:  
• Eliminates the need for toxic solubilizing agents such as cremaphor/ethanol  
• Eliminates the need for routine premedication  
• Allows more drug to reach the tumor  
• Decreases toxicity as a result of less active drug reaching normal tissues  
• Has potential to overcome resistance to the underlying chemotherapy drug  
• Similar or potentially better efficacy compared with standard taxanes  
 
Mechanism of Action  
Unlike vessels in healthy tissue, vessels in tumor tissue have openings, or pores, that make them 
porous to large molecules. OPAXIO molecules, which are larger than those of standard paclitaxel, 
leak through these pores and are preferentially trapped and distributed in the tumor tissue.  
Once in the tumor tissue, OPAXIO is taken up by tumor cells through a cellular process called 
endocytosis. Because the biopolymer OPAXIO is made of biodigestible amino acids, it is slowly 
metabolized by lysosomal enzymes (principally cathepsin B) inside the lysosome in the tumor cell. 
This metabolism releases the active chemotherapy agent, paclitaxel into the tumor.  
OPAXIO is taken up by tumor cells through a cellular process called endocytosis. Because the 
biopolymer OPAXIO is made of biodigestible amino acids, it is slowly metabolized by lysosomal 
enzymes (principally cathepsin B) inside the lysosome in the tumor cell. This metabolism releases the 
active chemotherapy agent, paclitaxel into the tumor.  
In addition to the potential metabolic advantages, polymer-linked cancer drugs are inactive while 
circulating in the bloodstream, which may also lower toxicity compared to the active cancer drug 
substance alone.  
 
Origin of the Technology  
We licensed the worldwide exclusive rights to polyglutamate and related polymers and their 
applications from PG-TXL Company in 1998. The technology was originally developed at The 
University of Texas M.D. Anderson Cancer Center. The initial patent, issued in  
November 1999, covers polyglutamate and related polymers coupled with commonly used cancer 
drugs such as paclitaxel, docetaxel, etoposide, teniposide, or camptothecins. The patented 
technology covers formulations of polyglutamate-conjugated paclitaxel that also include the use of 
human serum albumin and conjugation to epothilones.  
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Strategic Significance  
Through this novel polymer technology we have the opportunity to build a portfolio of potentially 
safer and more effective versions of well-known anti-cancer agents such as taxanes. Taxanes such as 
paclitaxel are widely used for the treatment of various solid tumors, including non-small cell lung, 
ovarian, breast, and prostate cancers. We believe that our polymer technology may lower the risks 
inherent in developing new drugs because we are linking polymers to well-defined and widely used 
classes of chemotherapy drugs, including taxanes.  
 
Genetic Polymer ™ Technology  
Streamlining Protein Pharmaceutical Development  
In the first half of 2007, we formed a spin-off company, Aequus BioPharma, Inc., to further develop a 
technology created by CTI scientists that extends the plasma half-life of recombinant DNA (rDNA) 
derived protein pharmaceuticals. This technology, called Genetic Polymer ™ technology, may simplify 
the development and manufacture of biologics reducing time to market and lowering costs.  
Biologics, especially pharmaceuticals derived from recombinant DNA (rDNA), represent the fastest 
growing segment of pharmaceutical sales. Current sales reach $51 billion worldwide and expected to 
hit $87 billion by 2010. Industrial-scale protein production technologies are currently being applied 
to the development of a wide variety of these drugs, including hormones, growth factors, antibodies, 
and cytokine modulators, to treat a vast range of human diseases.  
Extending Plasma Half-life  
Frequently, rDNA-derived protein pharmaceuticals have a relatively short plasma half-life. To rectify 
this problem, several physical, genetic, and chemical approaches have been developed to extend 
plasma half-life—without compromising efficacy or introducing safety issues such as immunogenicity 
and other off-mechanism toxicities.  
The most successful of these approaches include site-specific amino acid substitution, conjugation to 
carrier domains, and post-expression chemical conjugation. Genetic Polymer technology may simplify 
the use of chemical conjugation technology to extend plasma halflife by genetically attaching an 
amino acid polymer domain to a biologically active protein sequence to create a novel, unique, and 
patentable gene.  
 
Mechanism of Action  
To construct a Genetic Polymer, the DNA sequence encoding a specific amino acid polymer is ligated, 
or attached, to the DNA sequence encoding a biologically active peptide-or protein-based drug 
moiety in an expression vector designed for use in a bacterial, yeast, mammalian, or other 
recombinant protein expression system. The amino acid polymer can be attached to either the N-
terminus, C-terminus or both termini of a protein. Typically, DNA encoding a secretion-leader 
sequence is included in the expression vector to drive secretion of the expressed protein to the 
extracellular space to facilitate recovery and purification.  
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A prototypical Genetic Polymer protein is depicted in the schematic shown below. It should be noted 
that potential post-translational modifications (PTM) present on more than one amino acid repeat 
are omitted for clarity.  
 
Strategic Significance  
In addition to its potential for producing lower cost follow-on biologics, we believe this recombinant 
DNA technology might be used to develop novel biologics, in a wide array of malignant, 
inflammatory, or infectious diseases. The Genetic Polymer technology platform should be applicable 
to many different protein pharmaceuticals. This, in turn, may eliminate the need to develop 
individualized technology for extending the plasma half-life of each protein pharmaceutical, allowing 
for more convenient dosing.  
Our data also suggest that biosynthesis in traditional mammalian cell protein expression systems will 
allow for the production of a protein pharmaceutical with prolonged plasma half-life, but without the 
requirement for further chemical modifications subsequent to protein expression.  
It is our opinion that this proprietary Genetic Polymer technology creates novel compositions of 
matter, allowing for the commercialization of protein pharmaceuticals without infringing on the 
patents of other companies with competing technologies. The first protein pharmaceutical the 
company plans to move into preclinical and chemical development studies is a novel, long-acting G-
CSF biosimilar.  
 
Collaborations & Partnerships  
Mutually Beneficial Relationships  
We enter into partnerships and collaborations with companies to maximize commercial 
opportunities for all parties involved. We believe in leveraging the intellectual, financial, and 
commercial strengths of strategic corporate partnerships to bring the full potential of our product 
candidates to market. We also believe in the value of strategic timing.  
Before seeking development or commercialization partners, we develop our products through mid-to 
late-stage clinical development. As a result, we are best positioned to assess and realize their full 
value. Ultimately, this strategy will allow us to choose the best partner on more favorable terms than 
might be available if we entered into collaborative relationships during earlier stages of product 
development.  
Some of our current collaborations are described below.  
Novartis  
In September 2006, we entered into an exclusive worldwide licensing agreement with Novartis for 
the development and commercialization of OPAXIO ™ (paclitaxel poliglumex, CT-2103, formerly 
known as XYOTAX). The agreement also provides Novartis with an option to develop and 
commercialize pixantrone based on agreed terms. As part of the agreement, Novartis made a $15 
million equity investment in CTI.  
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PG-TXL Company, L.P.  
In June 1998, we entered into an agreement with PG-TXL Company, L.P. granting us an exclusive 
worldwide license for the rights to PG-TXL, now known as OPAXIO ™, and to all potential uses of PG-
TXL’s polymer technology.  
Under the terms of the agreement, we will fund the research, development, manufacture, 
marketing, and sale of anti-cancer drugs developed using PG-TXL's polymer technology. We are 
obligated to make payments upon the attainment of significant development milestones, as defined 
in the agreement.  
 
Additional Collaborations  
Additional collaborations came to CTI with our acquisition of Systems Medicine in July 2007, 
including:  
Nerviano Medical Sciences (NMS), Milan, Italy  
The largest pharmaceutical research and development facility in Italy and one of the largest 
oncology-focused, integrated discovery and development companies in Europe. NerPharMa, a 
pharmaceutical manufacturing company belonging to NMS in Nerviano, Italy manufactures 
pixantrone.  
The Translational Genomics Research Institute (TGen)  
A biomedical research institute that makes and translates genomic discoveries into advances in 
health.  
The Cancer Drug Development Laboratory  
A robotics-intensive division of TGen applying advanced genomic technologies (e.g., RNA 
interference) to translational drug development.  
TGen Drug Development Services  
An oncology-focused clinical research organization providing preclinical evaluation of the safety and 
efficacy of a drug using the most relevant animal models and genomic analyses.  
The Molecular Profiling Institute  
A specialty reference laboratory that helps cancer patients worldwide by applying the discoveries of 
the Human Genome Project to personalized medicine.  
Critical Path Institute  
An Arizona-based non-profit organization focused on enabling the accelerated development of new 
medications founded by FDA, the University of Arizona, and SRI International.  
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CERULEAN 45 
Cerulean Pharma Inc.  
840 Memorial Drive, 5th Floor  
Cambridge, MA 02139  
Tel 617-551-9600  
Fax 617-494-1544  
info@Ceruleanrx.com  
 
About Ceruleran  
Focused on novel, nanotechnology-based therapeutics  
Cerulean is a private biopharmaceutical company focused on the development of novel, 
nanotechnology-based therapeutics in the areas of oncology, inflammation, and cardiovascular 
diseases.  
Cerulean is pursuing three key strategies:  
• Achieving rapid and clinically significant human proof of concept with its technology.  
• Building a deep and diversified product pipeline and leveraging its proprietary nanotechnology 
platform.  
• Using a multi-faceted business model, with plans to retain some products for development and 
commercialization to achieve full company value creation, while at the same time collaborating on 
other products to leverage the resources and capabilities of partners.  
Cerulean has assembled a world-class management team, board of directors, and scientific advisory 
board that collectively have a significant track record of business building, product development, and 
scientific breakthroughs.  
 
Cerulean was founded in October of 2006 and is located in Cambridge, Massachusetts.  
 
Mission:  
Cerulean’s mission is to dramatically enhance patient outcomes in diseases of high unmet need 
through the application of nanotechnology and, in this way, enhance efficacy, lower toxicity and 
broaden the ability of combination therapy.  
Nanotechnology will provide an avenue through which the traditional drug development 
pharmacokinetics and drug metabolism obstacles can be overcome by localizing drugs to their target 
sites at therapeutic concentrations for prolonged periods of time while at the same time reducing 
their systemic exposure.  
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Technologies  
Nanopharmaceuticals: A New Approach to Designing Drugs with Enhanced Therapeutic Utility  
Cerulean is uniquely positioned to advance nanopharmaceuticals as the next generation 
therapeutics. Nanopharmaceuticals are particles of defined nanometer diameter size, which are 
designed to target and penetrate diseased tissue with “leaky vasculature” and then gradually release 
their drug payload at the target location. The unique characteristics of these nanoparticles allow for 
cellular uptake into cells as intact nanoparticles.  
This fundamentally different approach overcomes the shortcomings of short exposure at target site 
and high systemic toxicity of conventional drugs. The technology underlying Cerulean’s 
nanopharmaceuticals is particularly suited for oncology, inflammation, and cardiovascular disease.  
These drug-containing nanoparticles are designed to enhance the therapeutic utility of drugs and 
allow for: containing nanoparticles are designed to enhance the therapeutic utility of drugs and allow 
for:  
• Low systemic exposure  
• Preferential delivery of drugs to target tissue  
• Intracellular uptake in target cells; and  
• Controlled release of therapeutic concentrations of drugs over a prolonged period of time.  
 
The highly differentiated product attributes of Cerulean nanopharmaceuticals result in a profound 
increase of therapeutic utility. Efficacy is increased by maximizing the targeting, uptake, and 
retention in target tissue and releasing the active drug gradually from within the target tissue. The 
sustained release at the target site also offers the potential to treat resistant cell lines and may 
reduce the emergence of drug resistance. Maintaining the integrity of the nanopharmaceutical in 
circulation for a prolonged period of time minimizes non-specific systemic drug exposure, resulting in 
enhanced drug safety and improved side effects profile. Cerulean’s present focus is in the field of 
oncology, but the company plans to expand the utility of its technologies in other indications such as 
inflammation and infectious disease.  
 
CERULEAN NANOPHARMACEUTICALS  
Cerulean Nanopharmaceuticals Improve Clinical Outcome  
Nanoparticle Design and Development  
The ability to optimize drug loading, particle size, particle components, conjugation linker chemistry 
and formulation process leads to tailored nanoparticles that have superior biological properties 
compared to the free drug they contain. The physical-chemical properties of the nanoparticle, such 
as surface charge and surface composition, affect the distribution of the particle in the body and are 
used to passively target the nanoparticle into target tissues. The composition and linker chemistry 
are chosen to optimize the release of the free drug, achieving a much improved pharmacokinetic 
profile and reducing systemic exposure. During the design of the nanoparticle, scale-up and 
manufacturing are considered, ensuring the production of nanoparticle populations of consistent 
physical characteristics at scale.  
 - 118 - 
Cerulean has access to two complementary technologies within its nanoparticle platform. Both of 
these technologies provide for the formation of stable and consistent nanoparticles comprised of 
biocompatible components, which have high drug loading capacity, and are able to release active 
drug in a controlled fashion.  
The Polymeric Nanoparticle Technology (PNP) allows for nanoparticle customization through 
conjugation chemistry, particle composition, formulation, and fine-tuning of nanoparticle size. This 
technology has produced product candidates with compelling preclinical validation.  
The Cyclodextrin Nanoparticle Technology (CDP) produces self-assembled nanoparticles of a defined 
size range. The most advanced product (IT-101) from this technology is presently in Phase 1b/2a 
clinical development. This technology has been applied to several classes of molecules.  
 
Biological Impact  
When the Cerulean nanoparticles are administered in the bloodstream, they maintain their integrity 
in circulation, minimizing non-specific systemic drug dissemination and clearance.  
The size and surface properties of the nanoparticles favor extravasation through leaky vasculature, 
followed by deep penetration and retention at the tumor site. The physical properties of the 
nanoparticles facilitate endocytic intracellular uptake and help to avoid multi-drug resistance as the 
nanoparticles are not substrates of multi-drug transporters. The polymer-drug conjugation chemistry 
provides for controlled and sustained drug release, maximizing drug exposure to tumor target cells. 
The nanoparticles are made of biocompatible building blocks that allow for safe administration and 
excretion.  
Our nanoparticles produce significant and prolonged tumor growth delay and improved tolerability 
compared to free drug in multiple mouse cancer models. Favorable drug distribution supports 
enhanced nanoparticle localization to the tumor and the improved pharmacokinetic profile 
demonstrate the advantages provided by the nanoparticles such as sustained release and shielding 
of the active drug.  
Below is an example of nanoparticles produced with Cerulean’s PNP technology penetrating into 
tumor tissue far from blood vessels co-localizing with endosomes and demonstrating that these 
nanoparticles enter tumor cells as intact nanoparticles.  
 
CRLX228, Cerulean’s preclinical lead candidate from the PNP technology contains a widely used 
oncology drug and is presently progressing into IND enabling studies. CRLX288 shows substantial 
efficacy and safety improvement over parent drug in validated pre-clinical models and offers the 
potential to dramatically improve the therapeutic index of the parent drug.  
 
Profound Clinical Outcome  
These highly optimized Cerulean nanoparticles produce a profound clinical outcome by allowing for 
high and sustained therapeutic drug levels at the target tissue and, in this way, maximizing 
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therapeutic effects. The nanoparticles are active in drug-resistant diseases, are well tolerated, and 
enable full-course therapy with minimal toxicities. Because of these attributes, Cerulean's 
nanoparticles are highly compatible agents for combination therapies and provide for more effective 
disease management.  
IT-101, Cerulean's lead product from the CDP technology (a nanoparticle containing a highly potent 
topoisomerase 1 inhibitor, camptothecin) is advancing in Phase 1 and is expected to begin testing in 
Phase 2 studies in 2010. This nanoparticle has shown enhanced localization of drug in tumor and 
superior activity in 10 xengraft mouse models spanning 7 cancer types. To date, it has also 
demonstrated promising safety and pharmacokinetic datain humans. IT-101 has the opportunity to 
address large unmet medical needs in difficult-totreat tumor types.  
 
CERULEAN’S COMPETITIVE ADVANTAGE  
Intellectual Property  
PNP Technology - Cerulean has created an extensive patent estate around its internally developed 
PNP technology with patent applications directed to multiple inventions in this area including, for 
example, inventions related to the composition and use of the PNPs and specialized apparatuses and 
methods for producing the PNPS.  
CDP Technology -Cerulean’s exclusive license to the patent estates of California Institute of 
Technology and Calando Pharmaceutical provides broad worldwide coverage of its CDP technology 
platform and various uses thereof. Additional Cerulean patent applications provide coverage related 
to improvements to and new applications of the CDP technology with a particular focus on IT-101, 
Cerulean’s lead product candidate and related inventions.  
Cerulean’s exclusive license to the patent estates of California Institute of Technology and Calando 
Pharmaceutical provides broad worldwide coverage of its CDP technology platform and various uses 
thereof. Additional Cerulean patent applications provide coverage related to improvements to and 
new applications of the CDP technology with a particular focus on IT-101, Cerulean’s lead product 
candidate and related inventions.  
 
Nanopharmaceutical Development Capabilities  
Cerulean has built a unique set of capabilities critical for nanopharmaceutical development.  
In its short history, the company has been able to generate a suite of homegrown technologies as 
well as in-licensed complementary technologies. These technologies have the capacity to incorporate 
different drug classes and have been validated in various preclinical cancer models. Cerulean has also 
generated a sophisticated set of analytical and bioanalytical tools critical for lead development and 
optimization of its nanoparticles.  
  
 - 120 - 
Copernicus Therapeutics Inc. 46 
1000 Cedar Avenue  
Suite 145  
Cleveland, OH 44106-3052  
United States  
Founded in 1995  
 
Phone: 216-231-0227  
Fax: 216-231-9477  
www.cgsys.com  
 
About Copernicus Therapeutics Inc.  
Copernicus Therapeutics, Inc., a biotechnology company, develops a non-viral delivery system for the 
non-toxic delivery of nucleic acid drugs in the United States. Its non-viral delivery system is suitable 
for the delivery of nucleic acid drugs that permits various therapies for human diseases. The 
company focuses on the development of therapies to treat diseases that have therapeutic options, 
including diseases causing blindness, airborne viral diseases, and diseases of the brain. Copernicus 
Therapeutics, Inc. was formerly known as Copernicus Gene Systems, Inc. and changed its name to 
Copernicus Therapeutics, Inc. in 1997. The company was founded in 1995 and is based in Cleveland, 
Ohio  
 
Business Strategy  
Copernicus intends to become a leading biopharmaceutical company by utilizing breakthrough DNA 
nanoparticle technologies to produce safe and effective DNA drugs maximize shareholder value, 
Copernicus is exploiting its expertise in lung gene transfer by fi developing products for the $2 billion 
plus cystic fibrosis market. Copernicus' recent Phase I CF clinical trial results demonstrate that DNA 
nanoparticles efficiently transfer their DN payload into the nucleus of differentiated airway cells, and 
do so without causing a significant toxicities. With additional funding, the Company also will be able 
to devel products to treat diseases involving the central nervous system including various causes 
blindness. Copernicus has developed proof of concept data using an animal model Parkinson's 
disease; it also has proof of concept data in treating a mouse model of gene blindness (retinitis 
pigmentosa -RP). With demonstrated effectiveness of its technology treating three different organs 
of the body (lung, brain, eye), the company will focus its intern efforts to develop these three specific 
treatments while partnering with others to treat the diseases impacting these organs. The core 
competencies demonstrated by the Copernic platform technology will position the Company to 
become the preferred partner of company holding rights to genomic information and therapeutic 
genes, and/or who wish to expand product development in our field indications. The outcome of this 
strategy is to provide the Company with early revenue streams obtained from research, 
development, and manufactory agreements from corporate partners while the Company also 
develops its own intern programs. Copernicus intends to be the GMP-manufacturer of all gene 
transfer products bas on DNA nanoparticles, thereby leveraging our core competency to provide 
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additional sources revenue. Copernicus can provide assistance from preclinical proof-of concept to 
DNA drug production. Each product developed utilizes similar modular Copernicus platform 
technology. This modular nature reduces the risk of product development and permits Copernicus 
perform the needed tasks faster, smarter, and for less cost.  
 
Copernicus' lead product is for cystic fibrosis. A planned second therapeutic will be for treating 
blindness (RP) with a third product being a treatment for Parkinson's disease. Copernicus believes it 
has opportunities available to it and potential corporate collaborators in the following fields:  
 
 
 
Technologies  
Copernicus: Delivering the Promise of Nucleic Acids as Therapeutics Nucleic acid-based therapies are 
a natural progression from development of genetic engineering in the 70's and the Human Genome 
Project of the late 90's. These emerging therapies introduce nucleic acids into cells to correct or 
modify genetic information to restore normal functionality. This technology can also silence aberrant 
or disease-causing genetic sequences. In each of these cases, nucleic acids intervene at the primary 
control point for cellular activity, gene expression. Nucleic acid therapeutics potentially offer novel 
therapies that cannot be addressed using conventional small molecule drugs or proteins. 
Additionally, these therapies provide a high level of cellular targeting with improved specificity of 
action, which can lower toxicity risks. A whole new way of treating disease is possible.  
As stated by Nobel Prize winner Inder Verma, the major hurdle impeding nucleic acid-based 
therapies is "delivery, delivery, delivery." Dr. Verma is talking about the ability to safely and 
efficiently deliver nucleic acids to the cells of interest.  
Most of the initial attempts at delivery have involved the use of engineered viruses. This was a logical 
path to follow as Nature had already designed viruses to deliver their own nucleic acid into cells. 
However, many shortcomings have been associated with the use of engineered viruses, both minor 
and major (including death and causing cancer).  
Alternatively, non-viral Most of the initial attempts at delivery have involved the use of engineered 
viruses. This was a logical path to follow as Nature had already designed viruses to deliver their own 
nucleic acid into cells. However, many shortcomings have been associated with the use of 
engineered viruses, both minor and major (including death and causing cancer).  
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Alternatively, non-viral approaches have been attempted and were often found to be inefficient, 
especially in nondividing cells, which include essentially most of the cells of the body. Non-viral 
systems were also transient in their effects and often included toxicity issues. Copernicus 
Therapeutics, Inc. ("CTI") has developed an innovative nonviral approach based on condensing 
nucleic acids into nanoparticles, which has been found to avoid the many pitfalls associated with 
both viral and previous non-viral approaches. This CTI technology provides a very attractive 
alternative to prior delivery systems. The Company's nucleic acid nanotechnology platform is 
validated in humans with the development of a first-in-class therapeutic product for the treatment of 
Cystic Fibrosis. Additionally, CTI's collaborative research supports the development of first-in-class 
therapies to treat other serious diseases that have few therapeutic options, including diseases 
causing blindness (macular degeneration, diabetic retinopathy, and retinitis pigmentosa), airborne 
viral diseases (influenza A, SARS, and avian flu), and diseases of the brain (Parkinson's disease, stroke 
and Alzheimer's). The Copernicus technology addresses the delivery issue and is poised to deliver the 
promise of nucleic acids as therapeutics.  
 
 
  
 - 123 - 
CytImmune Sciences Inc. 47 
CytImmune Sciences  
9640 Medical Center Drive  
Rockville, MD 20850  
Phone: (301) 825-3041  
 
About CytImmune Sciences Inc.  
CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, 
development and commercialization of multifunctional, tumor-targeted therapies. Based on an R&D 
strategy which harnesses the unique properties of gold nanoparticles, cytotoxic agents, and biology 
of tumors, the Company is developing a pipeline of proprietary drug candidates binding potent anti-
cancer agents --whose toxicity profiles currently prevent or severely limit clinical use --to its patented 
colloidal gold tumortargeting nanotechnology.  
Leveraging its expertise in colloidal gold-based nanomedicines, CytImmune has also developed a 
patented, semi-synthetic in vitro immune system capable of producing fullyhuman monoclonal 
antibody (mAb) therapeutics. The Company’s ability to produce fully human mAbs provides an 
additional pathway to develop proprietary anti-cancer therapeutics using its platform technology to 
create a separate class of nanomedicines.  
The goal is to mitigate the risks of drug development and build from these core technologies families 
of first-in-class therapeutics with accelerated clinical timelines, new commercialization value, and – 
ultimately – greater patient benefits.  
Founded in 1988, CytImmune has emerged as a global leader in the field of nanomedicine with the 
successful completion of its first-in-man targeted nanotherapeutic clinical trial. The  
Company has more than 60 issued and pending patents for its colloidal gold nanotechnology and 11 
issued and pending patents for its mAb technology in the US, EU, Japan and Canada.  
 
Technologies  
CytImmune’s tumor-targeting technology is highly versatile and may be used for the safe and 
systemic administration of drugs that traffic directly to the site of disease - avoiding uptake by or 
accumulation in healthy organs and surrounding tissues.  
The Company’s nano-scale development strategy is to engineer new colloidal gold-based drug 
compounds which harness the therapeutic potential of potent anti-cancer agents, limit their 
biodistribution primarily to tumor sites, and add to TNF’s biological actions. This core platform is the 
key to realizing improved patient outcomes.  
CytImmune’s approach offers the potential to enable and/or expand the clinical benefit of a variety 
of toxic agents (such as tumor necrosis factor alpha (TNF), interleukins/interferons, monoclonal 
antibodies, chemotherapeutic agents, etc.) which may be used to treat multiple types of solid tumors 
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- either as monotherapies or in combination with existing standards of care. The Company¹s 
nanomedicines function independent of tumor specific biochemistry and, therefore, do not depend 
on the type of cancer treated.  
Having completed dosing of its Phase 1 trial, the early clinical data indicate that: (1) CytImmune 
safely and systemically delivered TNF in humans far beyond concentrations attained in previous 
human studies and (2) based on tissue biopsies from treated patients, Aurimune accumulates in and 
around tumor sites, avoids uptake by the liver and spleen, and is essentially absent from surrounding 
healthy tissues.  
 
What is Colloidal Gold?  
The use of colloidal gold as a human therapeutic dates back to the 1930's when it was shown to 
temporarily relieve joint inflammation associated with rheumatoid arthritis.Yet the lack of 
understanding of its mechanism of action has limited its therapeutic potential. The Company believes 
that the potential for colloidal gold in medicine is very broad, and, through an aggressive patent 
strategy the Company will seek to capture both its therapeutic and commercial potential. The 
Company made a rather surprising observation: animals injected with native cytokine exhibited 
strong toxicological responses, whereas animals receiving injections of cytokines bound to colloidal 
gold did not. This singular observation lead us to conclude that colloidal gold may be a universal, 
clinically safe, commercially sound drug/gene delivery system aggressive patent strategy the 
Company will seek to capture both its therapeutic and commercial potential. The Company made a 
rather surprising observation: animals injected with native cytokine exhibited strong toxicological 
responses, whereas animals receiving injections of cytokines bound to colloidal gold did not. This 
singular observation lead us to conclude that colloidal gold may be a universal, clinically safe, 
commercially sound drug/gene delivery system  
 
How Does It Work?  
 
 
• Polyethylene glycol (PEG) masks particles from immune recognition preventing uptake by liver and 
spleen  
• Nanoparticles exit circulatory system only at the tumor neovasculature due to leakiness of blood 
vessels  
• Particles too large to exit circulation elsewhere  
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• TNF targeting molecule on particle’s surface binds to receptors causing vascular disruption in and 
around tumor sites.  
Tumor Targeted Therapies  
One of the most promising areas in the treatment of cancer has been the development of targeted 
anti-cancer therapeutics. However, past attempts to systemically deliver cytotoxic agents directly to 
the site of disease have been met with limited success. With the completion of its Phase 1 trial for 
Aurimune, a first-in-class tumor-targeted nanomedicine,  
CytImmune believes that such site-specific drug delivery is now possible. areas in the treatment of 
cancer has been the development of targeted anti-cancer therapeutics. However, past attempts to 
systemically deliver cytotoxic agents directly to the site of disease have been met with limited 
success. With the completion of its Phase 1 trial for Aurimune, afirst-in-class tumor-targeted 
nanomedicine. 
CytImmune believes that such site-specific drug delivery is now possible.  
The mechanism underlying CytImmune’s tumor-targeted delivery can be ascribed to the size and 
composition of the nanoparticles --regardless of tumor type. By simultaneously binding  
TNF and PEG-Thiol to the surface of colloidal gold nanoparticles, the therapeutic payload travels 
safely through the blood stream avoiding immune detection and is preferentially delivered to the site 
of disease. At 27 nanometers in size, Aurimune primarily and preferentially exits the circulation 
through leaky, newly formed vasculature at tumor sites, selectively passing through gaps in blood 
vessel walls (fenestrations).  
Preliminary data from our Phase 1 clinical trial indicate that Aurimuneis preferentially delivered to 
the site of disease with minimal accumulation in healthy tissue, as the electron microscopic analysis 
(below) of tissue biopsies from a cancer patient treated with Aurimune suggests.  
 
Human Monoclonal Antibodies  
Leveraging its expertise in colloidal gold-based nanomedicines, CytImmune has also developed a 
patented, semi-synthetic in vitro immune system capable of producing fully human monoclonal 
antibody (mAb) therapeutics. The Company’s ability to produce fully human mAbs provides an 
additional pathway to develop proprietary anti-cancer therapeutics using its platform technology to 
create a separate class of nanomedicines.  
CytImmune has developed a method to generate fully human monoclonal antibodies (mAbs) using 
lymphocytes from normal donors. The technology uses the properties of gold nanoparticles to create 
an “antigen presentation” system, which loosely mimics the natural presentation of antigens by cells. 
The Company has begun proof of principle studies with antibodies against multiple components of 
the interleukin-2 receptor to block the production of T-cells for the treatment of leukemia and 
lymphoma.  
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DELCATH Systems48  
810 Seventh Avenue  
Suite 3505  
New York, NY 10019  
Telephone: (212) 489-2100  
Fax: (212) 489-2102  
 
info@delcath.com  
 
ABOUT DELCATH  
Delcath Systems (Nasdaq: DCTH) is at the forefront of the regional treatment of cancer with a 
promising therapy to shrink tumors in the liver. Delcath’s Percutaneous Hepatic Perfusion (PHP™) 
technology allows physicians to deliver significantly higher doses of anti-cancer drugs to the liver 
without exposing the patient's entire body to those same potent levels of drug. PHP™ is an 
investigational treatment currently undergoing testing in Phase III and Phase II clinical trials.  
 
Technologies  
The Delcath System™, or Percutaneous Hepatic Perfusion (PHP)™, offers a new regionalized 
approach for the treatment of unresectable hepatic malignancies in which the drug Melphalan is 
administered via the hepatic artery and the venous effluent of the liver is collected and filtered using 
a percutaneously placed catheter and filtration system. The treatment is investigational, but 
observed benefits of the procedure include:  
Minimally invasive – PHP™ utilizes a series of catheters and extracorporeal filters to infuse high doses 
of chemotherapeutic agents to tumors in the liver with minimal systemic exposure.  
Higher Dosing – PHP™ allows infusion doses exceeding those of systemic or intra-arteriaal 
administration. Treatment Flexibility -PHP™ can be performed in an operating room or in a radiology 
suite under local or general anesthesia.  
Repeatable Procedure - Unlike surgical isolated hepatic perfusion (IHP), which can be performed only 
once, PHP™ can be repeated several times. Patients within the trial usually receive the treatment at 
four-week intervals and up to ten treatments have been administered to a patient.  
Decreased Toxicity - Filtration of the hepatic venous effluent can reduce systemic exposure of 
chemotherapy by 80% to 90% compared to hepatic artery infusion alone.  
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DIATOS49 
166 Boulevard of Montparnasse 
Paris, 75014 
France 
Phone: 33153809340 
 
John Tchelingerian, Ph.D., President & CEO  
c/o Astrid Heinesch,      
Assistant to General Management    
+33 (0)1-53-80-93-62     
jtchelingerian@diatos.com   
 
About Diatos 
Diatos S.A., a biopharmaceutical company, focuses on the research, development, and 
commercialization of targeted anti-cancer drugs. The company is developing a portfolio of 
drug candidates with new compounds that utilize its Vectocell delivery technology or its 
Tumor-Selective Prodrug technology, as well as with in-licensed candidate and marketed 
cancer therapies. Its drugs and drug candidates are designed to target various solid tumors, 
including breast cancer, prostate cancer, esophagus cancer, lung cancer, colorectal cancer, 
pancreas cancer, brain cancer, head and neck cancer, melanoma and Kaposi’s sarcoma, and 
AML. The company’s product portfolio includes DaunoXome, a drug marketed for the 
treatment of Kaposi’s sarcoma; and DTS-301 and DTS-201, which are in clinical development 
for the treatment of various solid tumors. It also has a preclinical development drug, DTS-
108, which aims to increase the efficacy of SN-38 while reducing the toxic effects of 
irinotecan. Diatos has a research and development collaboration agreement with Servier SA 
in order to develop the biodistribution of one of Servier's anti-cancer oncology candidate 
drugs by means of the Vectocell technology platform. The company was founded in 1999. 
Diatos is headquartered in Paris, France, and operates subsidiaries in Belgium and the United 
States 
Diatos is a product-driven biopharmaceutical company dedicated to the development and 
commercialization of novel anti-cancer therapies.  The company’s therapeutic candidates 
DTS-201 and DTS-301, respectively a doxorubicin prodrug and a novel paclitaxel formulation, 
are planned to enter Phase I and Phase II clinical trials in 2005.  Diatos is also expanding its 
product pipeline with new compounds that utilize the Diatos Peptide Vector (DPV) intra-
cellular/intra-nuclear VectoCell® delivery technology or its Tumor-Selective Prodrug (TSP) 
technology as well as with in-licensed clinical-stage cancer therapies.  Diatos has entered 
into research collaboration agreements with several European and US biotechnology and 
pharmaceutical companies for the use of Vectocell® technology.  
Founded in 1999 as a spin-off from Institut Pasteur, Diatos has raised 33 million Euros to 
date from Sofinnova Partners (France), GIMV (Belgium), InterWest Partners (USA), Credit 
Agricole Private Equity (France), AGF Private Equity (France), Innoven Partenaires (France), 
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Société Générale Asset Management (France), NIF Ventures (Japan), Biotech Fund Flanders 
(Belgium), Sopartec (Belgium) and Institut Pasteur (France).  Diatos has 43 employees, is 
headquartered in Paris and has operations in Belgium and the US.   
Technologies 
The Diatos Peptide Vector (DPV) intra-cellular/intra-nuclear Vectocell® delivery technology 
allows direct intra-cellular delivery using cell-penetrating peptides and provides access to 
previously inaccessible intra-cytoplasmic or intra-nuclear targets. Vectocell alters the 
biodistribution of small molecules, which may result in lower toxicity of therapeutic 
compounds.  Servier and Diatos have been working together on applications of the Vectocell 
technology to Servier’s development portfolio prior to entering this agreement.    
“Our proprietary Vectocell® delivery technology is already being used to develop new 
therapies to treat cancer; and this key collaboration with a pharmaceutical partner is 
another example of the aptness of our technology in the efficient delivery of small-molecule 
therapeutics,” said Dr. John Tchelingerian, President and Chief Executive Officer of Diatos.   
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ENZON Inc.50  
Corporate Headquarters  
(908)541-8600  
Email Inquiries  
Investors: investor@enzon.com  
Employment Candidates: careers@enzon.com  
Partnership Opportunities: partnering@enzon.com  
 
About Enzon  
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing important 
medicines for patients with cancer. Enzon's drug development programs utilize several cutting-edge 
approaches, including its industry-leading PEGylation technology platform and the Locked Nucleic 
Acid (LNA) technology. Enzon's receives a royalty revenue stream from licensing partnerships for 
other products developed using the proprietary PEGylation technology.  
 
Technologies  
We continue to apply our PEGylation technology to a broad range of therapies, such as the PEGylated 
version of SN38, which has shown very encouraging results in preclinical studies.” — Hong Zhao 
Ph.D., Director, Organic and Medicinal Chemistry. Enzon is dedicated to developing innovative 
therapies through a variety of advanced technologies. Enzon’s proprietary PEGylation technology is a 
proven means of enabling or enhancing the performance of pharmaceuticals with delivery 
limitations, through the chemical attachment of polyethylene glycol or PEG via a linker. Advantages 
of PEGylation include increased efficacy, reduced toxicity, increased stability, and enhanced 
solubility. Click here to learn more about Enzon’s PEGylation technologies. Enzon has also developed 
Customized Linker Technology™, which utilizes linkers designed to release the native molecule at a 
controlled rate.  
 
PEGylation  
We continue to apply this technology to a broad range of therapies, such as the PEGylated version of 
SN38, which has shown very encouraging results in preclinical studies.” — Hong Zhao Ph.D., Director, 
Organic and Medicinal Chemistry. Enzon is dedicated to developing innovative therapies through a 
variety of advanced technologies. Enzon’s proprietary PEGylation technology is a proven means of 
enabling or enhancing the performance of pharmaceuticals with delivery limitations, through the 
chemical attachment of polyethylene glycol or PEG via a linker. Advantages of PEGylation include 
increased efficacy, reduced toxicity, increased stability, and enhanced solubility. Click here to learn 
more about Enzon’s PEGylation technologies. Enzon has also developed Customized Linker 
TechnologyTM, which utilizes linkers designed to release the native molecule at a controlled rate.  
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Customized Linker Technology  
Enzon's PEGylation expertise includes linker chemistries designed to incorporate a stable chemical 
bond between the native molecule and the PEG. Enzon's Customized Linker  
Technology utilizes linkers designed to release the native molecule at a controlled rate. The 
customized linkers expand the utility of the Enzon's existing PEGylation technology, and offer a 
choice of releasable or permanent linkages to match each native drugs requirements.  
Using this technology Enzon can potentially overcome the pharmacologic limitations for a broad 
universe of molecules and generate compounds with substantially enhanced therapeutic value over 
their unmodified forms.  
 
Locked Nucleic Acid (LNA)  
Enzon currently has a HIF-1 alpha antagonist in development and a Survivin Antagonistin clinical 
development and several additional targets in early preclinical research.  
 
Royalty Products  
We receive royalties on three marketed products that successfully utilize our proprietary PEGylation 
platform, namely PEGINTRON®, Macugen®, and CIMZIA®, with PEGINTRON being the largest source 
of our royalty income. We also could receive royalties on Hematide, which is currently in Phase III 
development, if approved.  
PEGINTRON is a PEG-enhanced version of Merck's alpha interferon product, INTRON® A, which is 
used both as a monotherapy and in combination with REBETOL® (ribavirin) capsules for the 
treatment of chronic hepatitis C. The product has also been submitted for approval for adjuvant 
treatment of patients with Stage III melanoma. The application was recommended for approval by 
the FDA Oncology Drugs Advisory Committee in October 5, 2009. However, on October 30, 2009, the 
FDA issued a complete response letter to the Merck's supplemental Biologics License Application 
regarding PEGINTRON for this indication. Merck continues to work closely with the FDA to respond to 
outstanding concerns related to the PEGINTRON melanoma filing.  
Macugen (pegaptanib sodium injection) is currently being marketed through a collaboration between 
OSI and Pfizer for the treatment of neovascular (wet) age-related macular degeneration, an eye 
disease associated with aging that destroys central vision.  
CIMZIA was approved in April 2008 for the treatment of Crohn's disease and is marketed by UCB. In 
May 2009, CIMZIA was approved for adult patients suffering from moderate to severe rheumatoid 
arthritis.  
Hematide is a synthetic peptide-based erythropoiesis-stimulating agent being evaluated by Affymax 
and Takeda Pharmaceutical in for the treatment of anemia in chronic kidney failure. At the end of 
Janaury 2010, Affymax announced that the Phase III trial was completed and top line results would 
be reported in the second quarter of 2010. If results are positive, the Company plans to submit an 
New Drug Application (NDA) later in 2010.  
 - 131 - 
ENDOCYTE 51 
Endocyte, Inc. (Headquarters)  
3000 Kent Avenue  
Suite A1-100  
West Lafayette, IN 47906  
Phone: 765.463.7175  
Fax: 765.463.9271  
info@endocyte.com  
 
Endocyte, Inc.  
8910 Purdue Road  
Indianapolis, IN 46268  
Phone: 317-876-1478  
 
About Endocyte  
Great progress has been made in the development of new drugs to treat cancer and other serious 
illness. However, these therapies are often administered at suboptimal doses because of their effects 
on healthy tissue. The value of these therapies is further diminished because of the inability to 
predict in advance if a patient will respond to a particular therapy. Endocyte is addressing both of 
these issues using a new "drug guidance" technology.  
Drug Guidance System  
Endocyte's novel drug guidance system is designed to improve the specificity, safety, and efficacy of 
potent drugs by targeting them directly to diseased cells. Our technology can be used to deliver a 
variety of drug therapies, from small molecule cancer drugs to larger proteins and RNA-based 
therapies.  
Predictive Medicine  
Endocyte is also developing powerful companion diagnostic agents (such as EC20 and EC0652) that 
are designed to predict in advance if a patient will respond to our drug therapy. By linking our drug 
guidance system to a diagnostic imaging agent, we can generate a patient-specific targeting profile to 
help identify likely responders.  
Strong Clinical Stage Pipeline  
Today, Endocyte has six targeted cancer drugs in clinical trials. We believe our patented technology 
may also have applications in developing better drugs to treat diseases such as rheumatoid arthritis, 
osteoarthritis, and atherosclerosis. This proprietary technology is being used today by a number of 
drug companies in collaboration with Endocyte.  
 
 
                                            
51
 www.endocyte.com 
 - 132 - 
Technologies  
A major problem in treating cancer and other serious illnesses is that highly toxic drugs are often 
administered at suboptimal doses because of their side effects on healthy tissues. By targeting drugs 
specifically to tumor cells or other diseased cells and avoiding normal healthy cells, it may be possible 
to treat patients with safer and more effective doses.  
Endocyte’s proprietary drug guidance system (DGS) is designed to deliver drugs directly to diseased 
cells. This DGS is composed of a targeting ligand that attaches to a drug and then binds to receptors 
over-expressed on the membranes of diseased cells.  
Our lead program uses the vitamin folate to target cancer cells. Folate is required for cell division, 
and rapidly dividing cancer cells over-express a receptor for folate. By attaching drugs to folate, we 
are able to target drugs directly at cancer cells with less potential toxicity to surrounding healthy 
cells.  
Our approach is unique from other targeting technologies, such as large antibodies. Our focus on 
small, high-affinity targeting ligands (300 times smaller than antibodies) facilitates their penetration 
into dense tumors and rapid clearance from the body, reducing the risk of toxicity to normal cells. 
This approach to targeted drug therapy opens up the potential for safer and more effective 
treatment approaches using:  
. High-potency drugs that may not have been developed due to toxicity. Our pipeline includes drugs 
that are 1,000 to 10,000 times more potent than existing cancer therapies like cisplatin.  
. A more effective dose-dense schedule to put constant pressure on the tumor. In early clinical 
studies, EC145 our a targeted super-potent vinca, was dosed daily for 3 consecutive weeks with 
minimal toxicity.  
. A new combination of drugs that could not be dosed due to overlapping toxicity. Our drug EC0225 
targets a combination of two highly potent chemotherapy drugs.  
Preclinical data showed this drug could cure even very large tumors.  
. Building a "Guided Drug"  
. Endocyte's drug-discovery engine is capable of producing a number of improved targeted drugs for 
multiple diseases. Building a guided drug involves a three-step process designed to reduce 
development and clinical risk.  
 
. Step 1: Validate the Guidance System  
Our process begins by screening diseased cells for unique receptors. After identifying a receptor, we 
design a guidance system or targeting ligand that binds with high affinity to the target receptor. The 
guidance system is then attached to a diagnostic imaging agent that is tested in humans to ensure 
the guidance system targets the diseased cells and not normal cells. EC20, our folate-receptor 
guidance system, has demonstrated targeting in cancer and other diseases.  
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. Step 2: Build a Pipeline of Targeted Therapies  
Once the guidance system (targeting ligand) has been validated in humans, a variety of potent 
therapeutic molecules are screened. We look for highly potent drugs with doselimiting toxicities. 
After a drug is identified, we attach it to the validated guidance system and compare it to the free 
drug in in-vitro and in-vivo models. If the guided drug is better than the free drug in terms of efficacy 
and safety, it is advanced into the clinic. By repeating this process for each drug, we are able to build 
a pipeline of unique drugs with potentially superior safety and efficacy.  
 
. Step 3 -Identify Patients Likely to Respond  
The final step is to use companion diagnostic imaging agents to identify patients likely to respond to 
a targeted therapy. These companion diagnostics use the same guidance system as the therapeutic 
drug and are incorporated into all of our clinical studies to determine whether each patient is an 
appropriate candidate for the therapeutic drug.  
 
Predictive Medicine  
A major problem with many drug therapies is the inability to predict patient response. New 
predictive medicine tools, such as companion diagnostic imaging, are needed to identify how well a 
patient will respond to a particular drug therapy.  
Recognizing this critical need for new predictive medicine tools, Endocyte has developed molecular 
imaging companion diagnostic tools for all of its therapeutic product candidates.  
The companion diagnostic agent attaches a molecular imaging agent to the same drug guidance 
system used for the therapeutic drug. The companion diagnostic provides a fullbody, real-time image 
that can be used to determine whether the guidance system is targeting the diseased cells.  
These powerful companion diagnostics are being used in all of our trials to identify the most 
appropriate patient population for clinical testing.  
The diagnostic images below were obtained following administration of our folate-receptor targeted 
imaging agent EC20-Tc99m. The patient on the left shows no targeting to tumor (negative profile). 
The patient on the right shows targeting to tumors (positive profile).  
 
Potential Applications  
Cancers that over-express folate receptors, such as ovarian, NSCLC, breast, colorectal, renal cell, and 
gastric cancer, affect more than 400,000 people in the United States. Folate is required for cellular 
division, and rapidly dividing cancer cells over-express receptors for the vitamin. It may be possible to 
treat these patients more effectively with a drug attached to a folate ligand that can be delivered 
directly to the folate receptors on the cancer cells. Endocyte is developing other targeting ligands 
beyond folate that may benefit additional cancer patients.  
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Looking beyond cancer, we are also advancing research to develop products that can target an 
essential immune cell – the activated macrophage – that plays a role in a number of diseases. 
Activated macrophages release pro-inflammatory agents, such as TNF and IL-2, which are the target 
of immune-modulating drugs such as Humira, Enbrel, and Kineret.  
Working in collaboration with the Mayo Clinic and Purdue University, Endocyte hasdesigned and 
validated drug guidance systems that target activated macrophages involved in inflammatory 
diseases, such as rheumatoid arthritis, osteoarthritis, and atherosclerosis.  
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Eurand52 
United States 
Pennsylvania 
790 Township Line Rd 
Suite 250 
Yardley, PA 19067 
U.S.A. 
Tel: +1.267.759.9400 
Fax: +1.215.968.2941 
 
Europe 
Milan, Italy 
Via Martin Luther King, 13 
20060, Pessano con Bornago 
Milan 
Italy 
 
About Eurand 
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes 
enhanced pharmaceutical and biopharmaceutical products using our proprietary drug formulation 
technologies. A publicly traded company (NASDAQ: EURX), Eurand has operating units in the United 
States and Europe.  
Eurand is dedicated to the continued development and commercialization of breakthrough products 
intended to satisfy patients’ needs. Research efforts are focused on the development of treatment 
options with enhanced efficacy, superior safety, and convenient dosing. Eurand has a number of 
products in development for the company and its co-development partners that are commercialized 
worldwide. Through continued investment in R&D, Eurand has a very exciting pipeline of products in 
various stages of development that, upon approval for the market, will continue to bring benefits to 
patients and their caregivers.  
Eurand’s business strategy is focused in the following areas: 
Sales and Marketing of Specialty Healthcare Products in the U.S. 
Eurand is focused on the research, development and commercialization in the United States of 
products for use in the treatment of Cystic Fibrosis and gastrointestinal-related diseases. 
Development & Licensing of Products and Technologies 
Eurand is a leading global pharmaceutical technology company and is focused on the co-
development of partnered products and the out-licensing of Eurand’s products worldwide.  
Eurand has one of the broadest ranges of drug delivery platforms in the industry, including: 
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 Bioavailability Enhancement 
 Customized Drug Release 
 Taste Masking / Orally Disintegrating Tablets (ODT) 
Eurand uses these technologies to develop and expand the company’s internal pipeline and to 
partner with pharmaceutical and biopharmaceutical companies to develop their products 
Success in Commercialization with Industry-leading Partners 
Eurand established partnerships with major pharmaceutical companies, as listed below. The 
relationships are based on either co-development of products using our partners' drug and Eurand’s 
pharmaceutical technologies, or the licensing and distribution of Eurand’s internally developed 
products. 
 
 
 
Technologies 
Biorise 
New Physical Entities (NPEs) are produced by breaking down the crystalline drug into nanocrystals 
and/or amorphous (noncrystalline) drug that is stabilized in a carrier system to maintain the drug in 
its activated form for the duration of its shelf life.  
This approach creates a greater surface area to volume ratio that increases the intrinsic solubility and 
dissolution rate of poorly water-soluble drugs, thereby enhancing their rate and extent of absorption.  
The Biorise technology can be applied to Class II compounds with solubilities in the range of <10 to 
500 μg/mL.  
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Eurand has developed 2 distinct proprietary activation systems to create NPEs by converting drugs 
into their stabilized, thermodynamically activated state. These systems provide flexibility and allow 
the technology to be applied to a range of compounds with differing physicochemical characteristics.  
The Biorise technology manufacturing process provides both time savings and cost efficiencies with 
its short cycle time, single processing step, batch consistency, and formulation stability. 
 
 
Biorise Proprietary Activation Systems  
Advantages of Biorise 
 Increases solubility of Class II compounds  
 Provides a faster onset of action, equivalent therapy at lower doses, and/or oral dosing of 
poorly soluble drug candidates  
 Short manufacturing cycle time and single processing step 
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Diffucaps  
Diffucaps is a multiparticulate bead system comprised of multiple layers of drug, excipients, and 
release-controlling polymers. The beads contain a layer of organic acid or alkaline buffer to control 
the solubility of a drug by creating an optimal pH microenvironment for drugs that exhibit poor 
solubility in intestinal pH, in environments with pH greater than 8.0, or in physiological fluids. 
Alternatively, the beads can contain a solid-solution of drug and crystallization inhibitor to enhance 
bioavailability by maintaining the drug in its amorphous state.  
 
Diffucaps technology is especially suitable for drugs that traditionally require multiple daily doses or 
drugs needing customized release formulations. Each Diffucaps bead has an inert core surrounded by 
drug and coated with a functional polymer membrane to control the rate of drug release.  
Diffucaps also can be combined with other proprietary Eurand technologies to optimize drug 
delivery. Diffucaps beads are <1.5 mm in diameter and can be filled into capsules or compressed into 
orally disintegrating tablets. In addition,as a multi-particulate system, Diffucaps products produced in 
capsules allow for the capsules to be opened and the contents used as a sprinkle on foods, providing 
a flexible dosage form for patients who experience difficulty swallowing tablets or capsules.  
 
The flexibility of the Diffucaps system allows for easy adjustment of the release profile and dosing 
strength to achieve targeted in vivo results. For drug development partners involved in clinical 
testing, this flexibility simplifies dose-ranging studies because the beads can be encapsulated 
separately to create separate study arms.  
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Eurand’s Diffucaps technology is used in several currently marketed products and in novel products 
in clinical development.  
Advantages of Diffucaps 
 Ideal for drugs exhibiting poor solubility in lower intestinal pH, in environments with pH 
above 8.0, or in physiological fluids  
 Can combine multiple drugs and/or multiple release profiles in the same dosage form  
 Simple formulation of dose-proportional strengths.  
 Can minimize food effect  
 
Diffutab 
Diffutab technology uses a blend of hydrophilic and hydrophobic polymers to control drug 
release via diffusion through, and erosion of, a matrix tablet. Diffutabs are particularly useful 
for high-dose products and drugs that require sustained release and/or once-a-day dosing.  
Advantages of Diffutabs  
 Matrix tablet utilizes a combination of water soluble particles and active drug 
 Suitable for high drug loading 
 Supports sustained-release, once-a-day dosing 
 
 
Orbexa 
Eurand’s Orbexa technology produces beads of a controlled size and density using 
granulation spheronization, and extrusion techniques. These beads provide high drug 
concentrations and can be coated with functional polymer membranes for additional release 
rate control.  
Orbexa beads can be filled into capsules or single-dose sachets.  
Advantages of Orbexa 
 Aqueous or solvent-based granulation  
 High-speed process is well suited for sensitive molecules like proteins  
 Suitable for high drug loading  
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IMMUNOGEN, Inc.53  
Headquarters:  
830 Winter Street  
Waltham, MA 02451-1477  
Tel 781-895-0600  
Fax 781-895-0611  
 
About Immunogen  
“ImmunoGen, Inc. develops targeted anticancer therapeutics using our expertise in cancer biology, 
engineered antibodies and highly potent cancer-cell killing agents.  
We have established expertise in the development and humanization of tumor-targeting antibodies. 
As is well accepted, engineered antibodies can do an excellent job of selectively binding to cancer 
cells, but are typically sub-optimal in their ability to actually kill cancer cells. Thus, we have 
developed specialized cancer-cell killing agents to serve as payloads – to be attached to such 
antibodies for targeted delivery to tumor cells.  
Our payload agents are 1,000-10,000 times more potent than traditional chemotherapy agents. We 
also have developed engineered linkers that keep the payload firmly attached to the antibody while 
the whole therapy is circulating through the bloodstream and then release it once the therapy has 
reached and entered a cancer cell.  
We use our Targeted Antibody Payload (TAP) technology – together with our strong antibody 
expertise – to develop our own product candidates. We also selectively outlicense our technology to 
other companies for use with their engineered antibodies.  
There are now many TAP compounds in clinical testing through our own product programs and those 
of our partners. The lead compound – trastuzumab-DM1 (T-DM1) – is in advanced clinical testing by 
Genentech* and Roche. Next are lorvotuzumab mertansine (IMGN901) for CD56+ solid tumors and 
multiple myeloma and SAR3419 for nonHodgkin's lymphoma.  
ImmunoGen is headquartered in Waltham, Massachusetts. Our GMP manufacturing facility is in 
Norwood, Massachusetts. We have approximately 200 employees in R&D, clinical research, 
manufacturing, and administrative functions.  
Our mission is to be the leader in the application of monoclonal antibodies for the treatment of 
cancer. We aim to achieve this by exploiting our expertise and experience in the identification of 
potential biological targets for cancer treatments, the development and humanization of monoclonal 
antibodies, and the creation of potent cell-killing agents designed for delivery by antibodies. Our 
Targeted Antibody Payload(TAP) technology uses tumor-targeting antibodies to deliver a highly 
potent cell-killing agent specifically to cancer cells to kill these cells with minimal damage to healthy 
tissue.  
We are committed to the highest standards of scientific excellence and integrity for the benefit of 
patients, the medical community, our partners, shareholders and employees.” 
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Technologies  
“We created our TAP technology to achieve more effective, better tolerated anticancer drugs.  
A TAP compound is designed to focus its activity on cancer cells – to kill these cells while minimizing 
damage to healthy tissue.  
A TAP compound consists of: a monoclonal antibody that binds specifically to a target – its antigen – 
found on cancer cells with a potent cell-killing agent attached. The antibody serves to target the 
compound specifically to cancer cells and the cell-killing agent serves to kill the cancer cells.  
We use our TAP technology with our own antibodies to create anticancer compounds. If an antibody 
is proprietary to another company and not available for our own product programs, we may 
outlicense our TAP technology to that company. This enables us to derive a potential economic 
return not otherwise possible and expands the application of our technology.  
ImmunoGen has established leadership in the field of antibody-drug conjugates (ADCs), with the 
most clinical publications on the most ADC compounds by the most companies across a range of 
cancers.”  
 
 
“Our Cell-Killing Agents  
Our cancer-cell killing agents (CKAs) are 1,000-to 10,000-fold more potent than traditional 
chemotherapy drugs. We developed them specifically for attachment to antibodies for targeted 
delivery to cancer cells.  
The CKAs used in the TAP compounds in clinical testing act by interfering with tubulin and kill cancer 
cells when they attempt to undergo cell division. We continue to expand our portfolio of CKAs to 
further extend the utility of our technology, and unveiled our IGN family of DNA-acting agents at a 
scientific conference last year.”  
 
“The Linker  
Our linkers serve to keep our CKAs attached to the antibody until the TAP compound has entered a 
cancer cell. They then control the release of the CKA to kill the cancer cell.  
Just as different cancers respond better to some drugs than others, we have found that different 
linkers work better for some cancers than others. Therefore, we have developed a portfolio of linkers 
to enable us, and our partners, to achieve the best product design for the cancer target. Our modular 
approach -separate linkers and CKAs -enables rapidly evaluation of different product designs.  
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We continue to expand our linker portfolio, and recently unveiled linkers that extend the utility of 
our TAP technology for cancers with multi-drug resistance.”  
 
“The Antibody  
Each TAP compound contains an antibody that binds specifically to an antigen found on cancer cells. 
Each different TAP compound contains a different antibody, enabling different cancers to be 
targeted. For example, T-DM1, IMGN901, and SAR3419 are in development for HER2+ cancers, 
CD56+ cancers, and CD19+ cancers, respectively, as their antibodies target these different types of 
cancers.  
While ImmunoGen is known for our TAP technology, we also have extensive antibody expertise.  
Our manufacturing facility in Norwood, MA, helps us and our collaborators rapidly advance new TAP 
compounds into human trials, as it facilitates the production of drug supplies for initial clinical trials. 
Our Norwood facility has four production suites and all of the functions needed to manufacture TAP 
compounds in compliance with FDA current Good Manufacturing Practices (cGMP). ImmunoGen has 
gained extensive, unique experience in the production scale-up and manufacturing of conjugate 
compounds that a growing body of other companies have paid us to access.”  
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NanoBioMagnetics, Inc.54  
124 N. Bryant Ave, Suite C-3  
Edmond, OK 73034  
Ph: 405.844.5118  
Fx: 405.844.4115  
 
About NanoBioMagnetics  
NanoBioMagnetics (NBMI) is a nanobiomaterials company pioneering an emerging area of 
nanomedicine referred to as organ-assisting-device (OAD) technologies, in which magnetically 
responsive nanoparticles (MNP), under the influence of external shaped magnetic fields, are 
magnetically vectored to cause or drive a desired physiological event. OAD healthcare applications 
are being developed under two proprietary platforms (patents pending):  
• Biostable Implants: MNP, implanted in tissue, nanomechanically drive tissue movement or 
vibration under the influence of an external oscillating magnetic field.  
• Site-Specific Drug Delivery: MNP-therapeutic constructs, under the influence of external shaped 
magnetic fields, are vectored to a target site, followed by cell uptake.  
As a nanobiomaterials company, NBMI has established collaborations with major research 
institutions for the validation of its OAD healthcare technologies. When successfully transferred to 
the clinical sector, OAD technologies will provide the physician and patient with new more effective 
therapeutic options for addressing the medical requirements of disease management.  
The company's business model calls for the development and validation of OAD healthcare 
applications through collaborations with academic and pharma organizations, followed by a spin-off 
of a business venture in conjunction with pharma partnerships. Once established, pharma partners 
will move the respective OAD technologies forward through clinical evaluations and FDA clearances.  
NBMI's proprietary magnetic vectoring technology also creates a pipeline of OAD technology 
applications, also under some stage of collaborative development, that include:  
• Early stage cancer diagnostics  
• Placement and positioning of stem cells  
• Magnetic based biosensors  
• Vectoring of down-regulating genes  
 
A US Patent was awarded in 2008 for Hearing Amplification technology, and the company currently 
has 8 patents pending.  
 
Technologies  
Magnetic Vectoring  
                                            
54
 www.nanobmi.com/ 
 - 144 - 
Nanotools for the Site-Specific Targeting of Therapeutics  
The application of nanotechnology to the miniaturization of biomedical devices (Nanomedicine) is an 
emerging field, anticipated over the coming years to deliver a range of new therapeutic tools that will 
offer the patient and physician new and more effective treatment options. Biomagnetic delivery 
systems have been under development since the late ‘70’s and early ‘80s. In general, historical 
magnetic delivery systems, while achieving tumor reduction via intra-arterial administration, have 
demonstrated little or no success through i.v. (systemic) administration.  
In general, previous magnetic delivery systems have relied on accumulation of drug-carrier 
constructs at the tumor site, using external magnets to create gradients that encompassed the target 
site. The magnetic carriers, generally micro in size as opposed to nano-scaled, were to be held in 
place at the target site long enough for the drug to desorb from the carrier in the vicinity of the 
target site with anticipated tumor uptake. In theory, such systems were supposed to have significant 
advantages over non-targeting systemic administration; however, in actuality, as evidenced by the 
failure of clinical trials, little difference was observed between this procedure and the non-magnetic 
controls.  
The solution to site-specific drug delivery is multi-factorial, combining stealthier constructs at the 
nanoscale, with more powerful shaped magnetic fields, the design of which present the potential for 
extending magnetic saturation to deeper tumor sites.  
Successful magnetic vectoring of drug-loaded magnetically responsive nanoparticles requires that (1) 
the magnetic vectoring device produce a magnetic field of sufficient to achieve saturation of the 
magnetite at a distance far enough from the magnet face to reach the volume containing the tumor, 
and (2) the magnet must produce a field gradient strong enough to manipulate the particles as 
required to enhance tumor extravasation. We have established that arrays/configurations of 
permanent magnets can be constructed to extend and shape the magnetic field, establishing a 
foundation for scaling the technology to clinical levels.  
We have successfully demonstrated the tumor-specific accumulation and extravasation of 
magnetically responsive nanoparticles on ovarian, breast and inflammatory breast cancer models in 
collaborations with scientists at the M D Anderson Cancer Center (Klostergaard J, Bankson J, Yuill W, 
and Seeney C., “Magnetic vectoring of magnetically-responsive nanoparticles within the murine 
peritoneum”, J Magnetism Magnetic Materials, Vol 311, Issue 1, April 2007).  
 
OAD Technology for the Site-Specific  
Delivery of Chemotherapeutics  
Overview: NBMI, in association with collaborators at The M D Anderson Cancer Center,  
Houston, TX, have demonstrated in a live mouse model, in a scientific first, that constructs of 
magnetically responsive nanoparticles (MNP) can be externally vectored to a tumor site. The 
collaboration is now focusing research efforts on the efficacy of MNP constructs as vehicles for the 
site specific delivery of chemotherapeutics. Under this concept, MNP/chemotherapeutic 
configurations (such as MNP-Paclitaxel) are to be evaluated for effectiveness in the vectored delivery 
of high therapeutic doses internal to the tumor structure.  
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Commercialization Focus: As a vectored delivery mechanism for treating cancerous tissues, this 
technology offers the potential to maximize chemotherapeutic dosage forms while minimizing 
harmful or debilitating side effects. The effectiveness of this treatment methodology will lead to a 
reduction in the number of treatment per cycle with a concurrent increase in survival rates over 
longer time frames. The capability to vector therapeutics site specifically will lead to treatment 
options that do not now exist. At present, with ovarian cancer as an example, most cases present in 
the late stages of the disease, resulting in a survival rate of approximately 50% and a 5-year survival 
rate of less than 20%. There is currently no early stage detection and treatment methodology for this 
disease. The patient cost/benefit ratio is significantly high and breakthrough technologies are 
necessary for improvements in both quality of life and patient survival.  
 
Patents are pending.  
Advantages: The advantages of vectored delivery over conventional chemotherapeutic treatments 
are several:  
• Increased effective dose forms  
• Reduced treatment cycles  
• Greater patient compliance  
• Increased patient cost/benefit  
 
Partnerships: NBMI is seeking joint development partnerships with major healthcare organizations 
with the vision and capacity for supporting the development and commercialization of new 
disruptive technology based on NBMI’s OAD technology for the delivery of chemotherapeutics.  
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NanoCarrier, Inc.55  
Head office and Lab  
5-4-19 Kashiwanoha, Kashiwa, Chiba 277-0882, Japan  
TEL: +81-4-7169-6550 FAX: +81-4-7169-6551  
Tokyo Office  
Yaesu Yamagata Bldg., 3-2-2 Nihonbashi, Chuo-ku, Tokyo 103-0027, Japan  
TEL: +81-3-3548-0213 FAX: +81-3-3548-0214  
 
About NanoCarrier  
Mission: 
 To contribute to the betterment of human health and medical progress by producing new drugs 
utilizing nanotechnology for improvement of patitents’ Quality of Life (QOL). 
Vision: 
 To be an innovative and leading biotech company, unrivalled in cancer field. 
 
Technology  
Micellar nanoparticles are composed of biocompatible block copolymers, comprising of hydrophilic 
polyethylene glycol (PEG) and hydrophobic polyamino acid. The formation of micelles, aggregates of 
20-100 nanometer-size spheres, occurs when the block copolymers diffuse in water. Drugs and 
biologically active substances can be stably encapsulated in the hydrophobic inner core of the 
micelles. This technology can be applied to various types of compounds by modifying amino-acid side 
chains, etc. PEG coating on the surface ensures the micelles' stability in the bloodstream.  
 
 
Micellar nanoparticle technology has a broad range of application in pharmaceutical development. 
For example, we can expect various benefits by controlling drug release from micelles: improved 
safety by lowering drug concentration below the level where adverse effects may occur; increased 
stability of drug in the bloodstream whose half-life is very short; and higher therapeutic efficacy by 
increasing the amount of drugs delivered to the targeted lesions etc.  
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 Nano Interface Technology, Inc.56  
Nano Interface Technology, Inc.  
Lorton, VA , USA  
 
About Nano Interface Technology  
Nano Interface Technology, Inc. (NITI) was incorporated in 1998. Our mission is “Innovation in the 
Nano-biotechnology and Nanotechnology.” We are a pioneering research organization committed to 
develop novel nanotechnologies in biotechnology, material sciences and the drug delivery areas. One 
of the major scientific challenges for the material scientists has been the development of processes 
that can help control the ultra-homogeneity in material properties at a molecular stage. We plan to 
commercialize our products by licensing technologies and developing products for the private 
companies. Most of our technologies are proprietary and is protected by the current patent law. We, 
at NITI, believe  
that we have hit upon the Holy Grail of material production, where we can synthesize molecules 
under highly controlled conditions for specific applications. With the right reaction system and 
specific ambient conditions, we can control the properties and purity levels of our products. All of 
these processes can be easily scaled up for large-scale production, at commercial levels. Our vision is 
to significantly alter the processes and purity levels of materials by creating them at the molecular 
level.  
 
Technologies  
1. Nano-biomaterials for biomedical applications  
The products and technologies developed by the NITI can be put to variety of uses. The target market 
has been chosen as the applications in the life sciences market. This market has been chosen in view 
of its relevance, ease of entry and potential size.  
a. Developed superior nano-biomaterials using innovative materials processing technologies.  
b. Focus on the development of the hydroxyapatite (HA) – used extensively as the latest material for 
the coating of the implants for the human body.c. The usage of HA synthesized by our process will 
decrease the failures of the implants, reduce the costs of the insurance and decrease the patient’s 
trauma.  
 
2. Nanorods  
Alternative of the Carbon Nanotubes for the High Volume Applications: The cost of the carbon 
nanotubes is $100,000 -$200,000 per pound depending on the quality of the nanotubes. At that 
price, one can’t use it for nanocomposites. In order to provide leap-frog improvement in the strength 
of nanocomposites and other applications, Nano Interface Technology has developed mesoporous 
nanorods which can provide nanorods of diameter  
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-32 nm and of length 100-500 nm. These nanorods are synthesized by sol-gel chemistry and self-
assembly of surfactants methods. Nanorods of silica, alumina or copper can easily be produced at a 
cost of $20 a pound.  
3. Nano-encapsulated Anticancer Drugs  
NITI is developing targeted controlled release of the chemotherapeutic agents which is already 
approved by the FDA for the human trials and was not successful due to the difficulty in maintaining 
high concentration of such anticancer drug around tumors. NITI’s innovative targeted drug delivery 
system will allow to maintain high concentration of such drug around tumor to kill tumor. Hence, 
clinical trials and drug approval can be carried out on the fast track basis. The chemotherapeutic 
agents have $10 billions per year in the US alone. The world market for such drugs is $20 billions per 
year.  
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NEKTAR  
U.S. Office Locations and Contact information  
Corporate Headquarters:  
201 Industrial Road  
San Carlos, CA 94070  
Tel: 650.631.3100  
 
Nektar Alabama:  
490 Discovery Drive  
Huntsville, AL 35806  
Tel: 800.457.1806  
Fax: 650.631.3150 Fax: 256.533.4805  
Email: nektarSC@nektar.com  
 
About Nektar  
Corporate Overview  
Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel 
therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also 
partners with the top biopharmaceutical companies to bring new products to market. To date, 
Nektar's technology and drug development expertise have enabled nine approved products for 
partners, which include leading biopharmaceutical companies.  
 
Technologies  
 
Nektar's proprietary Advanced Polymer Conjugate Technology platform allows for a custom 
approach that capitalizes on the properties of polymer medicinal chemistry and an understanding of 
both a drug's characteristics and the body's mechanisms.  
Our scientists identify specific drug molecules, both large and small, that with customized chemical 
modification using uniquely-designed polymers can be enabled or made more efficacious. With our 
proprietary conjugate approaches, suboptimal drugs can be designed to dial in desired therapeutic 
properties and create an optimized and potentially superior therapeutic  
Using our novel and proprietary polymer conjugate approaches, suboptimal drugs can achieve 
optimal therapeutic properties. With our expertise as a leader in the field of  
PEGylation, Nektar has created a set of new platform technologies. Nektar's Advanced  
Polymer Conjugate Technology can be tailored in very specific and customized ways to optimize a 
wide range of molecule classes:  
• Small Molecule Polymer Conjugates  
• Pro-drug conjugates  
• Large Molecule Polymer Conjugates  
• Antibody fragment conjugates  
 
Nektar has a dominant and broad patent estate with its technology platform across many 
therapeutic areas and modalities.  
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Background of PEGylation Technology  
PEGylation has been a highly effective commercial strategy for the development of blockbuster 
therapeutics, such as Roche's PEGASYS® (interferon) and Amgen's Neulasta® (G-CSF). Nektar is the 
world leader in enabling therapeutics with PEGylation technology.  
Every PEGylated product approved over the last fourteen years was enabled with Nektar technology. 
By partnering with the world's leading pharmaceutical companies, Nektar PEGylation technology has 
created over $6 billion in annual sales for our partners.  
PEG (polyethylene glycol), a versatile technology, is a water soluble, amphiphilic, nontoxic, non-
immunogenic compound that is safely cleared from the body. Its primary use to date in currently 
approved drugs is to favorably alter the pharmacokinetic properties of biologics. Early approaches to 
PEGylation were tremendously successful in creating blockbuster biologics but these did not fully 
leverage the flexibility and potential of the technology.  
The limitations of older PEGylation approaches used with biologics are:  
• Sub-optimal bioavailability and bioactivity  
• Product is altered by PEG remaining attached to parent drug  
• Limited ability to fine-tune properties of drug  
• Did not allow for oral administration  
• Not applicable to small molecules, antibody fragments, and peptides  
 
Small Molecule Polymer Conjugates  
This platform allows for the fine-tuning of the physicochemical properties of small molecule oral 
drugs to increase their therapeutic benefit. In addition, the approach can enable oral administration 
of parenterally-delivered small molecule drugs that have shown low bioavailability when delivered 
orally.  
Benefits of this approach are: improved potency, increased oral bioavailability, modified 
biodistribution with enhanced pharmacodynamics, and reduced transport across specific membrane 
barriers in the body, such as the blood-brain barrier. A primary example of this CNS-exclusion 
application is represented by Oral NKTR-118, a novel peripheral opioid antagonist in Phase 2 clinical 
development.  
 
Pro-Drug Conjugates  
The pro-drug polymer conjugation approach can optimize the pharmacokinetics and 
pharmacodynamics of a drug to substantially increase both its efficacy and side effect profile. Nektar 
is currently using this platform with oncolytics, which typically have suboptimal half-lives which can 
limit their therapeutic efficacy. With Nektar's platform, these drugs can be modulated to optimize 
bioactivity and increase the sustained exposure of active drug to tumor cells in the body.  
Nektar is using this approach with the two lead oncology candidates in our pipeline, NKTR102 and 
NKTR-105.  
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Large Molecule Polymer Conjugates  
This platform builds on Nektar's expertise in enabling the successful PEGylated biologics on the 
market today. The approach has been designed to enable peptides, which are much smaller in size 
than biologics. Peptides are important in modulating many physiological processes in the body. Some 
of the benefits of working with peptides are: they are small, easily optimized, and can be quickly 
investigated for therapeutic potential. However, peptide drug discovery has been slowed by the 
extremely short half-life and limited bioavailability of these molecules.  
Nektar scientists have designed a novel hydrolyzable linker that can be used to optimize the 
bioactivity of a peptide. Since the surface area of peptides is much smaller than larger biologics, the 
older PEGylation approaches can not be used. Through rational drug design and the use of Nektar's 
approach, a peptide's pharmacokinetics can be substantially improved and its half-life can be 
significantly extended. The approach can be used with proteins and larger molecules, as well.  
Nektar is in the early stages of research with a number of peptides that utilize this proprietary 
approach.  
 
Antibody Fragment Conjugates  
This approach uses a large molecular weight polyethylene glycol conjugated to antibody fragments. 
The specially designed PEG then becomes part of the antibody fragment Fc. Since the antibody 
fragment is more like a biologic, this conjugation has a branched architecture with either stable or 
degradable linkage.  
Where might this conjugation technique be beneficial?  
• Parenterally administered molecules  
• Need to enhance pharmacokinetics  
The target of this conjugation is improved toxicity profile, extended half-life, and ease of synthesis 
with the antibody  
 
Why use the Antibody Fragment Conjugates?  
• Reduce antigenicity  
• Reduce glomerular filtration rate  
• Identify to proper linkage site to facilitate the re-production of identical conjugates from batch to 
batch  
• Must still retain antigen-binding affinity and recognition  
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NeoPharm57  
 
About NeoPharm  
NeoPharm is a biopharmaceutical company developing and commercializing drugs for the treatment 
of various cancers and other diseases using enhanced and innovative drug delivery systems. 
NeoPharm is focused on providing life-saving and life-enhancing solutions to the drug delivery and 
oncology markets.  
NeoPharm has multiple drug candidates in various points of clinical development, including a LEP-
ETU Phase II trial for breast cancer, LE-DT Phase II trials for pancreatic and prostate cancers, an IL13-
PE38 Phase I trial for idiopathic pulmonary fibrosis and an IL13-PE38 Phase I trial for untreatable 
brain diseases in humans.  
NeoPharm's clinical trials have been structured to capitalize on broader indications of cancer and 
other diseases. With a reorganization strategy originally announced in April 2007, NeoPharm has 
achieved significant cost-savings and put into place an optimal cost structure which enables the 
company to focus primarily on the development of drug candidates. The company has significantly 
reduced its cash consumption rate and has resources available to fund current candidates in 
development into the third quarter of 2010.  
 
Key initiatives completed as part of this reorganization include:  
• Annualized cash consumption levels reduced to approximately $5 million  
• Cost structure realigned to optimize the progress of several drug candidates to next strategic event  
• Streamlined organization to include a core team of technical employees to support development 
activities and ensure regulatory compliance for all drug candidates.  
 
Formed a new management team with relevant experience and expertise.  
 
Technologies  
 
NeoLipid® DRUG DELIVERY  
NeoPharm uses novel proprietary lipids and improved procedures to entrap difficult-to deliver drugs 
in small, homogenous, and stable liposomes, which are microscopic membrane-like structures 
created from lipids (fats). Because tumor cells need to consume large amounts of fat to sustain their 
rapid growth, they recognize the liposomal drug as a potential source of nutrition.  
NeoPharm's NeoLipid® innovative system of delivering anticancer drugs to tumors can potentially 
improve pharmacokinetics and reduce the toxicity of potent drugs, creating an opportunity for more 
comfortable-to-administer, well tolerated, and safer treatments for patients.  
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NeoLipid® formulations are designed to produce small and homogenous drug particle sizes using 
simple, easy-to-use (ETU) reconstitutions of lyophilized (or freeze-dried) products with the goal of 
creating an extraordinarily stable liposomal product.. This is especially important during drug storage, 
reconstitution and administration to the patient.  
NeoPharm believes NeoLipid® technology may have applications in a variety of other areas in 
addition to the drug product candidates in clinical development.  
 
Potential advantages of NeoLipid® Drug Delivery Technology:  
• Higher anticancer potency  
• Broader range of drugs  
• Toxicity may be reduced  
• Fewer perceived side effects  
 
NeoPharm intends to explore the use of its proprietary NeoLipid® liposomal drug delivery technology 
in terms of life cycle management, with the goal of extending patent life and/ or modifying the 
pharmacokinetic profile of existing cancer drugs, and by utilizing the platform to develop new drugs. 
NeoPharm is aware of several widely used cancer drugs that are nearing patent expiration, as well as 
other widely used cancer drugs with patents that have expired. When a drug is combined with 
another agent or delivery system in a novel way, its patent life may be extended. Additionally, while 
many chemotherapeutic drugs have been effective for the treatment of cancer, these drugs have 
been limited in their use because of adverse side effects and difficulties in administration. 
NeoPharm's NeoLipid® drug delivery technology may increase the usefulness of these compounds as 
improved anti-cancer treatments. Finally, NeoPharm believes that its liposomal drug delivery 
technology may provide a platform for the development of novel therapeutic agents for cancer drug 
development.  
NeoPharm is aware of several widely used cancer drugs that are nearing patent expiration, as well as 
other widely used cancer drugs with patents that have expired. When a drug is combined with 
another agent or delivery system in a novel way, its patent life may be extended. Additionally, while 
many chemotherapeutic drugs have been effective for the treatment of cancer, these drugs have 
been limited in their use because of adverse side effects and difficulties in administration. 
NeoPharm's NeoLipid® drug delivery technology may increase the usefulness of these compounds as 
improved anti-cancer treatments. Finally, NeoPharm believes that its liposomal drug delivery 
technology may provide a platform for the development of novel therapeutic agents for cancer drug 
development.  
 
LEP-ETU  
LEP-ETU is NeoPharm's NeoLipid® liposomal formulation of the widely used cancer drug, paclitaxel. 
Paclitaxel, also known as Taxol® (Bristol-Myers Squibb Company), has been approved in the U.S. for 
the treatment of ovarian, breast and lung cancers. Despite paclitaxel's wide use and tumor cytotoxic 
characteristics, its effectiveness can be limited by its adverse side effects, which can include nausea, 
vomiting, hair loss and nerve and muscle pain. Because of the chemical characteristics of paclitaxel, it 
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cannot be introduced into the body unless it is first formulated in a mixture of castor oil 
(Cremophor®) and ethanol, which can lead to significant side effects such as hypersensitivity 
reactions and cardiac toxicities.  
The Company hopes to show that its proprietary NeoLipid® technology, which eliminates the need 
for Cremophor and ethanol, permits delivery of paclitaxel treatment with fewer side effects.  
In the first quarter of 2009, NeoPharm completed the targeted enrollment of 35 patients for the first 
part of its Phase II open-label, multi-center outpatient study in India designed to evaluate the anti-
tumor effect and safety/ tolerability of LEP-ETU in metastatic breast cancer. All of the patients in the 
first part of the study have received a dose of 275 mg/m2 every three weeks without the detection 
of any significant infusion related problems or unexpected toxicities and showed a response rate of 
46% compared to 11% with free Taxol® and 22% with Abraxane®.  
NeoPharm has started another Phase II trial for recurrent breast cancer to enroll 35 more patients 
while rapidly working to embark on a Phase III randomized trail of LEP with free Taxol® as a 
comparator arm in metastatic breast cancer patients with the goal being to achieve regulatory 
approval of LEP as an effective modality for the treatment of cancer patients as early as possible.  
 
LE-DT  
LE-DT is NeoPharm's NeoLipid® liposomal formulation of the anti-cancer agent docetaxel, which is 
the active ingredient in Sanofi Aventis' Taxotere®, approved for use in certain breast cancer, non-
small cell lung cancer, gastric adenocarcinoma, head and neck cancer indications, and prostate 
cancer.  
NeoPharm has completed a multi-center Phase I clinical trial for LE-DT for the treatment of patients 
with metastatic solid tumors. This Phase I study was designed to define the maximum tolerated dose 
("MTD") and was conducted at The Lombardi Comprehensive  
Cancer Center at Georgetown University and at TGen Clinical Research Services at Scottsdale 
Healthcare. The data from the trial demonstrated that LE-DT has minimal toxicities compared to 
Taxotere®, in particular, peripheral neurotoxicity and water retention (edema).  
In the first quarter of 2010, NeoPharm expects to enroll patients in a Phase II study of LEDT for locally 
advanced or metastatic pancreatic patients. The open-label, Phase II study is designed to determine 
the antitumor effect of LE-DT in locally advanced pancreatic cancer patients as evidenced 
radiologically with CA 19-9 as the surrogate biological marker.  
 
In addition, NeoPharm is planning another Phase II study of LE-DT for prostate cancer patients. This 
open-label, Phase II study will define the clinical activity of LE-DT as an antitumor response in soft 
tissues as defined by the serum Prostate Specific Antigen ("PSA") level as a biological surrogate 
marker, disease response, progression-free survival and quality of life in patients with metastatic 
prostate cancer. NeoPharm anticipates a total of 63 patients to be enrolled in this Phase II trial at up 
to six locations in the United States and overseas.  
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Depending on the outcome of these clinical trials, NeoPharm may decide to undertake multicenter 
and multinational Phase III trials in these indications after thorough discussions with the FDA.  
 
LE-rafAON  
A new formulation of LE-rafAON, NeoPharm's NeoLipid® liposomal formulation of the antisense 
oligonucleotide agent, c-raf, is expected to have minimal infusion-related toxicities. All preclinical 
studies related to the submission of a revised IND to the FDA have been completed and the data is 
positive.  
The antisense oligonucleotide agent, c-raf, has shown significant down regulation of the gene in 
Preclinical studies. Also, LE-rafAON has exhibited significant radiation sensitization and chemo 
sensitization with other anticancer agents such as Gemcitabine and Paclitaxel in human xenograft 
models in mice in Pancreatic and Prostate tumors. NeoPharm plans to perform the bridging Phase I 
trial with this newly formulated LE-rafAON and thereafter start  
Phase II trials in pancreatic and prostate cancer models where this gene seems to be potentially over-
expressed. Neopharm intends to further develop the NeoLipid® drug product candidates by using 
internal resources and by continuing to collaborate with other companies and leading governmental 
and educational institutions.  
 
LE-SN38  
LE-SN38 is NeoPharm's NeoLipid® liposomal formulation of SN-38, the active metabolite of 
Camptosar® (Pfizer Inc.), a chemotherapeutic pro-drug, which is used as a first-line and second-line 
colorectal cancer treatment. At the present time, without the NeoLipid® system, SN-38 is insoluble 
and can only be used to treat cancer by administering the pro-drug Camptosar®. A pro-drug is a 
compound that is converted into the active drug in the body. However, Camptosar® is converted into 
SN-38 in the liver at different rates by different patients, and this variability in conversion rates can 
result in suboptimal dosing and adverse side effects, such as severe diarrhea. We hope to show that 
our proprietary NeoLipid® technology permits delivery of SN-38 to the tumor cells without the need 
for conversion, therefore minimizing variability and optimizing dose with minimal side effects.  
Results from our 2004 Phase I clinical trial provided evidence of the safety and tolerability of LE-SN38 
and established a maximum tolerated dose (MTD) of 35 mg/m2 for all but a small subset of patients 
who metabolize SN-38 slowly. Pharmacokinetic analysis of blood samples from patients treated with 
LE-SN38 showed that blood levels and systemic drug exposure to SN-38 were comparable to or 
greater than that expected from the marketed Camptosar® dose based on previously published 
studies.  
 
During the second quarter of 2006, in conjunction with the Cancer and Leukemia Group B, or CALGB, 
NeoPharm initiated enrollment in a Phase II clinical trial with LE-SN38 in metastatic colorectal cancer 
patients, and completed enrollment of the 21st patient in December, 2006.  
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In March 2007, the Company announced that the interim analysis of data following the completion of 
treatment of the first 21 patients demonstrated disease stabilization, but the study did not achieve 
the primary tumor response endpoint. The Company is reviewing the data and, in particular, 
examining the patients' demography, prior chemotherapy exposure, advanced stage of the disease, 
and other related factors. It is possible that patients whowere enrolled in this trial were exposed to 
other chemotherapy regimens prior to enrolling and that this prior exposure may be the reason the 
study did not achieve its primary endpoint. The Company is also assessing the potential next steps for 
this project which may include additional data analyses and the possibility of other studies related to 
lung cancer and breast cancer with LE-SN38.  
 
Tumor Targeting  
Cintredekin Besudotox  
The drug product candidate which we have advanced the furthest is Cintredekin Besudotox, a tumor-
targeting toxin being developed as a treatment for glioblastoma multiforme, or GBM, a deadly form 
of brain cancer.  
Glioblastoma multiformes (GBM) is the most common type of malignant primary brain tumor in 
adults. They are very aggressive, having tentacles that spread and mix with normal brain tissue, 
damaging the adjacent tissue as they grow uncontrollably in the brain.  
Treatment success has not significantly changed over the last 20 years, with most patients living less 
than one year after diagnosis despite aggressive surgery, radiation and chemotherapy.  
Radiation therapy has been the most effective adjuvant therapy for these tumors, but the inherent 
resistance to radiation therapy and the risk of damaging the adjacent normal brain tissue limits its 
overall efficacy. GBM is intrinsically resistant to most chemotherapy and very few drugs cross the 
natural barrier present in the blood vessels of the brain (blood-brain barrier) which means that even 
drugs that work in the laboratory and in animals cannot reach the tumor cells within the brain. This 
unfortunate combination has resulted in only two FDA approved chemotherapy for this type of 
tumor with two forms of delivery, by vein or by local biodegradable wafers. The impact of these 
approved therapies increases survival in patients with this deadly tumor by only a few weeks.  
 
Cintredekin Besudotox delivered by convection-enhanced delivery (direct micro infusion into the 
brain), on the other hand, is designed to molecularly target the tumor cells while sparing the healthy 
brain tissue. This form of regional and molecular targeting may represent one of the first scientifically 
sound treatment regimens, providing hope for overcoming one of the greatest hurdles in brain 
tumor therapy. The very problem that prevented drugs from entering the brain may now be used to 
keep the drug in the brain.  
 
Cintredekin Besudotox is a recombinant protein consisting of a single molecule composed of two 
parts: a tumor-targeting molecule and a cytotoxic agent. The targeting component consists of 
interleukin 13(IL-13), an immune regulatory cytokine. Malignant glioma cells, as compared to normal 
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brain cells, express IL-13 receptors at a higher density. The cytotoxic agent is a potent bacterially 
derived toxin called PE38. Cintredekin Besudotox is designed to detect and bind IL-13 receptors on 
the surface of malignant glioma cells and selectively deliver PE38 to destroy tumor cells. Cintredekin 
Besudotox is administered by a technique known as convection-enhanced delivery, or CED, in which 
the drug is delivered through catheters inserted in brain tissue surrounding the tumor (peritumoral 
administration) or into the tumor (intratumoral administration) following surgical resection of the 
tumor. CED is designed to infuse Cintredekin Besudotox directly to the tumor site and adjacent brain 
tissue with the goal of killing resident tumor cells and preventing recurrence of tumor cell growth.  
We hope to show that this method of delivery minimizes both damage to the surrounding cell and 
toxicity from systemic drug exposure.  
We have exclusively licensed Cintredekin Besudotox from the NIH and the FDA, and have been 
developing this drug product candidate under a Cooperative Research and  
Development Agreement, or CRADA, with the FDA Center for Biologics Evaluation and Research, or 
CBER. Cintredekin Besudotox has received orphan drug designation in the US and Europe and FDA 
has designated it for the fast track drug development program. In addition, Cintredekin Besudotox 
has been selected to participate in the FDA's Continuous Marketing Application, CMA, Pilot 2 
program. We also hold a non-exclusive license to utilize a patented process owned by the U.S. 
government relating to convection enhanced delivery, or CED, for use with drugs, including 
Cintredekin Besudotox, in the treatment of gliomas.  
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Novosom AG58 
Weinbergweg 22 
06120 Halle 
Germany 
contact@novosom.com 
Telephone: +49 03455559836 
 
About Novosom AG  
Novosom AG has solved the major obstacle towards DNA therapeutics delivery of the therapeutic 
principle towards the cell interior. Since the discovery of DNA-based therapies such as siRNA, 
antisense or decoy oligonucleotides, there has been a running problem of how to transmit these 
delicate nucleic acids undamaged to the cell interior where they can exert their therapeutic effects. 
Novosom has developed a pioneering fully charge reversible liposomal delivery technology for these 
DNA- based therapeutics (SMARTICLES) and is working with its partners to develop a range of 
therapeutic products addressing inflammation, oncology and liver diseases. The company is located 
in Halle, Germany. 
 
Technologies  
SMARTICLES® 
Enabling Systemic DNA Therapeutics. 
The early promise of first generation DNA-based therapeutic approaches like si RNA, antisense or 
decoys foundered on the difficulty of delivering these nucleic acid therapies. Chemical modification, 
cationic vectors, modified cationic vectors, viral vectors and other technologies have been tried with 
limited success so far. Novosom’s solution has been develop a pioneering liposomal technology with 
a fully reversible surface charge: SMARTICLES. 
The SMARTICLES technology allows the delivery of active substances inside the cell either for topical 
or systemic applications. What makes them different from standard liposomal delivery technologies 
is that they have a fully reversible surface charge. This unique characteristic is ideally suited to the 
delivery of encapsulated nucleic acids from injection, through stable and aggregate-free travel within 
the bloodstream, across cell boundaries to release the oligonucleotides inside the cell. 
SMARTICLES are an enabler for the use of oligonucleotides in systemic and topical treatments. They 
have proven to be a safe and versatile technology that, as for March 2006, is available in GMP quality 
suitable for use in humans. Novosom has data with both singe stranded and double stranded 
oligonucleotide thecnologies in RA, IBD, transplant, liver diseases and xenograft oncology models. In 
addition, initial GLP toxicity studies have shown very high tolerability of the carrier. The company has 
secured SMARTICLES with a number of patent families that cover the technology, its components 
and manufacturing. 
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Mirus59  
 
About Mirus  
Mirus Bio LLC is a life science company focused on discovering, developing and commercializing 
innovative nucleic acid based technologies and products.  
Mirus R&D uniquely integrates nucleic acid delivery and chemistry, a core competency which is 
unmatched in the industry. This serves as the foundation for its novel research reagents  
Mirus is a recognized leader in developing innovative nucleic acid research reagents, distinguished by 
its many accomplishments:  
. First to develop an siRNA transfection reagent (2001)  
. Pioneered development of high efficiency/low toxicity transfection formulations  
. First to market a single step nucleic acid labeling technology  
. Unique technology to label native, biologically relevant short RNA species such as microRNA  
 
Mirus’ TransIT® Reagents are unique lipid and polymer formulations that achieve superior delivery 
efficiency of pDNA and siRNA with minimal cytotoxic effects. They have been optimized for In Vitro 
delivery in a variety of mammalian cells as well as for In Vivo delivery in small animals. The Ingenio™ 
Electroporation Solution allows researchers to deliver nucleic acids to cells that are resistant to 
transfections.  
The company’s Label IT® Kits employ proprietary chemistry to covalently attach labeling molecules to 
DNA and RNA. This simple one-step process is faster and more robust than traditional multi-step 
enzymatic labeling, and can be used for intracellular tracking, chromosome analysis, and microarray 
labeling.  
Technologies  
 
TransIT® In Vivo Gene Delivery System  
A nontoxic, polymer based In Vivo delivery system for the delivery of DNA or siRNA to the livers of 
laboratory mice using methods including hydrodynamic tail vein injection  
. Polymer Mediated DNA Delivery -Achieve higher levels of gene expression compared to polylysine 
and PEI methods.  
. Versatile Platform -Suitable for DNA delivery using methods including hydrodynamic tail vein 
injection to the mouse strain of your choice.  
. Low Toxicity - Normal mouse activity levels are restored within minutes after the injection  
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PCI Biotech Holding ASA60  
 
About PCI Biotech  
The strategy of PCI Biotech Holding ASA (PCI Biotech) is to commercialise a patented photochemical 
drug delivery technology for use in therapeutic treatment.  
The company was established in 2000 as a subsidiary of the Norwegian pharmaceutical company 
Photocure ASA. PCI Biotech has been listed on Oslo Axess since June 2008 following a demerger from 
Photocure ASA.  
PCI Biotech receives substantial public funding from the Norwegian Research Council and from the 
EU.  
Photochemical internalisation is a drug delivery technology for targeted delivery of macromolecules 
and other membrane-impermeable drugs.  
PCI can be used within many areas, including:  
• gene therapy  
• protein therapy  
• oligonucleotide therapy  
• chemotherapy  
• nanomedicine  
 
The PCI technology has great advantages as it may:  
• enhance and target drug delivery  
• make macromolecule delivery more efficient  
• make possible the therapeutic use of molecules that it has hitherto been impossible to use, due to 
e.g. too low delivery efficiency or too high toxicity in non-target tissues.  
 
Technologies  
PCI is a technology for light-directed drug delivery and was developed to introduce therapeutic 
molecules in a biologically active form specifically into diseased cells.  
PCI can enhance the delivery of all molecules taken into the cell by endocytosis. This includes most 
types of macromolecules, drugs carried by antibodies or nanoparticles, as well as some small 
molecule drugs.  
The basis of the PCI technology is a light-induced rupture of endocytic vesicles, releasing 
endocytosed molecules into the cell cytosol, from where they can reach their intracellular target of 
action, realizing their therapeutic potential.  
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The PCI effect is achieved by the use of photosensitising compounds specifically localising in the 
membranes of endocytic vesicles, destroying these membranes by an oxidative process after 
illumination. Photosensitising compounds:  
• can be administered systemically  
• will in many cases localise preferentially in diseased tissues (e.g. tumours)  
• generally have low toxicity in non-illuminated areas  
• are in clinical use for cancer and other therapies today (photodynamic therapy)  
 
The PCI technology has a potential to improve the effect both of existing drugs and of emerging 
treatments such as gene therapy and other therapies based on nanotechnology or on 
biotechnological principles.  
In the PCI technology, photosensitising molecules (photosensitisers) are used to exploit the energy in 
visible light for delivering drugs.  
Photosensitisers (S) are molecules that upon absorption of light become excited to an excited state 
(S*), initiating further photochemical reactions. The photochemical reactions of the photosensitisers 
used in PCI proceed mainly via a pathway where the energy from the excited photosensitiser 
molecule is transferred to oxygen, inducing formation of so-called singlet oxygen. Schematically: 
state (S*), initiating further photochemical reactions. The photochemical reactions of the 
photosensitisers used in PCI proceed mainly via a pathway where the energy from the excited 
photosensitiser molecule is transferred to oxygen, inducing formation of so-called singlet oxygen. 
Schematically:  
 
 
 
* Singlet oxygen is a highly reactive form of oxygen that can oxidize various biomolecules, inducing 
damage in various cellular structures.  
* Some photosensitisers localise in the membranes of endosomes and lysosomes, and light activation 
of such sensitisers destroys these membranes and releases the organelle contents into the cytosol. 
Thus, photochemical treatment may be used to translocate endocytosed therapeutic 
macromolecules from endocytic vesicles and into the cytosol, from where they have access to other 
intracellular compartments.  
 - 162 - 
* In cells, singlet oxygen has a very short short range of action (10-20 nm). Therefore, only targets 
very close to the generated singlet oxygen will be affected by the photochemical reactions, and the 
therapeutic molecules to be delivered will as a rule be left unaffected.  
* PCI Biotech is developing a proprietary photosensitiser specially designed for in vivo use with the 
PCI technology.  
 
The potential of PCI  
Macromolecules are widely acknowledged to have a large potential as therapeutic agents, and 
numerous clinical trials both with gene, protein and oligonucleotide therapy are underway.  
In order to have a therapeutic effect, many of these molecules have to enter into a target cell and 
reach an intracellular target of action. This is also the case for several other classes of therapeutically 
interesting molecules, e.g. molecules carried in nanoparticles.  
The therapeutic potential of such compounds is severely challenged by the obstacles of intracellular 
delivery, and many studies have been hampered by the lack of proper technologies for delivery of 
the therapeutic molecules to the target cells.  
 
Advantages of the PCI technology  
• PCI induces delivery of molecules into the cells by illumination.  
• PCI makes drug delivery efficient exactly at the site where drug activity is desired, sparing non-
target tissues from possible side effects of the drug.  
• PCI is very efficient for delivery of classes of molecules where other efficient delivery systems are 
still lacking.  
• PCI can unleash the therapeutic potential of a host of therapeutically very promising molecules.  
The PCI technology can also have important uses in vitro as a general technology for delivery of 
macromolecules into cells, and can be used both in academic research and for industrial applications 
(e.g. in drug target validation). PCI Biotech has developed a light source, LumiSouce®, for use in in 
vitro research.  
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Quest Pharmatech Inc.61  
 
About Quest Pharmatech  
 
Profile  
Quest is an Alberta-based biotechnology company developing a portfolio of product candidates for 
the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, 
photodynamic therapy, radioimmunotherapy or immunoadjuvants.  
 
Overview  
Quest is positioned as a drug development company focused on novel therapies for the treatment of 
cancer.  
• Maximize growth by concentrating resources on drug development and extracting value to support 
this activity through strategic partners.  
• Reduce risk by acquiring products or technologies that are close to attaining, or have already 
attained, clinical status.  
• Participate in high-growth markets, focus on diseases with unmet treatment needs or near-to-
market potential.  
• Develop proprietary, unique multi-tiered approach to the treatment of cancer.  
 
Technologies  
 
Did not have drug delivery systems yet  
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Seattle Genetics62  
 
About Seattle Genetics  
“At Seattle Genetics, we are focused on developing innovative antibody-based therapies that 
improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to 
addressing unmet medical needs, and strive to achieve that goal through excellence in clinical 
development.  
Focusing on Clinical Development Seattle Genetics is a clinical stage biotechnology company 
advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab 
vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients 
with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle 
Genetics' proprietary antibody-drug conjugate (ADC) technology. In December 2009, we entered into 
an agreement with Millennium: The Takeda Oncology Company under which Seattle Genetics retains 
full commercialization rights to brentuximab vedotin in the United States and Canada, while 
Millennium obtained rights to commercialize the product candidate in all other countries.  
In addition to brentuximab vedotin, Seattle Genetics is conducting clinical trials with four other 
product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of 
cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising 
preclinical candidates and have robust research and development capabilities that are our engine for 
innovation and long-term growth.  
Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug 
payloads. The drug payload is inactive until released from the antibody inside the targeted cancer 
cell, thereby sparing normal tissue the toxicity of traditional chemotherapy.  
In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are 
developing several preclinical ADC product candidates, including ASG-5ME, which is advancing 
towards planned 2010 clinical trials for prostate and pancreatic cancer.”  
 
“Expanding Our Opportunities Through Collaboration Collaborating with leading biopharmaceutical 
companies is a cornerstone of Seattle Genetics' business strategy.  
Product-focused collaborations, such as our collaboration agreement with Millennium: The  
Takeda Oncology Company to globally develop and commercialize brentuximab vedotin, provide 
significant near-and mid-term funding while bringing in additional resources and expertise to 
support, advance and expand promising development programs. Collaboration and license 
agreements around our proprietary ADC technology also generate cash for the company -
approximately $120 million to date -while providing further clinical validation of the ADC platform 
and, in some cases, opening the door to new product development opportunities.”  
 
Technologies  
Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology empowers monoclonal 
antibodies by attaching them to cell-killing payloads. Our ADCs employ highly stable linker systems to 
attach antibodies to synthetic, potent drugs. The linkers are designed to be stable in the bloodstream 
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but to release their drug payloads under specific conditions once inside target cells, thereby sparing 
healthy tissues many of the toxic effects of traditional chemotherapy.  
 
 
“The key components of our ADC technology are the stable, enzyme-cleavable linkers and the highly 
potent, synthetic cytotoxic drugs. Our novel linkers have been shown in preclinical models to be up 
to 10 times more stable in blood than conventional means of attaching drugs to antibodies. We have 
also developed a highly potent class of antitubulin drugs called auristatins, including monomethyl 
auristatin E (MMAE) and monomethyl auristatin F (MMAF). These auristatins are 100 to 1000 fold 
more potent than traditional chemotherapy drugs. Importantly, since both the linker and drug 
components are synthetic, our ADC technology is readily scalable, representing an improvement over 
natural product drug systems that are typically more challenging and expensive to produce.  
Our lead ADC, brentuximab vedotin (SGN-35), comprises an anti-CD30 monoclonal antibody attached 
to MMAE through an enzyme-cleavable linker system. CD30 is expressed on Hodgkin lymphoma, 
various types of T-cell non-Hodgkin lymphomas and other hematologic malignancies. In a phase I 
dose-escalation clinical trial of brentuximab vedotin for CD30-positive malignancies, primarily 
Hodgkin lymphoma, at doses of 1.2 milligrams per kilogram and higher administered every three 
weeks, 54% of patients achieved an objective response (complete and partial responses), of which 
39% were complete responses.  
Brentuximab vedotin was generally well tolerated with the majority of adverse events being Grade 1 
and 2. These promising findings are in contrast to clinical data with the unconjugated antibody, 
which did not induce objective responses in a similar population of Hodgkin lymphoma patients.  
 
We have also reported substantial preclinical data with brentuximab vedotin, including data 
demonstrating that the targeting ability of brentuximab vedotin results in concentrations of MMAE 
within tumors up to 30-fold higher than non-targeted drugs. Further, MMAE tumor concentrations 
were 1000 fold greater than MMAE blood concentrations following dosing with brentuximab 
vedotin. These preclinical data demonstrate that brentuximab vedotin effectively targets and 
releases its cell-killing payload, MMAE, within CD30-positive tumors.”  
 
ADC Product Candidates and Collaborations  
Brentuximab vedotin is in multiple clinical trials for Hodgkin lymphoma and other CD30positive 
hematologic malignancies, including a pivotal trial for relapsed and refractory Hodgkin lymphoma.  
We are also advancing a second ADC program, SGN-75, which is comprised of an antiCD70 
monoclonal antibody attached to MMAF. We have reported preclinical data on CD70 expression on a 
variety of solid tumors, including renal cell carcinoma, pancreatic, ovarian and lung cancer, as well as 
in multiple myeloma and non-Hodgkin lymphoma. SGN-75 has shown potent antitumor activity in 
several tumor models, underscoring its therapeutic potential in a range of cancer types. We initiated 
a phase I clinical trial with SGN-75 in November 2009.  
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Under our collaboration with Agensys, a subsidiary of Astellas Pharma, we are also advancing ASG-
5ME towards planned clinical trials in 2010. This ADC has potential in several types of solid tumors.  
Seattle Genetics has also licensed its ADC technology to multiple leading biotechnology and 
pharmaceutical companies in exchange for upfront payments, fees, milestones and royalties on net 
sales of products incorporating our technology.  
 
  
 - 167 - 
Starpharma Holdings, Ltda63  
 
About Starpharma Holdings, Ltda  
 
Starpharma is a world leader in the development of nanotechnology-based pharmaceuticals and, 
through its US-based subsidiary Dendritic Nanotechnologies (DNT), a range of lifescience and 
industrial uses.  
Starpharma is listed on the Australian Securities Exchange (ASX: SPL)and its securities also trade in 
the US under the American Depository Receipts (ADR) program (OTCQX: SPHRY).  
Starpharma’s lead development candidates are based on dendrimer nanotechnology.  
Dendrimers are man made, nano-sized compounds with unique properties that make them useful to 
the health and pharmaceutical industry as both enhancements to existing products and as entirely 
new products. Dendrimers are constructed by the successive addition of layers to the branching 
groups. Each new layer is called a generation. The final generation incorporates the surface 
molecules that give the dendrimer the desired function for medical, electronic, chemical and 
materials applications.  
Starpharma aims to create value through the commercialisation of its proprietary products based on 
dendrimer nanotechnology both directly and through DNT.  
Much of Starpharma’s value comes from its opportunities for substantial revenues from three key 
areas:  
VivaGel® (SPL7013 Gel): The most advanced product in Starpharma’s pipeline, VivaGel®, is being 
developed as a vaginal microbicide to prevent transmission of genital herpes and HIV. This is a mass-
market application in both developed and developing countries.  
VivaGel® is also under development as a condom coating and has been shown to possess potent 
contraceptive activity in animals.  
 
Technologies  
Starpharma has a number of products and platforms under development using dendrimer 
technology. Starpharma’s dendrimers are precisely defined, synthetic macromolecules that are well 
suited to pharmaceutical applications.  
Dendrimers fall under the broad heading of nanotechnology, which covers the manipulation of 
matter in the size range of 1-100 nanometers (one million nanometers equal one millimetre) to 
create compounds, structures and devices with novel, pre-determined properties.  
When making dendrimers, chemists can control their physical and chemical properties. The synthesis 
of dendrimers involves a core molecule with branching groups to which other branching molecules 
are added (see figure below) in layers. Each new layer is called a generation. The final generation can 
incorporate additional active groups that give the particular functionality to the dendrimer.  
 
The selection of core, branching and surface molecules determine the properties of the different 
dendrimers required for medical, electronic, chemical and materials applications.  
                                            
63
 www.starpharma.com 
 - 168 - 
 
Supratek Pharma Inc64  
 
About Supratek Pharma Inc.  
“Supratek Pharma Inc. is a patient and product oriented pharmaceutical company dedicated to the 
discovery, rapid development and commercialization of innovative anticancer therapeutics 
desperately needed by cancer patients with tumors that are resistant to available therapies. Many 
resistant cancers are at a metastatic stage. Late-stage metastatic cancers account for the majority of 
cancer deaths and represent one of the major unmet medical needs world-wide.  
Since 1994, our scientists have steadily built on their cutting edge breakthrough research.  
Their deep understanding of cancer progression and metastasis formation has resulted in the 
successful translation of scientific discovery into pre-clinical development and multiple novel clinical-
stage drug candidates.  
Thanks to its exciting science Supratek has attracted outstanding, highly productive multidisciplinary 
individuals to its management, clinical development and R&D functions.  
The Company has also established a network of outstanding opinion leaders with recognized 
expertise in critical areas of cancer research and anticancer drug development. They assist the 
Company in designing winning drug development strategies.”  
 
Technologies  
“Sustained product development is possible with our core technology platforms that include  
Biotransport™ and SP-MET-X™.” 
 
Biotransport™ nanomedicine technology  
 
“Involves the proprietary use of highly flexible block co-polymer chemistry to produce nanomedicine 
compositions of diverse molecules. Biotransport™ compositions consist of an active pharmaceutical 
ingredient (API) with specific polymer combinations resulting in beneficial biological response 
modification and targeted drug delivery.  
Biotransport™ compositions incorporate a drug molecule without chemical interactions; the resulting 
nano-systems, ranging from 10nm to 100nm in size, are formed spontaneously and are 
thermodynamically stable.  
This technology is applicable to new chemical entities and generic drugs and can be an effective tool 
for improving pharmacokinetics, bioavailability and provide drug life extension.”  
 
 
 
 
 
                                            
64
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SP-MET-X™ S100 pathway inhibition  
“S100A4 and some other S100 proteins are known biomarkers recently identified as unique targets in 
a pathway that occurs early in the signal transduction cascade leading to metastasis formation and 
cancer progression.  
SP-MET-X™ technology includes a new library of small molecules that embodies a number of new 
chemical entities (NCEs) with variable pharmacological properties that inhibit the newly identified 
pathogenic pathway mediated by the S100 proteins.  
S100 proteins play a significant role in promoting growth and the spread of cancers with poor 
prognosis. Tumors that overexpress these proteins include malignant melanoma, colorectal, breast, 
bladder, pancreatic, gastric and esophageal cancers.  
A new library of S100 targeted compounds has been created, from which several NCEs have been 
identified to be effective against this novel cancer target. The synthesized compounds are small 
molecules, with low toxicities, that are orally bioavailable and show good chemical and metabolic 
stabilities. A set of selected compounds is undergoing pre-clinical development.”  
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Tekmira Pharmaceuticals 
65 
About Tekmira  
 
As the fields of genetics, medicine and therapeutics continue to converge, the management of illness 
at its genetic source by silencing genes via RNA interference (RNAi) holds the very real potential to 
revolutionize treatment on a scale not seen in decades. Tekmira is one of a handful of biotech 
companies around the world working to exploit the potential of RNAi to treat disease. And it is from 
among these unique companies that the next wave of therapeutic breakthroughs will emerge.  
Tekmira is uniquely equipped to become a leading force in the field. Guided by a cohesive vision, the 
company possesses leading technology capabilities and a solid intellectual property portfolio in the 
area of lipid-based nucleic acid delivery, known as SNALP (Stable Nucleic Acid Lipid Particles) to 
deliver siRNAs (small interfering RNAs) as well as other oligonucleotides in the treatment of disease.  
With one RNAi drug candidate in clinical development and another in late preclinical development, 
plus a pipeline of up to five additional targets made possible through an agreement with RNAi leader 
Alnylam, Tekmira is well positioned to aggressively advance its product development strategy. In 
addition to Alnylam, Roche, Merck and Regulus all have access to Tekmira’s technology in the 
delivery of siRNAs and microRNAs.  
Finally, broad manufacturing capabilities and a strong capital position permit the company to move 
forward decisively and build a solid base for both near and longer term growth.  
 
Technologies  
Nucleic acids are relatively large molecules that are unstable in the bloodstream and unable to 
readily diffuse across membranes into target cells. To realize the tremendous therapeutic potential 
of RNAi-based drugs therefore, effective delivery is critical.  
 
SNALP  
Tekmira’s siRNA delivery technology platform is termed SNALP for “stable nucleic acidlipid particles”. 
SNALP are specialized lipid nanoparticles that fully encapsulate and systemically deliver a variety of 
nucleic acid molecules such as siRNA. Pre-clinical studies have shown them to be effective in 
delivering the drug to target organs and into cells where the nucleic acid-based drug can carry out its 
desired effect while minimizing systemic toxicity.  
SNALP technology relies on something called the “enhanced permeability and retention effect”, 
which occurs because these nucleic acid-containing particles have a long circulation time in the 
blood, resulting in increased accumulation at sites of vascular leak such as those found at sites of 
tumor cell growth, infection or inflammation. Once at the target site, cells take up the SNALP through 
endocytosis and the nucleic acid payload is delivered inside the cell resulting in unparalleled potency. 
hanced permeability and retention effect”, which occurs because these nucleic acid-containing 
                                            
65
 www.tekmirapharm.com 
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particles have a long circulation time in the blood, resulting in increased accumulation at sites of 
vascular leak such as those found at sites of tumor cell growth, infection or inflammation. Once at 
the target site, cells take up the SNALP through endocytosis and the nucleic acid payload is delivered 
inside the cell resulting in unparalleled potency.  
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Appendix 7 – Pharmaceutical R&D expenditure in Europe, USA and Japan (million of national 
currency units), 1990-2007 
 
 
Figure 13.4 - Pharmaceutical R&D expenditure in Europe, USA and Japan (million of national currency units), 
1990-2007. Source: EFPIA member associations, PhRMA, JPMA 
 
 - 173 - 
Appendix 8 – Pharmaceutical and Biotechnology Market: Revenues by Region (Global), 2008 
(source: Frost & Sullivan, 2010) 
 
 
Figure 13.5 - Pharmaceutical and Biotechnology Market: Revenues by Region (Global), 2008. Source: IMS 
Health, Frost & Sullivan 
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Appendix 9 – Pharmaceutical R&D expenditures (World), 2002-2012 (million USD)  
(source: Frost & Sullivan, 2009 A) 
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Appendix 10 – Percent R&D expenditures in total pharmaceutical market (World), 2002-2012 
(million USD) (source: Frost & Sullivan, 2009 A) 
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Appendix 11 – Venture capital investments in Biotech R&D (World), 2002-2012 (million USD) 
(source: Frost & Sullivan, 2009 A) 
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Appendix 12 – Government investments in biotech (World), 2002-2012 (million USD). 
(source: Frost & Sullivan, 2009 A) 
 
 
 - 178 - 
Appendix 13 – Targeted drug delivery companies and their location (Epsicom, June 2009). 
Target drug delivery company Location Therapeutical area of focus 
Access Pharmaceuticals, Inc Dallas, TX, USA Cancer 
Alkermes Waltham, MA, USA CNS disorders, addiction, diabetes 
and autoimmune disorders 
ArmaGen Technologies, Inc. Santa Monica, CA, USA Solutions to the 'blood-brain barrier' 
problem (CNS) 
Avidimer Therapeutics Ann Arbor, MI, USA Cancer 
Calando Pharmaceuticals, Inc. Pasadena, CA, USA Cancer, AIDS, hepatitis C, 
Huntington's disease 
Cell Therapeutics, Inc. Seattle, WA, USA Cancer 
Cerulean Pharma, Inc. Cambridge, MA, USA Cancer, inflammation, and CV 
diseases. 
Copernicus Therapeutics, Inc. Cleveland, Ohio, USA Diseases causing blindness, airborne 
viral, and diseases of the brain 
CytImmune Sciences, Inc. College Park, Md., USA Cancer 
Delcath Systems New York, NY, USA Cancer 
Diatos S.A. Paris Area, France Cancer 
Enzon Pharmaceuticals, Inc. USA Cancer 
Endocyte Inc. West Lafayette, IN; 
Indianapolis, IN, USA 
Cancer 
Eurand N.V. USA, France, The 
Netherlands and Italy 
Cystic Fibrosis and gastriointestinal 
ImmunoGen, Inc. Waltham, MA, USA Cancer 
NanoBioMagnetics, Inc. Edmond, OK, USA Cancer 
Nanobiotix Paris, France Cancer 
NanoCarrier, Inc. Japan Cancer 
Nano Interface Technology Lorton, VA , USA Cancer 
Nektar Therapeutics San Carlos, CA, USA across many therapeutic areas and 
modalities 
NeoPharm USA Cancer 
Novosom AG Germany Inflammation, Cancer and liver 
diseases 
Mirus Bio Corporation USA across many therapeutic areas and 
modalities 
PCI Biotech Holding ASA Oslo Area, Norway across many therapeutic areas and 
modalities 
Quest PharmaTech, Inc. Canada Cancer 
Seattle Genetics Bothell, WA, USA Cancer, and autoimmune diseases 
Starpharma Holdings, Ltd Australia across many therapeutic areas and 
modalities 
Supratek Pharma Inc. Canada Cancer 
Tekmira Pharmaceuticals 
Corporation 
Canada across many therapeutic areas and 
modalities 
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Appendix 14 – Drug delivery market: Deals between companies and Pharmaceutical and 
Biotechnology companies (Europe), 2004-2007 (source: Frost & Sullivan, June 2008 A). 
 
 
 
Figure 13.6 - Drug delivery market: Deals between companies and Pharmaceutical and Biotechnology 
companies (Europe), 2004-2007 
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Appendix 15 – E.U Pharmaceutical companies by therapeutic area (source: [online] Pharma 
Licensing and [online] Pharmaceutical Business Review). 
 
 
 
Cancer 
1. Abiogen 
2. Actelion Ltd 
3. Active Biotech AB 
4. Alizyme plc 
5. Ark Therapeutics Group plc 
6. AstraZeneca PLC 
7. Bayer AG 
8. Biovent 
9. BTG International Ltd 
10. deCODE genetics, Inc. 
11. Evotec Aktiengesellschaft 
12. F. Hoffmann-La Roche Ltd. 
13. Genmab A/S 
14. GENTIUM S.p.A. 
15. GPC Biotech AG 
16. GlaxoSmithKline plc 
17. Grupo Ferrer 
18. GW Pharmaceuticals plc 
19. Ipsen S.A. 
20. Italfarmaco 
21. Karo Bio 
22. Les Laboratoires Servier 
23. Medigen 
24. Menarini group 
25. Merck KGaA 
26. Mymetics Corporation 
27. Novartis AG 
28. Sanofi-Aventis 
29. Transgene 
30. Vernalis 
 
Immunology  
1. Actelion Ltd 
2. Active Biotech AB 
3. ALK-Abello A/S 
4. Allergy Therapeutics plc 
5. AstraZeneca PLC 
6. Bayer AG 
7. Biotest AG 
8. Elan Corporation, plc 
9. Evotec Aktiengesellschaft 
10. F. Hoffmann-La Roche Ltd. 
11. Italfarmaco 
12. GW Pharmaceuticals plc 
 
 
 
Cardiovascular  
1. Actelion Ltd 
2. Ark Therapeutics Group plc 
3. AstraZeneca PLC 
4. Bayer AG 
5. Boehring Ingelhem 
6. Chiesi Farmaceutica 
7. deCODE genetics, Inc. 
8. EGIS Pharmaceuticals Plc 
9. F. Hoffmann-La Roche Ltd. 
10. Gedeon Richter Plc. 
11. GENTIUM S.p.A. 
12. GlaxoSmithKline plc 
13. Grupo Ferrer 
14. Ipsen S.A. 
15. Italfarmaco 
16. Karo Bio 
17. Krka d.d. Novo Mesto 
18. Les Laboratoires Servier 
19. LifeCycle Pharma A/S 
20. Meda AB 
21. Merck  
22. Novartis AG 
23. Nycomed International Management 
GmbH 
24. Rafarm 
25. Sanofi-Aventis 
26. Schwable Pharmaceuticals 
27. Schwarz Pharma AG 
28. Orion Corporation 
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Musculoskeletal and Inflammation 
1. Abiogen Pharma 
2. Ablynx NV 
3. Chiesi Farmaceutici 
4. Crucell N.V. 
5. Dr. Kade Pharmazeutische Fabrik 
Gmbh 
6. Genmab A/S 
7. GlaxoSmithKline plc 
8. Novartis AG 
9. Noxxon Pharma AG 
10. Palau Pharma 
11. Rafarm 
12. Revotar Pharmaceuticalsd 
13. UCB Group 
 
 
Genito Urinary System and Sex Hormones 
1. GlaxoSmithKline plc 
2. Novartis AG 
3. Rafarm 
4. Schwable Pharmaceuticals 
 
Central Nervous System 
1. Abiogen Pharma 
2. Actelion Ltd 
3. Addex Pharmaceuticals 
4. Amarin Corporation plc 
5. AstraZeneca PLC 
6. Biomedica Foscama 
7. BTG International Ltd 
8. EGIS Pharmaceuticals Plc 
9. Elan Corporation, plc 
10. Evotec Aktiengesellschaft 
11. F. Hoffmann-La Roche Ltd. 
12. Gedeon Richter Plc. 
13. GlaxoSmithKline plc 
14. Grupo Ferrer 
15. GW Pharmaceuticals plc 
16. H Lundbeck A/S 
17. Ipsen S.A. 
18. Italfarmaco 
19. Karo Bio 
20. Krka d.d. Novo Mesto 
21. Les Laboratoires Servier 
22. Merz 
23. Neurosearch 
24. Newron 
25. Novartis AG 
26. Orion Corporation 
27. Rafarm 
28. Sanofi-Aventis 
29. Schwarz Pharma AG 
30. UCB Group 
31. Vernalis 
 
Respiratory 
1. Abiogen Pharma 
2. AstraZeneca PLC 
3. Chiesi Farmaceutici 
4. Crucell N.V. 
5. Eurand N.V.  
6. Evotec Aktiengesellschaft 
7. GlaxoSmithKline plc 
8. Grupo Ferrer 
9. Krka d.d. Novo Mesto 
10. Meda AB 
11. Novartis AG 
12. Nycomed International Management 
GmbH 
13. Rafarm 
14. Schwable Pharmaceuticals 
15. Schwarz Pharma AG 
16. UCB Group 
 
Metabolic Disorders 
1. Alizyme plc 
2. Biomédica Foscama 
3. deCODE genetics, Inc. 
4. F. Hoffmann-La Roche Ltd. 
5. GENTIUM S.p.A. 
6. GlaxoSmithKline plc 
7. Grupo Ferrer 
8. Krka d.d. Novo Mesto 
9. Les Laboratoires Servier 
10. LifeCycle Pharma A/S 
11. Novartis AG 
12. Sanofi-Aventis 
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Appendix 16 – Potential customers 2009 turnovers  
 
Table 0.1 – DPM pharmaceutical companies targeted turnover 
Company Name Turnover 2009 (US$m) 
Abiogen Pharma 82,62 
Allergy Therapeutics plc  58,53 
Ark Therapeutics Group plc  1,75 
AstraZeneca PLC  31.601,00 
Bayer AG  48.408,82 
Biomedica Foscama   NA 
BTG International Ltd  160 
Boehring Ingelheim 25.302,07 
Chiesi Farmaceutici 1.132,64 
Dr. Kade Pharmazeutische Fabrik GmbH 80,17 
Eurand N.V – Resp. 144,91 
EGIS Pharmaceuticals Plc  565,05 
F. Hoffmann-La Roche Ltd.  42.237,96 
Gedeon Richter Plc.  1.392,02 
GlaxoSmithKline plc  45.947,17 
Grupo Ferrer   NA 
GW Pharmaceuticals plc  22,22 
Lundbeck .  2.238,49 
Ipsen S.A  1.427,97 
Italfarmaco 389,67 
Krka d.d. Novo Mesto 1.396,94 
Les Laboratoires Servier 5.441,18 
Meda AB   
Menarini group 3.633,02 
Merck 11.114,71 
Merz 5,399 
Novartis AG  42.584,00 
Nycomed International Management GmbH 4.923,53 
Orion Corporation   NA 
Rafarm   NA 
Sanofi-Aventis  42.377,94 
Schwable Pharmaceuticals 746,87 
  
 
 
 
Table 0.2 – R&D pharmaceutical companies targeted turnover 
 
Company Name 
Turnover 
(US$m) 
ALK-Abello A/S  353,97 
Biovent 11,293 
LifeCycle Pharma A/S  33,75 
Vernalis   NA 
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Table 0.3 - DPM biopharmaceutical companies targeted turnover 
 
Company Name 
Turnover 
(US$m) 
Actelion Ltd  1.364,36 
Biotest AG  622 
Crucell N.V.  392,65 
Elan Corporation, plc 1.000,00 
GENTIUM S.p.A.  10,94 
GPC Biotech AG  18,19 
Medigen 51,96 
Neurosearch 240 
Pharming Group N.V. 0,97 
Schwarz Pharma AG 624,78 
UCB Group  5.295,59 
 
 
 
 
Table 0.4 – R&D biopharmaceutical companies targeted turnover 
Company Name 
Turnover  
(US$m) 
Ablynx NV  25 
Active Biotech AB  8,3 
Addex Pharmaceuticals  24,88 
Alizyme plc  3,51 
deCODE genetics, Inc.  58,1 
Amarin Corporation plc  2400 
Evotec Aktiengesellschaft (small molecules)  58,25 
Genmab A/S 147,84 
Karo Bio  1,71 
Mymetics Corporation 0,1 
Newron  NA 
Noxxon Pharma AG   NA 
Palau Pharma   NA 
Revotar Biopharmaceuticals   NA 
Transgene 136,38 
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Appendix 17 – Intensity of competition by therapeutic area of focus  
 
Table 0.5 – Therapeutic area of focus of target drug delivery companies. 
Target drug delivery company Therapeutical area of focus 
Access Pharmaceuticals, Inc Cancer 
Alkermes CNS disorders, addiction, diabetes and autoimmune 
disorders 
ArmaGen Technologies, Inc. Solutions to the 'blood-brain barrier' problem (CNS) 
Avidimer Therapeutics Cancer 
Calando Pharmaceuticals, Inc. Cancer, AIDS, hepatitis C, Huntington's disease 
Cell Therapeutics, Inc. Cancer 
Cerulean Pharma, Inc. Cancer, inflammation, and CV diseases. 
Copernicus Therapeutics, Inc. Diseases causing blindness, airborne viral, and diseases of 
the brain 
CytImmune Sciences, Inc. Cancer 
Delcath Systems Cancer 
Diatos S.A. Cancer 
Enzon Pharmaceuticals, Inc. Cancer 
Endocyte Inc. Cancer 
Eurand N.V. Cystic Fibrosis and gastriointestinal 
ImmunoGen, Inc. Cancer 
NanoBioMagnetics, Inc. Cancer 
Nanobiotix Cancer 
NanoCarrier, Inc. Cancer 
Nano Interface Technology Cancer 
Nektar Therapeutics across many therapeutic areas and modalities 
NeoPharm Cancer 
Novosom AG Inflammation, Cancer and liver diseases 
Mirus Bio Corporation across many therapeutic areas and modalities 
PCI Biotech Holding ASA across many therapeutic areas and modalities 
Quest PharmaTech, Inc. Cancer 
Seattle Genetics Cancer, and autoimmune diseases 
Starpharma Holdings, Ltd across many therapeutic areas and modalities 
Supratek Pharma Inc. Cancer 
Tekmira Pharmaceuticals 
Corporation 
across many therapeutic areas and modalities 
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Table 0.6 – Total number of companies per therapeutic area 
Therapeutic area Total number of 
companies 
Total number of 
companies (%) 
Cancer 20 54,1 
CNS 2 5,4 
Immunology 2 5,4 
Inflammation 2 5,4 
CV 1 2,7 
OTHERS 5 13,5 
Across many therapeutic areas 5 13,5 
 
 
Table 0.7 – Intensity of competition Assigning Values 
% 
Intensity of 
competition 
0-5 10 
5 a 10 9 
10 a 20 8 
20 a 30 7 
30 a 40 6 
40 a 50 5 
50 a 60 4 
60 a 70 3 
70 a 80 2 
80 a 90 1 
90 a 100 0 
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Appendix 18 – Positioning factors interviews 
 
Questionnaire used to pharmaceutical companies targeted companies interviews 
 
Considering the criterias that most influence your company, in the decision of be the licensee of a 
new and versatile drug delivery system,  classify the following factors in a scale between 0 (nothing 
important) to 5 (extremely important). 
Price 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product Quality 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Possibility of application the drug delivery system to different API’s 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
R&D STAFF prestige 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organizational Image 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Innovation for the final product 
0 1 2 3 4 5 
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Environmental concerns (related to the process and products) 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Who is the contact person (job function) inside your company that should be contacted in case of 
present a new drug delivery to your marketable products? 
__________________________________________________________________________________
________________________________________________ 
 
Do your company has already purchase for a license of a drug delivery system? 
YES  
 
NO  
 
 
IF you answer affirmatively, which is the licensor company? 
___________________________________________________________________________
_______________________________________________________ 
Do your company; develop research in the area of drug delivery systems? 
YES  
 
NO  
 
 
Just one question about you: 
What is your job function inside the company? 
________________________________________________________________ 
 
 
Thank you very much! 
 
Note: This information it will only be used for the purpose of a master thesis in Biotechnology. 
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Questionnaire used to drug delivery companies interviews 
 
Considering the positioning criterias of your company, classify the following factors in a scale 
between 0 (nothing important) to 5 (extremely important). 
Price 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product Quality 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Possibility of application the drug delivery system to different API’s 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
R&D STAFF prestige 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organizational Image 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Innovation for the final product 
0 1 2 3 4 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Environmental concerns (related to the process and products) 
0 1 2 3 4 5 
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Does your company have targeted delivery systems? 
YES  
 
NO  
 
 
If you answer affirmatively, what are the names of the products? 
___________________________________________________________________________
_______________________________________________________ 
 
Have you already license some of your drug delivery systems? 
 
 
 
If you answer affirmatively, what is the name of the licensee? 
__________________________________________________________________________________
________________________________________________ 
_________________________________________________________________ 
 
 
Just one question about you: 
What is your job function inside the company? 
________________________________________________________________ 
 
Thank you very much! 
 
Note: This information it will only be used for the purpose of a master thesis in Biotechnology. 
YES  
 
NO  
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Interviews positioning factors results: 
 
Were made efforts in order to contact all the pharmaceutical targeted companies as well all the 
targeted drug delivery companies referred in this marketing plan as competitors. However many 
companies did not answer, other ones did not fill the questionnaire because of company policies, and 
some of the companies that completely filed the questionnaire ask for confidentiality related to their 
company brand. 
In the Appendix 1 are present the contact persons of company’s staff that answer the questionnaire 
without asking for confidentiality. 
 
Average classifications of Pharmaceutical companies positioning factors valuation: 
 
Price 
 
Product 
Quality 
 
Possibility of 
application the 
drug delivery 
system to different 
API’s 
 
R&D 
STAFF 
prestige 
Organizational 
Image 
 
Innovation 
for the 
final 
product 
 
Environmental 
concerns 
3 5 5 4 4 5 3 
 
 
 
Average classifications of Drug delivery companies positioning factors valuation: 
 
Price 
 
Product 
Quality 
 
Possibility of 
application the 
drug delivery 
system to different 
API’s 
 
R&D 
STAFF 
prestige 
Organizational 
Image 
 
Innovation 
for the 
final 
product 
 
Environmental 
concerns 
4 5 4 3 4 4 3 
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Appendix 19 – Template of Exclusive patent license agreement (adapted from exclusive 
patent license agreement template made by Portuguese Industrial Property Office) 
 
EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN UNIVERSIDADE NOVA DE LISBOA AND 
INSTITUTO SUPERIOR TÉCNICO AND LIFE DELIVERY 
 
Between 
 
Universidade Nova de Lisboa (UNL), legal person no. xxx, with its head office at …, …-… Lisboa, 
represented by xxx, in his/her capacity as Rector of UNL, and Instituto Superior Técnico (IST), legal 
person no. xxx, with its head office at …, …-……, represented by xxx, in his/her capacity as Director of 
IST, with powers for the fact, hereinafter referred to as the R&D, Licensor or First Party; 
And 
LIFE DELIVERY, legal person no. …, with its registered office at …, …-… …, represented by Pedro 
Vidinha, in his/her capacity as CEO, with powers for the act, hereinafter referred to as the COMPANY, 
Licensee or Second Party;  
 
Whereas: 
a)  The R&D is the sole owner of a PENDING PATENT APPLICATION submitted in … under 
number 08398007.8  dated 19/06/2008, published in … under number … with the title 
“SYNTHESIS AND APPLICATION OF A FAMILY OF NEW MATERIALS RESULTING FROM THE 
CHEMICAL CROSS-LINKING BETWEEN GELATINE AND ORGANIC SALTS”, to European Patent 
Office (EPO)  (hereinafter referred to as the Office) (hereinafter referred to as PATENT 
08398007.8; 
 
PATENT RIGHT applied for in United States under number 12/142960 dated …, with the title “”, 
granted by … (hereinafter referred to as the Office) on … (hereinafter referred to as PATENT A); 
US  
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b) The R&D, as the sole owner of PATENT A, shall bear all the costs of its preparation and 
submission to the Office, those incurred with all prior art searches, the remaining procedures 
needed for its grant and subsequent maintenance, including all Patent Attorney fees and all 
other fees, charges and expenses and that said PATENT A is free of any encumbrances, third 
party rights and/or options and expenses; 
c) R&D, acting as owner of PATENT A, wishes to license the exploitation of the invention 
patented through persons or entities authorised by him; 
d) The COMPANY wishes to obtain from the R&D an exclusive license for exploitation of the 
invention claimed in PATENT A; 
e) It is necessary to settle the contractual terms of the license;  
 
The parties accept the following EXCLUSIVE PATENT LICENSE AGREEMENT, which is subject to the 
Clauses: 
ONE  
(Object) 
Under this agreement, the parties establish the scope and conditions of the granting by R&D to the 
COMPANY of a license to exploit the invention claimed in PATENT A.  
TWO 
(License General Conditions) 
2.1. The R&D, as Licensor, grants to the Company, as Licensee, an invention exploitation license, 
which covers the manufacture, use, sale and lease of the artefacts or products claimed in and 
pertaining to PATENT XXX and the use or application of the methods, means and processes claimed 
in said PATENT XXX, subject to Licensee full compliance with the conditions and obligations set out 
below. 
2.2. The R&D, as the Licensor, grants to the COMPANY, as Licensee, an EXCLUSIVE EXPLOITATION 
LICENSE, with the following general conditions: 
2.2.1. Scope – This license covers the patent right of PATENT XXX “…”, number …, all 
subsequent international extensions of the same patent application and all subsequent 
national phases validated in the meantime. Its scope or extension cannot therefore be 
divided or split by either party; 
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2.2.2. Exclusive – The R&D undertakes, for the entire period granted for the license, not to 
grant any other license to a third party, as set out in Clause Four below; 
2.2.3. Temporary – This license shall be granted for a period of … years, possibly extendible, 
in accordance with Clause Five below;  
2.2.4. Under Payment – The Licensee undertakes to pay, in return for the exclusive use of 
the Technology, the amounts due accordingly with Clause Six below; 
2.2.6. With the possibility of sublicensing by the Licensee, in accordance with Clause Eight 
below; 
2.2.7. Performance Clause – The Licensee undertakes to actually exploit the licensed 
Technology, under the sanction of agreement termination by the Licensor, as set out in 
Clause Twelve; 
2.2….. Restricted to a specific field of use – This license entitles the Licensee to exploit the 
aforementioned Technology with a SPECIFIC RESTRICTION TO THE FIELD OF Drug delivery 
systems, as set out in Clause Eight; 
2.3. This license does not cover any other patent rights or other industrial property rights owned by 
R&D.  
2.4. No use of R&D´s commercial name, trademark or other distinctive signs owned by R&D is 
allowed, except on the conditions set below. 
 
THREE 
(Patent rights maintenance and registration) 
3.1. The R&D undertakes to keep PATENT XXX fully valid, along with any extensions licensed under 
this agreement, on pain of immediate agreement termination thereof. 
[…, which will also occur should PATENT XXX, while pending, be refused or not granted for any 
reason.] 
3.2. The Licensee undertakes to proceed with the register of the license at the designated Patent 
Offices at its own expense and to inform the R&D immediately of these acts in writing, considering 
the provisions of Article 30.1.b) of the Portuguese Industrial Property Code. 
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FOUR 
(Exclusivity; Improvements by the Licensee) 
4.1. The R&D, as Licensor, shall refrain from granting other licenses for the Technology to any third 
party or from performing any other acts that may encumber, compress or limit the rights granted for 
the length of this agreement and in any extensions, without prejudice to the following paragraph. 
4.2. The R&D shall maintain the right to use the licensed technology in its own non-commercial 
research activities, provided that it does not infringe the rights granted or the confidentiality 
provisions set out in this agreement. 
4.3. Should the Licensee or any employee, in compliance with an employment agreement or as a 
service provider, perform modifications to the licensed technology that constitute an improvement 
to its performance or make an invention for which it obtains a patent depending on PATENT XXX, it 
undertakes to grant the R&D a free license with no territorial restrictions and extending to all 
applications of a non-exclusive nature for the exploitation of said patent and/or associated or 
dependent know-how. 
4.4. In the case provided for in paragraph 4.3, the Licensee also undertakes, if granting paid licenses 
for the dependent patent, to give the R&D … % (… percent) of the gross profits obtained from these 
licenses. 
 
FIVE 
(Duration) 
5.1. This license has temporary nature and is granted for a period of … years, as of the date of signing 
of this agreement. 
5.2. The license may be extended by unanimous agreement of the parties. 
5.3. This license shall always have a maximum limit of 20 (twenty) years as of the date of submission 
of the first application for PATENT XXX. 
 
SIX 
(Licensors Financial compensation) 
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6.1. The Licensee undertakes to pay to R&D as direct, necessary compensation for the use and 
exploitation of the Technology, in the form of an initial payment, together with a minimum quarterly 
royalty independent of any exploitation, plus periodic royalties indexed to gross profits from 
exploitation, all as set forth in the following clauses.  
6.2. The R&D, as Licensor of the patent right referred to in the first part of 2.2.1, is entitled to receive 
from the Licensee an initial upfront payment of € 39.253,77. 
6.3. The payment referred in 6.2 shall be made to the R&D by the Licensee on the date of signing of 
this agreement. 
6.4. The payment due in 6.2 is totally independent from the remaining royalty obligations that the 
Licensee accepts in the following paragraphs. 
6.5. Without prejudice to the previous paragraphs, the R&D is also entitled to receive from the 
Licensee periodic royalties indexed to the gross profits obtained by the Licensee in the exploitation of 
the licensed Technology, at a fixed percentage of … % (… percent), to be reported quarterly in writing 
in a document certified by an official auditor by the Licensee to the R&D. It shall always owe to the 
R&D as a minimum quarterly royalty the amount of €… (… euros).  
6.6. The payments provided for in 6.5 shall be made within a maximum of 60 (sixty) days as of the 
end of the quarter that generated the obligation to pay. 
6.7. “GROSS PROFITS” are any income received by the Licensee arising from: 
 Technology incorporation in its own products and processes, in its own or subcontracted 
production and irrespective of its commercial efforts; 
 The manufacture, use and sale of products incorporating the Technology; 
 Commercial exploitation of any process belonging to the Technology. 
 
SEVEN 
 (Information duties and audit clause) 
7.1. The Licensee shall submit to the R&D, within a maximum of 90 days of the end of each calendar 
quarter, a written, hard-copy report with reasonable accounting detail, billing and gross sales 
reflecting the actual exploitation of the licensed Technology and subject to the calculation criteria for 
royalties set in Clause Six. 
7.2. The quarterly report described in paragraph 7.1 shall contain gross sales data and the result of 
the application of the calculation criteria for royalties. 
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7.3. The Licensee shall keep in its possession certified accounting data in reasonable detail on the 
production, use, distribution, sales and other acts pertaining to the Technology. 
7.4. Provided that it gives 30 days prior notice, the R&D is entitled, at its own expense, to conduct, or 
to commit a third party appointed by it, an audit of the records kept by the Licensee, in order to 
check the relevant accounting figures and thereby certify the compliance with the royalties plan that 
the Licensee undertook to follow. 
7.5. Any audit based on the previous paragraph shall be conducted within office hours and in such a 
way to disrupt the Licensee’s activities as little as possible. The Licensee may not refuse an audit or 
deny access to any accounting documents or others such as agreements, contracts, promissory or 
option contracts, invoices, receipts, shipping notes, letters, commercial bids, estimates and 
electronic communications, access to premises, vehicles, IT resources or media, be they hardware or 
software, contact with workers, customers, agents or suppliers, physical checks of inventory or any 
other form of check and audit that the Licensor and/or the appointed auditors see fit.   
7.6. If the results of an audit diverge materially from the data provided by the Licensee, it shall be 
responsible for returning the royalty amount difference and all audit costs borne by the R&D. 
EIGHT 
(Agreement Assignment) 
The Licensee may not assign its position in this agreement without the R&D’s written consent. 
NINE 
(Agreement Termination)  
9.1. This agreement may be revoked at any time upon Parties unanimous agreement. 
9.2. The R&D has the right to terminate this agreement if the Licensee breaches or fails to properly 
fulfil any of the agreement accepted terms, conventions and obligations therein and in the specific 
case set out in the next Clause. 
9.3. The Licensee has 30 (thirty) days after full acquaintance of the R&D’s intention to terminate the 
agreement to correct or remedy any fault committed or fulfil obligations not complied with. If this is 
not done in a timely fashion, R&D has the right to terminate this agreement. 
9.4. The R&D has also the right to terminate the agreement, if any of the following events occur: 
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 The Licensee fails to make any of the payments that it undertook to make in this agreement, 
such as those in Clause Six, in good time and fails to do so even after being so ordered within 
8 (eight) days, in written form, by the R&D; 
 The Licensee is declared insolvent, requests credit protection or is declared bankrupt, under 
current legislation. In this case, the agreement shall be terminated immediately after the 
R&D informs the Licensee of its intention; 
 During the exercise of the R&D’s right to information and auditing set forth in Clause Seven, 
R&D or a third party appointed by it finds a difference or discrepancy of more than 20% in 
the Licensee’s data relevant to the calculation of royalties in each 3 (three) month period. 
9.5. In the event of the stoppage of the effects of this agreement, the Licensee shall, as of the date of 
said cessation, be forbidden to continue the invention exploitation, including the ability to sell, 
exchange or transfer free of charge any item of goods or service covered by this license. 
9.6. This agreement may expire in the case set out in 3.1 above. In this case, the parties expressly and 
unconditionally recognise and accept the non-retroactivity of the effects of the agreement expiration 
and the nature of continued performance of this agreement. There shall therefore be no 
reimbursement of any amounts paid or owed by the Licensee under this agreement in return for the 
use of PATENT A. 
9.7. The obligation to maintain confidentiality set out in 12.4 shall survive any of the cases of 
cessation of the effects of this agreement and shall remain fully valid and effective. 
 
TEN 
(Performance Clause) 
10.1. The Licensee undertakes to actually exploit the licensed rights in accordance with 2.2.7 above 
and shall initiate steps towards effective exploitation within a maximum of … days as of the date of 
signing of this agreement and give sufficient proof thereof. 
10.2. If the Licensee fails to respect the time limit set out in the previous section, the R&D has the 
right to terminate this agreement unilaterally, provided that it gives 30 (thirty) days’ notice. 
10.3. If the Licensee begins or resumes exploitation of the licensed rights and provides sufficient 
proof of this exploitation before the end of the 30 (thirty) days’ notice of termination of the 
agreement by the R&D or submits to it, within the same period, a reprogramming of the exploitation 
strategy that is accepted by the R&D, the right to dissolve this agreement shall be automatically 
suspended. 
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ELEVEN 
 (Parties Responsibilities) 
11.1. The Licensee is solely responsible for the licensed Technology before end users, for any reason, 
and in relation to any third parties and undertakes to compensate the R&D for any amounts that it 
may have to disburse due to lawsuits, complaints or legal action against it on the grounds of the 
Technology. 
11.2. The R&D, in turn, does not by any means guarantee the operability or adaptability for any use, 
the safety, efficacy, approval by national and other regulatory authorities, the time and any costs of 
the development and/or opening of the Technology licensed in this agreement. 
11.3. Neither does the R&D declare or, as a result, guarantee that the Technology licensed by this 
agreement does not infringe other patent rights already owned by or pending for third parties or that 
there are no causes that may affect the validity of the right covered by this agreement. 
11.4. The parties undertake to cooperate in the defence of PATENT XXX against any actions by third 
parties, such as violations of the right or lawsuits based thereon.   
 
TWELVE 
(Confidentiality) 
12.1. The Parties expressly undertake to treat and maintain absolutely confidential all information 
regarding this agreement or either of the parties that may come to their knowledge within the scope 
of this agreement or the preliminary negotiations prior to its signing and shall also refrain from any 
use of said information outside its scope and irrespective of the purpose, either to their own benefit 
or that of a third party. 
12.2. Each Party is also obliged to treat in the way mentioned above all information regarding 
internal and/or commercial or business matters of the other party to which it has access in any way. 
12.3. Information transmitted in the following ways is exclusively excepted from this duty of 
confidentiality: 
 To the managers, consultants and other personnel belonging to the research teams of the 
R&D and Licensee, provided that they are directly involved in compliance with the 
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agreement and the performance of the activities regulated by it. Said parties undertake to 
guarantee equivalent confidentiality commitments for all their employees involved in 
compliance with this agreement; 
 Within the framework of the information to be provided by the R&D and/or Licensee to their 
corporate bodies for the purpose of fulfilling obligations laid down by law or their Statutes or 
the obtaining of the authorisations necessary for full performance of this agreement; 
 All information belonging to the public domain or for which the transmitter has expressly 
waived the obligation set out herein. 
12.4. The obligation set out in this clause shall be binding on the parties for a period of 5 (five) years 
as of the actual disclosure of the information, irrespective of the cessation of this agreement for any 
reason. 
12.5. The burden of proof of the exceptions set out in 12.3 to the obligation to maintain 
confidentiality lies with the recipient of the information. 
 
THIRTEEN 
(Law and Dispute Resolution) 
13.1. This agreement is subject to Portuguese Law. 
13.2. The courts of Portugal shall be competent to settle any disputes arising from it. 
13.2. In the event of a disagreement or dispute between the Parties on the interpretation, validity or 
application of this Agreement that they are unable to settle by consensus, either Party may submit it 
to an arbitration court, expressly renouncing to the intervention of any other court. 
13.3. The arbitration court shall be set up and function as established by the Voluntary Arbitration 
Law (Law no. 31/86 of 29 August with the amendments introduced by Decree-Law no. 38/2003 of 8 
March) and shall consist of three arbiters, one appointed by each Party and a third by cooption by 
the Parties. If they are unable to agree on the appointment of the third arbiter, s/he shall be 
appointed by the Presiding Judge of the Lisbon Court of Appeal at the request of either Party. 
13.4. The arbitration procedure shall take place in Portuguese, in Lisbon, unless otherwise agreed by 
the parties in the arbitration procedure. 
13.5. Whenever there is a disagreement or dispute regarding industrial property, the ARBITRARE 
Arbitration Centre shall be competent to settle said conflicts, to the express exclusion of any other, in 
which case the Arbitration Centre’s regulations shall apply.  
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13.6. The arbitration tribunal and/or arbitration centre shall appreciate the facts and rule in 
accordance with Portuguese law. Its decisions shall not be subject to appeal. 
The parties declare that they are cognisant of and fully accept the terms of this agreement. 
 
It shall now be signed by the legal representatives of the R&D and the Licensee and each of the 
Parties shall retain a signed copy initialled by all on each page. 
 
Lisbon, … … … 
 
For the R&D 
 
 
For the COMPANY  
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Appendix 20 – Drug delivery license deals during 2009 
 
Licensor Licensee Product/Technology Therapy area(s) Deal terms Month 
signed 
BioDelevery 
Sciences 
Media Onsolis (fentanyl 
buccal soluble film) 
Breackthrought pain 
in opcid-tolerant 
patients with cancer 
£3 million for 
worldwide 
distribution 
rights(except 
Taiwan and South 
Korea) 
January 
Pharmathen Recordati Undisclosed Undisclosed Undisclosed January 
Elan Schein 
Pharmaceutical 
(now Watson) 
Medipad minimal 
invasive 
microinfusion pump 
Genetic blood 
disorders associated 
with iron overload 
Undisclosed March 
Altea 
Therapeutics 
Amylin and Lilly Altea’s proprietary 
PassPort transdermal 
delivery system 
Type 2 diabetes Up to $46 million; 
exclusive 
worldwide licence 
April 
Aegis 
Therapeutics 
Phylogica Intravail tranmucosal 
delivery formulations 
of Phylomer peptides 
Undisclosed N/A April 
Neuromed Mallinckrodt Exalgo 
(hydromorphone 
HCI) extended-
release tablets 
Pain US rights for $15 
million up front; 
more than $90 
million in 
milestones 
June 
Calando 
Pharmaceuticals 
Cerulean 
Pharma 
Cyclodextrin co-
polymer based drug 
delivery technology 
Oncology Exclusive 
worldwide rights 
June 
Penwest 
Pharmaceuticals 
Otsuka 
Pharmaceutical 
TIMERx oral 
controlled-release 
technology 
Undisclosed Undisclosed June 
Almac Discovery Archimedes 
Pharma 
ChisSys intranasal 
delivery technology 
Chemotherapy-
induced nausea and 
vomiying 
Archmedes 
responsible for 
development to 
Phase II 
June 
Endo/Penwest Veleant 
Pharmaceuticals 
Oxymorphone 
extended-release 
(opana ER) 
Pain Rights in Canada, 
Australia and New 
Zealand 
June 
Access 
Pharmaceuticals 
Two unnamed 
companies 
Access’s Cobalamin 
oral drug delivery 
technology 
Diabetes Companies 
considering 
entering licensing 
discussions 
June 
Flamel 
Technologies 
Baxter Controlled-release 
preparations of blod 
clotting factor 
replacement 
therapies 
Blood clotting 
disorders in 
haemophilia 
Flamel will receive 
technology access 
fees totaling €2.5 
million; Baxter to 
pay all 
development costs 
July 
Biocompatibles 
International 
Eisai DC Bead and 
PRECISION Bead 
system 
Vascular 
embolization of 
malignant 
hypervascularised 
tumours 
Elsai paid $3 Million 
up front; further 
undisclosed 
regulatory and 
commercial 
milestone 
July 
Depomed Merck & Co Metformin extended-
release technology 
Fixed-dose 
combinations of 
$10 million for non-
exclusive licence 
July 
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sitagliptin and 
extended-release 
metformin 
AstraZaneca Astellas Symbicort 
(budesonide plus 
formoterol), inhaled 
Bronchial asthma ¥3.0 billion($31.5 
million) up front; 
up to ¥5.5 billion in 
milestones 
August 
ProStrakan Endo 
Pharmaceuticals 
Transdermal, once-
daily, 2% gel 
formulation of 
testosterone 
Hypogonadism $210 million for US 
licensing and 
distribution rights 
August 
London School of 
Pharmacy 
Encap Drug 
Delevery 
Phloral colonic drug 
delivery system 
Crohn’s disease 
ulcerative colitis 
Undisclosed September 
Surmodics Genentech Biodegradable 
microparticle system 
for sustained drug 
delivery formulation 
of Lucentis 
(ranibizumab 
injection) 
Wet age-related 
macular 
degeneration 
$3.5million up 
front; up to $200 
million in fees and 
milestones 
October 
Sosei Pharmasol Development stage 
sublingual spray 
formulation of 
fentanyl  
Pain Undisclosed October 
Lupin 
Pharmaceuticals 
Salix 
Pharmaceuticals 
Bioadhesive drug 
delivery technology 
for use with rifaximin 
Diarrhea $5 million up front 
plus further 
payments 
October 
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Appendix 21 – Promotional options  
 
Advertising 
 
Advertising channel Proposal Price Contact 
Drug Delivery 
Technology 
Button 120x120 
pixels 15 KB Flash 
SWF 
£200 per JPG, GIF / 
month 
Ralph Vitaro 
rvitaro@drugdeliverytech.com 
European 
Pharmaceutical 
Review magazine 
Website banner 
advertising 
(home page banner 
in the center with 
100 x 300 pixels) 
$995/month Robin Johnson – 
rjohnson@russellpublishing.com 
 
Membership associations:  
Note: Information souce - [online] Europabio 
 
Europabio (the European Association for Bioindustries)  
“EuropaBio's mission is to promote an innovative and dynamic biotechnology-based industry in 
Europe. EuropaBio, (the European Association for Bioindustries), has 66 corporate and 7 associate 
members operating worldwide, 4 Bioregions and 22 national biotechnology associations representing 
some 1800 small and medium sized enterprises.” 
Benefits of EuropaBio membership 
“Membership means a strong voice within Europe” 
“At the European level we ensure you an effective representation to European Institutions by 
EuropaBio’s board and members. Our close liaison with European regulators and opinion leaders led 
to successful lobbying initiatives resulting in a variety of positive legislative, regulatory and policy 
improvements.” 
“Members also have opportunities to play a role in expert committees, lobbying, policy development 
alongside the promotional activities such as: 
 Having a representative voice in Europe; 
 Participation in European workshops and plenary discussions;  
 Access to information concerning European  and worldwide biotechnology developments;  
 Access to information related to the current European legislation;  
 Information updates, workshops and seminars relating to technology promotion;  
 Access to a variety of events and network opportunities which are part of a trade association;  
 Contacts with non-European associations for bioindustries (BIO, JBA, AfricaBio etc.) and life 
science companies.” 
“We lead an innovative and dynamic industry, helping our members find continuing success and 
opportunities.” 
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Appendix 22 – Brief Technology Presentation 
 
Powerpoint version 
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Appendix 23 – Non Disclosure Agreement (NDA) Template (adapted from bilateral NDA 
template made by Portuguese Industrial Property Office). 
 
BILATERAL CONFIDENTIALITY AGREEMENT (With Comments) 
Between 
LIFE DELIVERY, with its registered office at …, legal person no.…, represented by …, in his/her capacity 
as CEO, with powers of representation under the Law, as the First Party 
and 
…, with its registered office at …, legal person no. …, represented by …, in his/her capacity as …, with 
powers of representation under the Law, as the Second Party 
Whereas: 
 Contacts have been initiated by the parties for the purpose of develop and fit  the DELIVES 
technology to an product or products of the Second Party; 
 There is a need in this context to exchange restricted and/or non public information between 
the parties; 
 Said information is a critical asset of the parties, with its own value, irrespective of whether 
or not any cooperation instrument is signed between them or between one of them and any 
third parties; 
 
The parties enter into this CONFIDENTIALITY AGREEMENT, which is subject to the following clauses: 
 
ONE 
(Object) 
1.1. The aim of this agreement is to guarantee the confidentiality and protection of the information 
classified as protected, confidential, non public or other similar description exchanged by the parties 
with the exclusive purpose fixed in Clause Two below. 
1.2. Protected or confidential information, hereinafter referred to generally as the “Information”, is 
all information that, irrespective of the medium used, comprises: 
 Unpublished works of any nature, such as graphic, written or sound; 
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 Unpublished  compilations or selections of information; 
 Financial documents; 
 Know-how, technological data, methods, formulas, demonstrations, samples or studies; 
 Computer programs, software or software programming blocks in the form of source code 
or object code; 
 Commercial documents, such as customer lists; 
 Reports, drafts and memoranda; 
 Any intellectual assets, as a set of any and all research results, whether or not they are 
protected by any industrial property right; 
 Any other information disclosed by the Disclosing Party to the Recipient in said context. 
1.3. In the meaning set out in this agreement, the parties shall be called the “Disclosing Party” and 
“Recipient” in accordance with their capacity in the exchange of Information to be regulated. 
 
TWO 
(Purpose of disclosure and duty of confidentiality) 
2.1. The Information shall be disclosed for the exclusive purpose of develop and fit the DELIVES 
technology to an product or products of the Second Party; 
2.2. The First and Second Parties undertake not to use, disclose or transfer, for any reason or 
interest, in Portugal or abroad, the information disclosed by the other party for any purpose other 
than that set out in 2.1, unless authorised to do so in writing by the Disclosing Party. 
2.3. The Recipient must protect the information disclosed by the Disclosing Party using the same 
degree of care that it uses to prevent the unauthorised dissemination and publication of its own 
information. 
2.4. The Recipient shall take all necessary measures to prevent improper use of the information by 
any person who has access to it and guarantee the appropriate means to prevent the disappearance 
or loss of the information. It shall always inform the Disclosing Party of the occurrence of incidents of 
this nature, although said notification does not rule out its liability. 
2.5. The Recipient undertakes to return any copies, excerpts or parts of the Information referred to in 
1.2 above within 8 (eight) days on mere request on the part of the Disclosing Party. 
 
THREE 
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(Ownership and integrity of the information) 
3.1. The Information is the exclusive property of the Disclosing Party. 
3.2. Disclosure of the Information to the Recipient does not grant it any intellectual property right, 
authority to apply for protection of any rights or any licence for any right or pending application for 
an industrial property right related to any information, on pain of application of Article 34.1.a) of the 
Industrial Property Code. 
3.3. The Disclosing Party does not directly or indirectly warrant any kind of protection of the 
Information, namely by copyright or industrial property rights under this agreement. 
3.4. The Recipient agrees and acknowledges that this agreement does not restrict the Disclosing 
Party’s right to modify the information without prior notice.  
3.5. Said modifications do not entail any responsibilities for the Disclosing Party nor do they oblige it 
to develop, announce, hand over, maintain or finance any products or business plans based on the 
Information. 
 
FOUR 
 (Internal Disclosure of the Information) 
The Recipient shall limit the disclosure of the Information to managers and employees to the extent 
that is strictly necessary for the purpose of this agreement. It shall give them appropriate instructions 
to this effect and enter into an equivalent written confidentiality agreement with them. The Recipient 
shall be fully liable to the Disclosing Party for its staff compliance with the commitments established 
herein and the Disclosing Party may claim proof of these agreements from the Recipient at any time. 
 
FIVE 
 (Duration) 
4.1. This agreement shall come into full effect on the date of signing by both parties and the recipient 
shall be bound by this confidentiality commitment on the exact terms stipulated above for a period 
of three years from the date of the last disclosure of Information pursuant to this agreement. 
4.2. The parties may by agreement, at any time, revoke or amend the provisions of this agreement 
wholly or in part, provided that the confidentiality of the Information is not jeopardised. 
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4.3. Its effects may also cease on signing of any contractual commitment between the Parties that 
stipulates the confidentiality of the information and thereby replaces the terms of this contract, 
without prejudice to the following paragraph. 
4.4. Nonetheless, under no circumstances are the parties bound under this agreement to enter into 
any legal business in the future. 
SIX 
 (Liability) 
The recipient is liable to the Disclosing Party for any losses or injuries, including material losses and 
lost earnings, resulting from breach of or defective compliance with its obligations to maintain 
confidentiality, without prejudice to any criminal liability incurred in the event of breach of this 
obligation, under applicable Portuguese law. 
.2. Without prejudice to the previous paragraph, breach by the recipient of any of the obligations set 
out in this agreement shall entail payment to the Disclosing Party, as penalty clause, the sum of EUR 
… (…). 
 
SEVEN 
(Exceptions to Confidentiality) 
6.1. An item of Information IS NOT CONSIDERED TO BE COVERED by duty to maintain confidentiality: 
 If its disclosure has been expressly authorised by the Disclosing Party. Said authorisation 
must be requested by the recipient and granted by the Disclosing Party in writing within 8 
(eight) working days, after which, in the absence of an answer, authorisation shall be 
deemed to have been refused;  
 If it has been published, made public or in some other way clearly become part of the public 
domain before the time of disclosure; 
 If it has been made public after disclosure or become part of the public domain for reasons 
not imputable to the recipient by way of intent or negligence; 
 If the recipient can prove by means of written evidence that it was already in its possession 
before receiving from the Disclosing Party;; 
 If it was received by the Recipient from third parties with no duty to maintain confidentiality, 
provided that they had the right to provide this information and that they did not obtain it 
directly or indirectly from the Disclosing Party under conditions of  confidentiality; 
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 If the Recipient is obliged by law or judicial decision to disclose it, provided that the recipient 
notifies the Disclosing Party immediately and cooperates with it in all reasonable efforts to 
contest or limit the scope of said disclosure. 
 If it is developed independently by the recipient. 
6.2. The burden of proof of all exceptions to the obligation to maintain confidentiality set out in 
paragraph 6.1 lies exclusively with the recipient. 
 
EIGHT 
(Law and Conflict Resolution) 
7.1. This agreement is subject to Portuguese Law. 
7.2. The courts of the Portugal shall be competent to settle any disputes arising from it. 
 
7.2. In the event of a disagreement or dispute between the Parties on the interpretation, validity or 
application of this Agreement that they are unable to settle by consensus, either Party may submit it 
to an arbitration court, expressly renouncing to the intervention of any other court. 
7.3. The arbitration court shall be set up and function as established by the Voluntary Arbitration Law 
(Law no. 31/86 of 29 August with the amendments introduced by Decree-Law no. 38/2003 of 8 
March) and shall consist of three arbiters, one appointed by each Party and a third by cooption by 
the Parties. If they are unable to agree on the appointment of the third arbiter, s/he shall be 
appointed by the Presiding Judge of the Lisbon Court of Appeal at the request of either Party. 
7.4. The arbitration procedure shall take place in Portuguese, in Lisbon, unless otherwise agreed by 
the parties in the arbitration procedure. 
7.5. Whenever there is a disagreement or dispute regarding industrial property, the ARBITRARE 
Arbitration Centre shall be competent to settle said conflicts, to the express exclusion of any other, in 
which case the Arbitration Centre’s regulations shall apply.  
7.6. The arbitration tribunal and/or arbitration centre shall appreciate the facts and rule in 
accordance with Portuguese law. Its decisions shall not be subject to appeal. 
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The parties recognise and accept the provisions of this Agreement, the content of which shall replace 
all previous negotiations and contacts between the parties. 
 
DATE AND PARTIES’ SIGNATURES 
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Appendix 24 – 2011 Drug delivery conferences. Source: [online] On drug delivery 
 
Date (2011) Conference Title Location Organiser 
January 17-18 Drug Delivery & Formulation Berlin, Germany WTG Group 
January 19-20 3rd Annual Prefilled Syringes 
Conference 
London, UK SMi 
February 1-2 6th Annual Drug Delivery 
Systems 
London, UK Visiongain 
February 23-24 Pharmapack Paris, France Canon 
Communications 
February 23-24 BIOMEDevice Paris, France Canon 
Communications 
March 8-9 Aerosol Forum Paris, France Oriex 
Communication 
March 24-25 Injectable Drug Delivery - 
Devices, Technology & 
Development 
London, UK Management Forum 
March 28-29 Skin Forum, 12th Annual 
Meeting 
Frankfurt, 
Germany 
APV Mainz 
March 30-31 8th Conference on Controlled 
Release 
London, UK SMi 
April 4-5 Nasal & Buccal Drug Delivery London, UK Management Forum 
May 3-4 Pharmaceutical and Medical 
Packaging 2011 
Copenhagen, 
Denmark 
Hexagon 
May 3-6 RDD Europe 2011 Berlin, Germany RDD Online / Aptar 
Pharma 
October 18 Drug Delivery Devices 2011 
(DDD'11) 
Copenhagen, 
Denmark 
Hexagon 
October 19 Medical Plastics 2011 (MP'11) Copenhagen, 
Denmark 
Hexagon 
October 25-27 CPhI Worldwide Messe, 
Frankfurt, 
Germany 
UBM 
October 25-27 ICSE Messe, 
Frankfurt, 
Germany 
UBM 
November 7-11 Universe of Prefilled Syringes 
& Injection Devices 
Basel, 
Switzerland 
PDA 
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Appendix 25 – Geographical distribution of clients 
 
 
 
Figure 0.1- Geographical distribution of clients focused on cardiovascular therapies 
  
  
 
Figure 0.2 - Geographical distribution of clients focused on Inflammation and Musculosketal therapies 
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Figure 0.3 - Geographical distribution of clients focused on Immunologic therapies 
 
 
 
Figure 0.4 - Geographical distribution of clients focused on Metabolic Disorders therapies 
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Appendix 26 – Scientific Park of Madrid Advantages 
 
General services: 
 
 Reception 
 General Secretariat 
 Reception and mail delivery 
 Sending and receiving fax 
 Meeting rooms, classrooms, audiovisual equipment 
 Photocopying and binding 
 Basic office furniture 
 Internet 
 24h Access  
 Cleaning 
 Surveillance and security 
 Parking 
 Canteen and vending machines 
 Transportation to / from the Train station 
 Social Debit 
 
Specific services: 
 
 Bioincubator Unit 
 Economic - Financial Unit 
 Projects Unit 
 Business Assistance Unit 
 Technological Promotion Unit 
 Human Resources Unit 
 Communication Unit 
 Information Technology Unit 
 Technology Transfer Unit 
 
 
Professional services: 
 
 Taxation R + D + i 
 Aid and subsidies 
 Patents and Trademarks 
 Legal and accounting consulting 
 Economic Intelligence 
 Company Valuation 
 Risk Capital 
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Strategic Partnerships: 
 
 
 
Source: Cátia Rabaça (PCM Business Development Unit)  
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Appendix 27 – Website creation and management proposal 
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